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1 Abbreviations 
 
AhR Aryl hydrocarbon receptor 
ARNT Aryl hydrocarbon receptor nuclear translocator 
bHLH basic helix loop helix 
BNIP3 Bcl2/adenovirus EIB 19kD-interacting protein 3 
ChIP Chromatin immunoprecipitation 
CREB Cyclic-AMP response element 
DCT Dopachrome tautomerase 
EGF Epidermal growth factor 
EMSA Electrophoretic mobility supershift assay 
ENO-1 Enolase-1 
EPO Erythropoietin 
FIH-1 Factor inhibiting HIF-1 
GADD45a Growth arrest and DNA-damage-inducible, 45alpha 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GLUT-1 Glucose transporter-1 
HIF-1 Hypoxia inducible factor-1 
HRE Hypoxia response element 
LDHA Lactate dehydrogenase A 
L-PK L-type pyruvate kinase 
MC1R melancortin 1 receptor 
MEFs Mouse embryonic fibroblasts 
MITF microphthalmia-associated transcription factor 
MPTP mitochondrial permeability transition pore 
ODD Oxygen-dependent degradation domain 
PAI-1 Plasminogen activator inhibitor type-1 
PDK1 Pyruvate dehydrogenase kinase 1 
P4Hα(I) Prolyl-4-hydroxylase α (I) 
PHD Prolyl hydroxylase domain containing 
PI3K Phosphatidylinositol 3-kinase 
PGK Phosphoglycerate kinase 
pO2 Oxygen partial pressure 
POMC Pro-opiomelanocortin 
pVHL Von Hippel-Lindau tumor-suppressor protein 
qPCR real-time quantitative PCR 
ROS Reactive oxygen species 
shRNA short hairpin RNA 
TAD Transactivation domain 
TERT Telomerase reverse transcriptase 
TRP-1 Tyrosinase-related-protein 1 
TYR Tyrosinase 
USF Upstream stimulatory factor 
VEGF Vascular endothelial growth factor 
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2 Summary 
 
Deprivation of oxygen is a main characteristic of solid human tumors. It was 
discovered in the 90’s that a novel transcription factor termed Hypoxia Inducible Factor 1 
(HIF-1), α subunit (HIF-1α) gradually accumulated during markedly reduced oxygen partial 
pressures (pO2), a state otherwise known as hypoxia. So far, the heterodimeric HIF-1 α/β-
complex has been implicated in targeting more than 70 genes involved in cell metabolism, 
cell cycle and proliferation, apoptosis and angiogenesis. As a consequence, HIF-1 is 
instrumental in promoting tumor growth and survival in most experimental models. To date, 
control of the HIF pathway via the O2-requiring hydroxylations of specific alpha-subunit 
proline and asparagine residues, leading to the factors’ ubiquitylation and proteasome 
catalyzed degradation and suppressing its interaction with vital co-activator proteins in 
(re)oxygenated cells, respectively, is relatively well understood. In contrast, much remains to 
be discovered in regard to critical oxygen-independent controls that also impinge on HIF-1 
signaling in tumor cells.  
A previous study had documented the binding of HIF-1 to two of three hypoxia 
response cis-elements (HREs) within the promoter of the globin-2 gene of Daphnia magna 
(phb2), as a strict requirement for the reporter’s maximal hypoxic activation in transfected 
hepatoma (Hep3B) cancer cells. However, binding of an unknown and constitutive 
transcription factor to the third phb2 motif, a CACGTG E-box palindrome, in human 
hepatoma cells (Hep3B), significantly weakened the HIF/HRE-mediated hypoxic induction. 
This observation suggested that CACGTG-complexes might function to fine-tune or inhibit 
HIF-driven gene responses in cancer cells and prompted a two-fold objective for the present 
work: a) was to identify this CACGTG-binding transcription factor in different human cancer 
cells, and b) to study the co-regulation of human genes through HIF-1 and this CACGTG-
mediated signaling pathway in vitro and in vivo. 
As a first step of this PhD thesis, gel supershift and oligonucleotide pull-down assays 
were used and consistently and reproducibly identified the basic-helix-loop-helix/leucine 
zipper (bHLH/ZIP) upstream stimulatory factors 1 and 2 (USF1 and 2) as the major phb2 
CACGTG binding factors in human hepatoma cells (Hep3B), human cervical carcinoma cells 
(HeLa) and human breast carcinoma cells (MCF7). Next, a genome-wide computational scan 
for human HRE/E-box promoters, i.e. those containing the CACGTG palindrome adjacent to 
or overlapping with a HRE, was carried out and retrieved with lactate dehydrogenase A 
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(LDHA), Bcl2/adenovirus E1B 19kD-interacting protein 3 (BNIP3), 4E-binding protein 1 
(4EBP1) and vascular endothelial growth factor C (VEGFC) etc. as known hypoxia targets. 
Having verified the human-mouse-rat conservation of this HRE/E-box constellation with 
regard to the following selected HRE/E-box genes, we either received as generous gifts 
(BNIP3) or generated ourselves (LDHA, 4EBP1 and melanocortin 1 receptor MC1R) HRE/E-
box promoter luciferase reporter plasmids, along with HIF-1 (i.e. prolyl hydroxylase domain 2 
PHD2) or USF-specific (i.e. tyrosinase TYR) reporter controls, to systematically investigate 
the interaction of HIF-1 and USF pathways at DNA level. 
Of these four HRE/E-box candidate genes only LDHA and BNIP3 reporter revealed a 
prominent hypoxia-mediated up-regulation in Hep3B, HeLa and MCF7 cells. Towards the co-
regulation of LDHA and BNIP3 promoters by HIF-1 and USFs, co-overexpression of HIF-1α 
and USF plasmids revealed a significant attenuation of the HIF-dependent hypoxic up-
regulation of the BNIP3 luciferase reporter by exogenous USF1 and 2a in Hep3B and HeLa 
cells. Similarly, the endogenous HIF-dependent hypoxic induction of LDHA was significantly 
reduced by over-expressed USF1 and 2a in MCF7 cells. To further evaluate the specificity of 
the expression manipulation of either HIF or USF on this regulation of LDHA reporter, a 
stable USF2a knockdown MCF7 clone was generated by short-hairpin RNA (shRNA) 
technology while a stable HIF-1α knockdown MCF7 clone was  kindly provided to us by Dr. 
D. Stiehl (group of Prof. R. Wenger, University Zurich).  
Luciferase assay in these stable MCF7 knockdown clones revealed a reduction of 
LDHA promoter activity upon silencing of USF2a transcription cells and an independent 
transactivation of LDHA promoter by HIF-1 and USF cascades. We also confirmed the 
competitive effect on the BNIP3 regulation by HIF-1α and USFs signaling in Hep3B cells by 
transiently silencing HIF-1α, USF1 or USF2a expression through specific siRNAs. The 
following luciferase assay revealed for the USF1 knockdown a significantly increased 
hypoxic activity of the BNIP3 promoter reporter. 
In vivo binding of HIF and USF within the promoters of LDHA and BNIP3 was 
shown by chromatin immunoprecipitation (ChIP) assays for Hep3B, HeLa and MCF7 cells. 
Regarding the BNIP3 promoter, the ChIP assay revealed chief occupancy in deoxygenated 
cells by HIF-1 along with the weak and constitutive attachment of USF1 and 2a to this DNA. 
Remarkably, some HIF-1α had successfully escaped proteolytic degradation since we 
detected it bound, as heterodimer, to the BNIP3 promoter even in normoxic cells. The native 
LDHA promoter (region: -2533/-2376 from translation start site) was dominated by bound 
HIF-1 in hypoxic MCF7 cells, while USF1 and USF2a co-occupied this regulatory DNA 
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during periods of normoxia (Hep3B, MCF7). The latter finding implied upstream stimulatory 
factors as physiological drivers of aerobic glycolysis in cancer cells (Warburg effect). We also 
noted that during hypoxia, both USFs maintained their association with this DNA, which 
offers additional support of the notion that maximal LDHA transcription during low pO2 
arises from the cooperative transcriptional control by HIF-1 and USF1/2a. 
Additional gel supershift assays mapped the exact in vitro HIF-1 and USF binding 
sites within the promoter of LDHA to the CACGTG motif (-2465/-2460; HIF-1 and USFs), 
the CACGTG palindrome at -2367/-2362 (USFs only) and the GACGTG HRE at -2353/-2345 
(HIF-1 only). Thus, distinct binding sites in the LDHA promoter might facilitate the 
independent transactivation of the gene by both signaling pathways. In contrast, HIF-1 and 
USFs were found to have either identical or overlapping binding locations within the DNA 
surrounding the -251/-246 HRE in the BNIP3 promoter, again in line with a mutually 
displacing, competitive mode of interaction at DNA level.  
Currently, I am extending this study to human melanoma cells, since in these cells 
HIF-1 and USF pathways are induced by physiological stimuli, i.e. hypoxia and tanning-
response conferring ultraviolet radiation, respectively. This will allow to examine the 
response of co-regulated BNIP3 and LDHA promoters in melanoma cells that have been 
subjected to hypoxia plus UV dual stimulation.  
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3 Zusammenfassung 
 
Eine negative Bilanz zwischen der Sauerstoffversorgung und dem Sauerstoffverbrauch 
ist ein klinisch signifikantes Charakteristikum der meisten bösartigen Tumore. Die 
resultierende O2-Mangelsituation (Hypoxie), die sich lokal im Tumorgewebe ausbilden kann, 
wird von den Zellen primär durch einen Transkriptionsfaktor registriert. Dieser Hypoxie-
induzierbare Faktor 1 (HIF-1) wird bei reduziertem Sauerstoffpartialdruck (pO2) aktiviert und 
kann DNA in Form eines, aus einer α und β Untereinheit bestehenden, heterodimeren 
Komplexes binden. Erwiesenermassen kontrolliert HIF-1 in hypoxischen Zellen die 
Transkription von mehr als 70 Genen. Das veränderte Abschreiben dieser Zielgene zieht 
zelluläre Anpassungen innerhalb des Stoffwechsels, Zellzyklus, Apoptose und Angiogenese 
nach sich. In den meisten Tumormodellen fungiert ein aktiver HIF Signalweg daher als 
Protagonist von zellulärem Wachstum, Hypoxietoleranz, Metastaseneigung und 
Therapieresistenz. Dank jüngerer Arbeiten ist die O2-abhängige Kontrolle von HIF-1 und dem 
nahe verwandten HIF-2 Komplex relativ gut verstanden. Von zentraler Bedeutung für diese 
Kontrolle sind enzymatische Hydroxylierungen einzelner Proline und Asparagine in den HIF-
1α und HIF-2α Untereinheiten. Als Folge dieser Signale werden bei einem pO2 Anstieg beide 
HIF-α Faktoren nicht nur transkriptionell inaktiviert, sondern auch ubiquitinyliert und 
proteolytisch abgebaut. Diese O2-verbrauchenden post-translationalen Hydroxylierungen von 
HIF-1α/-2α bedingen, dass in normoxischen oder re-oxygenierenden Zellen der HIF 
Signalweg sehr schnell zum Erliegen kommt. Für eine effektivere Bekämpfung von HIF in 
einem chronisch desoxygenierten Milieu, müssen jedoch auch die Hydroxylierungs-
unabhängigen Kontrollen dieses Signalwegs noch eingehender erforscht und therapeutisch 
einbezogen werden. 
Eine frühere Arbeit befasste sich mit der hypoxisch-induzierbaren Expression von 
Globingenen, insbesondere des hb2 Gens, in dem planktonischen Süsswasserkrebs 
(„Wasserfloh“) Daphnia magna. Im Rahmen sogenannter heterologer Transfektionen von 
humanen Hepatomazellen (Hep3B Zellen) wurde festgestellt, dass die kooperative Bindung 
von HIF-1 an zwei von drei funktionellen HIF-1 Bindungsstellen (hypoxia-response element, 
HRE) im Promoter von hb2 (phb2) für die maximale hypoxische Induktion eines vom 
Promoter abgeleiteten Luziferase (LUZ) Reportergen Plasmids unbedingt erforderlich war. 
Ein O2-unabhängiger (konstitutiver) Faktor hingegen interagierte mit der dritten 
Bindungsstelle, einem CACGTG Palindrom, im phb2/LUZ Konstrukt. Nach seiner Bindung 
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an das Palindrom war der CACGTG Komplex in der Lage die HIF/HRE-vermittelte 
Aktivierung des Daphnia  phb2 Reportergens deutlich zu schwächen. Möglicherweise liegt 
die Funktion dieses CACGTG-Komplexes in Hep3B Zellen in der Feinregulierung der durch 
HIF-1 gesteuerten Genaktivität. Ziel der vorliegenden Arbeit war es daher diesen 
unbekannten Bindungskomplex in verschiedenen Krebszelllinien zu identifizieren und die 
Regulation humaner Gene als Folge der Wechselwirkung von HRE- und CACGTG-
Komplexen zu untersuchen. 
Zur Identifikation des unbekannten Faktors kamen electrophoretic mobility shift 
assays (EMSA) und Oligonukleotid Pull-down Techniken zum Einsatz. Upstream Stimulatory 
Faktor 1 und 2 (USF1, USF2), ihrerseits Mitglieder der bHLH-leucine zipper (bHLH/ZIP) 
Transkriptionsfaktorfamilie, konnten als die primären, phb2-CACGTG bindende Faktoren in 
menschlichen Hepatoma- (Hep3B), Zervikalkarzinom- (HeLa) und Brustkarzinomzellen 
(MCF7) identifiziert werden. Zur weiteren Übertragbarkeit dieser Befunde auf menschliche 
Tumorzellen, wurde ein bioinformatischer Screen des humanen Genoms durchgeführt, um 
sogenannte HRE/E-box Genkandidaten zu erfassen. Humane HRE/E-box Gene tragen, phb2-
ähnlich, CACGTG-Palindrome und HIF-bindende HREs unmittelbar benachbart in ihrem 
Promoter. Mehrere bekannte Hypoxie Zielgene waren unter den HRE/E-box Kandidaten, u.a.: 
Laktat Dehydrogenase A (LDHA), 4E-bindendes Protein 1 (4EBP1) und der vaskuläre 
endotheliale Wachstumsfaktor C (VEGFC). Die jeweiligen Palindrom und HRE Motive sind 
in den Promotoren der homologen Mensch-, Maus- und Rattengene sämtlich konserviert und 
damit von wahrscheinlicher Funktionalität. Nach erfolgter Klonierung dieser HRE/E-box 
Promotoren als LUZ Plasmide (i. LDHA; ii. 4EBP1; iii. Bcl2/adenovirus E1B 19kD-
interagierendes Protein 3, BNIP3; iv. Melanocortin 1 Rezeptor, MC1R), untersuchte eine erste 
Serie von Reportergen Transfektionen die Hypoxie-vermittelte Induktion sämtlicher HRE/E-
box Konstrukte in Hep3B, HeLa und MCF7 Zellen. Niedrige Sauerstoffkonzentrationen (1% 
O2/16h) aktivierten von den getesteten Plasmiden lediglich die LDHA und BNIP3 Reporter in 
allen drei Zelllinien. Bezüglich einer HIF/USF-Ko-Regulation von LDHA- und BNIP3-
Promotoren, wurden HIF-1α, USF1 und 2a in Hep3B, HeLa und MCF7 Zellen überexprimiert. 
Diese Ko-Transfektionen zeigten, dass die HIF-1α-abhängige hypoxische Erhöhung der 
BNIP3-Promotor-Aktivität signifikant durch exogenes USF1 und USF2a, nicht aber durch 
USF2b, abgeschwächt wurde. Ferner unterdrückte die Überexpression USF1/2a in MCF7 
Zellen die endogene hypoxische Induktion von LDHA.  
Um die spezifischen Einflüsse von HIF-1 oder USF1/2a auf ein HRE/E-box Konstrukt 
unabhängig von Überexpressionen zu prüfen, wurden stabile USF2a und HIF-1α shRNA 
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knockdown (kd) Klone in MCF7 Zellen generiert. Der MCF7 HIF-1α kd Klon wurde uns 
freundlicherweise durch Dr. D. Stiehl (Gruppe Prof. Wenger, Univ. Zürich) überlassen. Die 
folgenden Luziferase-Versuche zeigten, dass die Aktivität des LDHA-Promoters in kd USF2a 
Klonen unter Normoxie reduziert war und dass die HIF-1 und USF Kaskaden im LDHA-
Promoter größtenteils unabhängig voneinander agierten. Umgekehrt bestätigten Versuchsreihen 
mit transientem (siRNA basierenden) knockdown von HIF-1α, USF1 und USF2a in Hep3B 
Zellen die Kompetition beider Signalwege auf Ebene des BNIP3-Promoters. Die hypoxische 
Aktivität des BNIP3 Reportergens war signifikant in Hep3B Zellen erhöht, die mit siRNAs 
gegen USF1, nicht aber gegen USF2a, transfiziert wurden.  
Um sicher zu stellen, dass die HIF-1 und USF1/2a Signalwege auch unter 
physiologischen Bedingungen auf die Bindungsstellen im LDHA- und BNIP3-Promotor 
konvergieren, wurden Chromatin Immunopräzipitation- (ChIP) und EMSA-Experimente 
durchgeführt. Diese Arbeiten zeigten für BNIP3, dass USF1 und 2a schwach und konstitutiv 
an dieselbe Stelle, die schon als funktionelle HRE erkannt wurde, binden können. Interaktion 
von HIF-1 mit der BNIP3 HRE war der dominierende Einfluss in hypoxischen Zellen. 
Allerdings wurde HIF-1, gebunden am BNIP3 Promoter, auch in normoxischen Kernen 
detektiert. Ferner binden HIF-1, USF1 und USF2a unter physiologischen Bedingungen an den 
LDHA Promoter (ChIP-Daten). Während die regulatorischen LDHA Elemente unter hohem 
pO2 vornehmlich durch USF1/2a besetzt waren, überwog der HIF-1 Besatz in hypoxischen 
Zellen (MCF7). Die USF Faktoren behielten allerdings ihre Bindung am LDHA Promoter 
auch unter Hypoxie bei, was gegen eine Verdrängung durch HIF-1 spricht und einen weiteren 
Nachweis für die unabhängige HIF/USF Bindung an die LDHA Motive liefert. Die EMSA-
Versuche zeigten, dass HIF-1 und USF1/2a vornehmlich an ihre eigenen cis-Elemente im 
LDHA Promoter binden, d.h. hier, relativ zum BNIP3 Gen, nur eine schwache Konkurrenz 
zwischen HIF/HRE und USF/Palindrom Komplexen vorherrscht. Allem Anschein nach 
korreliert die Präsenz individueller Bindungsstellen mit der größtenteils unabhängigen 
Konvergenz von HIF-1 und USF Signalwegen auf das LDHA Gen. Demgegenüber resultiert 
aus der Konkurrenz von HIF-1 und USFs um eine gemeinsame Bindungssequenz im BNIP3 
Promoter die dargestellte negative Wechselwirkung beider Signalwege auf Genebene.  
In fortlaufenden Experimenten in humanen Melanoma Zellen wird zurzeit die Ko-
Regulation der LDHA- und BNIP3-Expression durch HIF-1 und USFs durch strikt 
physiologische Stimuli (Hypoxie ? HIF-1; UV ? USFs) erforscht. 
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4 Introduction 
 
4.1 Tumor hypoxia 
Landmark studies by Gray et al. and Thomlinson and Gray in the 1950s established 
the direct link between radio-sensitivity and oxygen tension in tumor tissue, thereby initiating 
the area of research around the many aspects of tumorigenesis that are mediated and 
accelerated by deprivation (hypoxia) or complete lack (anoxia) of oxygen [1, 2]. Generally 
speaking, hypoxia occurs when the ambient oxygen partial pressure (pO2) has fallen to or 
below the level required to maintain minimal aerobe activity in an organism, tissue or cell. It 
is the cells’ own specific critical oxygen threshold (pC) which separates the aerobe-
oxyregulated (pO2 > pC) from the anaerobe-oxyconforming (pO2 < pC) physiological state. 
Thus, cells or tissues are hypoxic at specific pO2 < pC levels of oxygenation and not at some 
stereotypically applicable numerical oxygen concentration. Common responses to such level 
of oxygen scarcity include the switch from aerobe to anaerobe metabolism, and from 
oxyregulated (i.e. O2 consumption rate is more or less constant across a wide range of pO2) to 
oxyconforming respiration (i.e. O2 consumption rate declines in direct proportion with falling 
pO2).  
During the five decades following Thomlinson’s and Gray’s pioneering work, radio-
biologically effective degrees of  hypoxia (i.e. pO2 measures ≤ 5 mmHg (∼0.7% O2; 7.35 
mmHg ≅ 1% O2) have been firmly documented in most solid tumors, including brain, lung, 
breast, pancreatic, cervical, prostate, and head and neck cancer [3-6]. In comparison, median 
pO2 data of many normal tissues lie between 40-50mmHg and demonstrate excellent 
homeostatic control when switching from a resting to an actively working physiological state 
(e.g. skeletal muscle). It is now understood that, as tumors evolve from a single malignant cell 
into a multi-cellular mass, oxygen tension and nutrient delivery in the tumor 
microenvironment drops as the passive diffusional capacity of the existing blood supply is 
surpassed. Assuming typical values for intracapillary oxygen tensions and oxygen 
consumption rates, the oxygen diffusion distance in tissue approximately corresponds to 150 
μm [7]. Up until this 150 μm distance from the nearest capillaries, O2 diffuses in form of a 
gradient. Beyond this distance, necrotic cells tend to amass. Thus, tumor hypoxia develops 
along this gradient due to the mismatch between high oxygen demands of deregulated growth 
on the one hand and inadequate nutrient supply via abnormal vessels, erratic blood flow and 
deteriorating diffusion geometry (vessel-necrosis distance > oxygen diffusion radius) on the 
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other [3-6]. This high demand-low supply imbalance is responsible for the hostile 
microenvironment in solid tumors, as is characterized by deprivation of oxygen and nutrients 
(i.e. ischemia), low extra-cellular pH and reduced growth factor availability [8]. Intra-tumoral 
O2 depletion is a powerful stimulus of angiogenesis for a large variety of survival responses 
(next paragraph). As a result of these cellular adaptations to low oxygen levels, presence of 
tumor hypoxia frequently associates with a decreased efficacy of many conventional therapies 
and the emergence of a more virulent, metastasis-prone neoplastic variety of cells. 
The genetic or epigenetic changes, that enable cancer cells to adapt to hypoxia 
commonly comprise acquisition of [9]: 1)  self-sufficiency from growth factor signals due to 
over-expression or dysfunction of various growth factor receptors and/or gained insensitivity 
to anti-proliferative signals; 2) genetic instability with subsequent selection of more 
aggressive, therapy-resistent cell clones [10]; 3) increased capacity of cell survival and 
apoptotic evasion via dysregulation of the apoptotic machinery [11]; 4) sustained 
angiogenesis by altering the balance between pro- and anti-angiogenic signals, and in 
particular, by exhibiting increased expression of the pro-angiogenic vascular endothelial 
growth factor (VEGF) [12, 13]; 5) invasive and metastatic behavior owing to the activation of 
extra-cellular proteases and altered binding specificities of cadherins and intergrins [14, 15]; 6) 
unlimited replicative and proliferative potential due to telomere maintenance via up-regulated 
expression of the telomerase components; 7) increased reliance on glucose uptake and 
glycolytic ATP production via up-regulation of glucose-transporters genes encoding of 
glycolytic enzymes [16]; and 8) hypoxia tolerance through ability to slow down or arrest ATP 
costly macromolecular synthesis and cell cycling processes during periods of O2 and nutrient 
depletion [17-20]. 
Several hypoxia-sensitive transcription factors have been described [21], like hypoxia-
inducible transcription factor-1,-2 (HIF-1, 2), metal transcription factor-1 (MTF-1) [8], 
nuclear factor κB (NF-κB) [22], c-Fos and c-Jun (AP-1) [23], E26 transformation-specific 
sequence-1 (ETS-1) [24], Specificity protein-1 (SP-1) [25, 26], CCAAT enhancer-binding 
protein β (C/EBPβ) [27, 28] and early growth response-1 (EGR-1) [29-31]. Of these, HIF-1 
and -2 are considered key transcriptional regulators of hypoxia-responsive genes in both 
primary and neoplastically transformed cells. Immunohistochemical studies of tumor biopsies 
indicate that HIF-1α and -2α are over-expressed in multiple human cancers, malignancies 
including carcinomas of the lung, colon, brain, prostate, breast, skin and so on. In contrast, in 
normal and oxygenated tissue, as well as benign, noninvasive growths either of these proteins 
remains undetectable. Consequentially, many clinical reports of HIF-1/-2 expression levels in 
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cancers find them to be strong and independent markers for poor treatment and survival 
prognoses [32-34].  
 
4.2 Hypoxia-inducible factor overview  
First documented in 1988, the stimulatory influence of hypoxia on certain genes was 
decisively shown with the induced synthesis of human erythropoietin (EPO), the hormone 
which stimulates red blood cell production during periods of diminished oxygen supply [35]. 
Subsequent work elicited the existence of a hypoxia-inducible enhancer region 3’ to the 
human EPO gene and, furthermore, unearthed the existence of a functional hypoxia-
responsive element (HRE) contained within the 3’ sequence. The HRE was required for the 
hypoxia-mediated transcription of EPO [36]. Affinity-chromatography utilizing an 
immobilized EPO HRE-containing oligonucleotide led Wang and Semenza in 1995 to 
eventually isolate from human cancer cell extracts the hypoxia-inducible factor-1 (HIF-1) as 
the EPO-HRE binding protein constituent [37, 38]. 
4.2.1 Structure of hypoxia-inducible factors 
Transducing minutes to hours of hypoxic pO2 onto the level of DNA is chiefly 
accomplished by HIFs. In mammalian cells, several hundred potential [39] and more than 70 
validated hypoxia-responsive gene targets of HIF have been identified [40]. Across the animal 
kingdom, HIF signaling is highly conserved down to the smallest molecular details [19, 41, 
42]. Considerable progress has also been made in understanding the molecular basis of HIF 
and its regulation by oxygen [43, 44]. From mammals to teleosts, Drosophila, the crustacean 
Daphnia magna, and the nematode Caenorhabditis elegans, the HIF complex functions as 
heterodimer of homologous α-subunits and β-subunits which both belong to the family of 
basic helix-loop-helix (bHLH)/PER-ARNT-SIM homology (PAS) transcription factors [19, 
41, 42]. To date, three different oxygen-dependent HIF α subunits (HIF-1α, -2α and -3α) 
have been reported in mammals. All three alpha subunits can heterodimerize with the 
constitutively present HIF β subunit (also known as aryl hydrocarbon receptor nuclear 
translocator (ARNT)). HIF-α and ARNT factors have similar structural domains, including 
N-terminal domains required for DNA binding (basic region) and protein-protein interaction 
(HLH domain and PAS-A and PAS-B repeats). Domains in the central reading frame and 
towards the C-terminal end are implicated in controlling stability of HIF-1α and -2α subunits 
(oxygen dependent degradation domain, ODD) and the transactivating competence of the 
factor (C-terminal transactivation domain, TAD-C). The ODD of HIF-1α/-2α also contains 
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the so-called N-terminal transactivation domain (TAD-N). HIF-3α and ARNT exhibit only 
one transactivation domain and due to the lack of  ODD-like sequences, both proteins are 
rendered stable during normoxic conditions (Fig.1) [44].  
Regulation of HIF by oxygen occurs, in cultured cells at least, at protein level, 
primarily through enzymatic hydroxylation of specific α subunit prolyl and asparaginyl 
residues (Fig. 1). The in vitro transcription of HIF-1α/-2α genes usually does not exhibit any 
significant O2-dependence. In contrast, some, though not all [45], studies reported a marked 
induction of HIF-1α mRNA during low pO2 in several human and mouse tissues [46, 47].  
 
 
Figure 1 Isoforms of hypoxia-inducible factor (HIF)-1α, 2α, 3α and 1β. bHLH: basic helix-loop-helix; 
PAS:Per-ARNT-Sim; TAD: transactivation domain; ODD: oxygen-dependent degradation domain. [44] 
4.2.2 HIF-1 signaling pathways 
At protein level, the most important degradation pathway operates through the 
hydroxylation of two proline residues embedded in the ODD of HIF-1α and HIF-2α when O2 
is sufficiently available. The efficacy of this control mode is mirrored by the <5 min half-life 
of HIF-1α upon re-oxygenation [48] and an instantaneous hypoxic induction of the 
transcription factor [49]. The long sought after HIF oxygen sensors, so-called prolyl 
hydroxylase domains 1-3 (PHD1-3) dioxygenases, control the abundance of either HIF-α 
protein during high or rising pO2. As hallmark achievements in hypoxia research, these three 
HIF-prolyl hydroxylases were discovered and cloned in 2001 by several leading laboratories 
[50-53]. According to their data, PHDs catalyze in the presence of oxygen and 2-oxoglutarate, 
the Fe(II)-dependent hydroxylation of two distinct ODD proline residues, i.e. Pro402 and 
Pro564, in human HIF-1α, and Pro405 and Pro531 in human HIF-2α (Fig. 2) [43, 54]. Further 
support of the current sensing paradigm stems from hypoxia-mimicking agents such as iron 
chelators (e.g. desferrioxamine, DFO) or transition metals such as cobalt. Incubation of cells 
in non-toxic micromolar concentrations can either scavenge (DFO) or perhaps substitute (Co) 
the catalytic iron of PHDs, hence resulting in the inhibition of PHD catalysis. PHD activity 
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can be also inhibited by some physiological substrates such as succinate and fumarate, two 
components of TCA cycle. Accumulations of succinate and fumarate in tumors with loss-of-
function mutations in succinate dehydrogenase (SDH) and fumarate hydratase (FH)- subunits 
yielded HIF-1 stabilization in a pseudo-hypoxia environment [55, 56]. A reduction in the HIF-
1α hydroxylation under hypoxic conditions, and the genetic loss-of-function impact on HIF 
stability of the C. elegans PHD homolog Egl-9 [51], provided the final proof that the PHDs 
function as HIF oxygen sensors, from “worm to man”. The PHD/HIF hypoxia sensing axis is 
further complemented by the von Hippel Lindau tumor suppressor protein (VHL), whose 
function lies in recognizing hydroxylated HIF-α subunits and linking them to a proteolytic 
degradation machinery.  
Evidently, prolyl hydroxylation is the oxygen-regulated step governing ubiquitination 
and proteasomal degradation of HIF-1α/-2α. At center stage of this process is VHL, a 
component of E3 ubiquitin-ligase complex, which mediates the recruitment of accessory 
factors, like elongin C, elongin B, cullin 2 and RBX1 to bound (=hydroxylated) HIF-α 
subunits [57]. The complete E3 ligase assembly will then interact with E1 ubiquitin-activating 
and E2 ubiquitin-conjugating enzymes, thus mediating ubiquitin-tagging of the index protein 
(in this case HIF-α) and initiating its subsequent degradation in the 26S proteasome [52, 58, 
59]. Consequently, VHL loss of function lesions in renal carcinoma (RCC) or in VHL 
hereditary cancer syndrome results in an increase in HIF-1α/-2α protein levels in non-
hypoxic cells due to the block in the ubiquitylation and proteasomal degradation of either 
substrate protein [60]. Similarly, proteasomal inhibitors (MG132), a mutation of the ubiquitin-
activating enzyme E1, or inhibition of PHDs by pharmacological (e.g. dimethyloxaloylglycine, 
DMOG) small molecular weight compounds, all cause the stabilization of  HIF-α proteins 
under normoxic or re-oxygenating conditions which switch the inducible pathway into a 
constitutively active cascade [61, 62]. 
Additional VHL-mediated HIF-1 degradation is triggered upon acetylation of HIF-1α 
Lys532 which is also located in the ODD domain. Lys532 is acetylated by an acetyltransferase 
called arrest-defective protein 1 (ARD1). This post-translational modification facilitates the 
interaction of HIF-1α with VHL and leads to HIF-1 degradation. Although activity of ARD1 
is not directly affected by oxygen concentration and its catalysis operates in an oxygen-
independent manner, it was reported that mRNA and protein level of ARD1 decrease under 
hypoxia. It suggested that low oxygen might lead to less acetylated HIF-1. To date, however, 
the relevance of HIF-1α acetylation, and the role of  ARD1 in particular, in hypoxic signaling 
are highly controversial issues [63].  
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The TAD-C domain is required for the transactivation of HIF-1 or HIF-2 by means of 
recruiting and interacting with the co-activator p300 and CREB binding protein (p300/CBP) 
with either alpha subunit. A second O2-requiring hydroxylation modifies an asparagine within 
the TAD-C domain of HIF-1α (Asn803) or HIF-2α (Asn851) under aerobic pO2. This reaction 
is carried out by the asparaginyl hydroxylase factor inhibiting HIF (FIH). Hydroxylation of 
the TAD-C Asn residue prevents the recruitment of co-activator and histone acetyltransferase 
p300/CBP, thereby leading to the suppressed transcriptional activation of HIF target genes 
under high oxygen [64, 65]. Unlike the proline modification, the hydroxylation of the TAD-C 
Asn residue catalyzed by FIH in the presence of oxygen culminates in the inhibited 
transcriptional activity of HIF-1α or -2α without altering the protein levels. It does become 
clear, however, that oxygen impinges on HIF signaling twofold, by controlling both the 
abundance and transcriptional activity of the factors sensory alpha subunits.   
The fact that HIF’s maximal signaling activity specifically occurs during low pO2 and 
declines towards both normoxic and anoxic concentrations of oxygen is the combined result 
of strikingly low oxygen affinities of the PHD and FIH-1 sensor proteins together with a 
pronounced hypoxia-driven transcriptional induction of some of the sensor genes (i.e. PHD2, 
PHD3). The in vitro and apparent KM (of short HIF-1α peptide substrates) values for oxygen 
of ~64 mmHg (FIH-1) and 178 mmHg (average for PHD1-3) imply that HIF hydroxylases 
operate in vivo at pO2 levels far below their KM values [66, 67]. Thus, the oxygen affinity of 
the PHD enzymes actually lies above the concentration of dissolved oxygen in air, which 
means that the availability of oxygen is predicted to be limiting for activity of HIF 
hydroxylases over the entire physiological range. The KM data are therefore consistent with 
the enzymes function as bona fide sensors of graded levels of oxygen. Moreover, the HIF-
mediated hypoxic up-regulation of PHD2 and 3 gene expression [68] prepares for the rapid 
destruction of HIF-α subunits following reoxygenation [69], and enables PHD enzymes, due 
to their increased protein levels, to stay operative even under low pO2 conditions [70]. This 
negative feedback loop not only limits the HIF response but also resets the hypoxia threshold 
by down-shifting the HIF set point towards further O2 depletion [70]. Conversely, cells grown 
in high [O2] reset their HIF set point upward through the downregulation of PHD genes [71]. 
Thus, activation of the HIF system can adapt to hypoxia due to its flexible and perhaps tissue-
specific O2 thresholds. These thresholds are adjusted according to the previous cell exposure 
to low or high [O2], and, in turn, are responsible to steadily hold the pathway responsive to 
varying tissue oxygenation. 
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Despite these various adjustments to extend the oxy-sensory function of HIF prolyl 
hydroxylases into hypoxia, once the cell faces pO2 < pC degrees of hypoxia, and of course 
anoxia, the hydroxylation of prolyl and asparaginyl residues is sufficiently diminished to shift 
the equilibrium towards the transcriptionally active form of HIF. Due to inhibition of 
hydroxylation, enough HIF-1α and HIF-2α will escape proteolytic degradation and, following 
phosphorylation by various kinases and chaperoning through accessory factors, like heat 
shock protein 90 (HSP90), translocate into the nucleus. Here, the alpha subunits 
heterodimerize with HIF-1β/ARNT through intermolecular interactions between HLH and 
PAS domains. Next, the HIF-1/-2 heterodimer interacts with different transcriptional co-
activators such as p300/CBP, SRC-1 and TIF2 [72-75] and initiates the hypoxia-triggered 
control of target gene expression by binding to the HRE(s) mostly from within the 5’or 3’ 
flanks of the gene (Fig. 2).  
A complete HIF-mediated transactivation pathway therefore includes HIF-1α/-2α 
post-translational phosphorylation events, nuclear translocation, heterodimerization with 
ARNT, recruitment of different co-activators, DNA binding and transcriptional up- or down-
regulation of gene expression [76]. There are two main phosphorylation cascades which are 
known to regulate HIF-1 activity: one is conducted by the rather well characterized pathway 
of p42/p44 (Erk2/Erk1) mitogen-activated protein kinases (MAPKs) [77, 78]. The other is 
conducted through phosphatidylinositol (PI)-3-kinase (PI3K) signaling. Activation of PI3K 
represents an important stimulus of HIF-1α phosphorylation, which, subsequently can lead to 
an increased HIF-1 protein level [79]. However, PI3K signaling as motor for HIF-1 
abundance was recently challenged by Arsham et al. [80]. Additionally, several growth 
factors, most notably insulin-like growth factor-2 (IGF-2) and transforming growth factor-α 
(TGF-α) are able to initiate autocrine signaling of HIF-1 through enhanced translation of the 
transcript [81]. 
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Figure 2 HIF-1 pathway. Under normoxia, hypoxia-inducible factor 1α (HIF-1α) is hydroxylated by prolyl 
hydroxylases at Pro402 and Pro564 within the ODD domain of HIF-1α. Subsequently, this hydroxylated HIF-1α is 
immediately bound by the von Hippel-Lindau tumor-suppression protein (VHL). VHL recruits elongin-B, 
elongin-C, CUL-2 and RBX-1 to the alpha subunit. This VHL/elongin-complex, together with ubiquitin-
activating (E1) and ubiquitin-conjugating (E2) enzymes, mediates the ubiquitination of HIF-1α, resulting in its 
degradation via the proteasome. During hypoxia, the hydroxylation of HIF-1α is suppressed and HIF-1α  
becomes stable. This stabilized HIF-1α translocates into the nucleus, dimerizes with HIF-1β, recruits cofactors 
such as CBP/p300 and binds to hypoxia-responsive elements (HREs) to regulate gene expression in response to 
hypoxia (taken from [43]). 
 
There are several stimuli known to trigger HIF-1 signaling even in non-hypoxic cells. 
Firstly, several growth factors, such as insulin, insulin growth factor 1 and 2 (IGF-1 and -2), 
epidermal growth factor and fibroblast growth factor, are known to stimulate HIF-1 
expression which can  lead to an enhanced proliferation rate of murine embryonic fibroblasts 
(MEFs) and embryonic stem (ES) cells [82]. Secondly, stimulation of vascular hormones, 
such as thrombin, can elevate HIF-1α protein level via the generation of reactive oxygen 
species (ROS) and the subsequent induction of PAI-1 and VEGF gene expression in human 
vascular smooth muscle cells (VSMC) [83]. Thirdly, it was also demonstrated that treatment 
of interleukin-1β (IL-1β) in normoxic human hepatoma cells (HepG2) increased HIF-1 
protein level and caused a moderate activation of HIF-1 binding to the HRE of EPO [84]. 
Lastly, various viral proteins can increase both the stability transcriptional activity of HIF-1 
and trigger intensified angiogenesis [85, 86].  
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4.2.3 HIF-1 target genes 
Functional HIF binding sites, or HREs, are composed of mandatory consensus 
sequence 5’-VNVBRCGTG-3’ (V=not T; N= any; B=not A; R=A or G). Through binding to 
such cis-elements, mammalian HIF-1 is known to control expression of more than 70 
validated targets. These genes are involved in regulating oxygen supply, cell metabolism, 
energy expenditure, angiogenesis, cell growth and apoptosis [40] as summarized in Table 1 
below. 
Table 1. Selected validated HIF-1 targeted genes. 
Gene name Function References 
Aldolase-A Glucose metabolism, Glycolysis [87, 88] 
Carbonic anhydrase-9 (CAIX) pH regulation [89] 
Bcl2/adenovirus E1B 19kD-interacting protein 3 
(BNIP3) 
Apoptosis [90] 
DEC1/Stra13 Transcriptional regulation [91] 
DEC2 Transcriptional regulation [91] 
Endothelial nitric-oxide synthase (eNOS)  Vasodilation [92] 
Enolase-1 Glucose metabolism, Glycolysis [87, 88] 
Erythropoietin (EPO) Erythropoiesis, Cell survival [93, 94] 
Glucose transporter-1, and -3 (GLUT-1,-3) Glucose uptake [95, 96] 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Glucose metabolism, Glycolysis [97] 
Hexokinase-2 (HK-2) Glucose metabolism, Glycolysis [98] 
L-type pyruvate kinase (L-PK) Glucose metabolism, Glycolysis [99] 
Lactate dehydrogenase A (LDHA) Glucose metabolism, Glycolysis [100] 
Nip like protein X  (NIX) Apoptosis [101] 
Nitric oxide synthase-2 (NOS-2) Vascular tone, cell survival [102] 
6-Phosphofructokinase-2-kinase/fructose-2,6-
biphosphatase 
Glucose metabolism [103] 
Plasminogen activator inhibitor-1 (PAI-1) Angiogenesis, Fibrinolysis [104] 
Prolyl hydroxylase domain 2 (PHD2) O2 sensing [105] 
Prolyl-4-hydoxylase α (I) (P4Hα(I)) Collagen metabolism [106] 
Pyruvate dehydrogenase kinase (PDK) Mitochondrial activity, Respiration [98] 
Telomerase reverse transcriptase (TERT) Cell proliferation, DNA replication [107, 108] 
Transforming growth factor-α (TGF-α) Cell proliferation [109] 
Transferrin  Iron transport [110] 
Transferrin receptor Iron transport [111, 112] 
Vascular endothelial growth factor (VEGF) Angiogenesis, Cell survival [113, 114] 
VEGF receptor-1 (flt-1) Angiogenesis [115] 
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In mammals, products encoded by these 70 targeted genes can be divided into two 
main functional categories:  
1) improving or maintaining tissue oxygenation via up-regulated angiogenesis, 
vasodilation and erythropoiesis, 
2) switching aerobic to anaerobic substrate consumption and ATP maintenance via 
increasing glucose uptake and glycolytic flux.  
 
EPO: a major player of erythropoiesis 
One example is erythropoiesis, particularly with regard to the functional division of 
labor between HIF-1 and HIF-2. The glycoprotein hormone erythropoietin regulates the cell 
mass of erythrocytes and represents a potent stimulus for erythropoiesis. EPO is produced by 
the fetal liver and the kidney of the adult mammal during hypoxia. While previous findings 
considered the human EPO gene as being targeted by HIF-1, recent findings point more 
towards HIF-2 as the main transcriptional driver of EPO transcription. For example, HIF-2, 
rather than HIF-1, was reported to regulate the hypoxia-mediated expression of liver EPO via 
preferential binding to EPO 3’enhancer HRE in ChIP assays [116, 117]. Whatever the 
mechanistic details, induction of EPO mRNA and protein levels will confer a strongly 
amplified synthesis of red blood cells in the bone marrow [36]. During erythropoiesis, 
however, the bone marrow also needs more heme. Thus, the iron demand will increase 
concomitantly with erythrocyte production. To prevent that inadequate iron supply might 
limit the rate of erythropoiesis, HIF also upregulates a series of genes which facilitate the 
transport of iron to the bone marrow. This genes include transferrin, the iron transporter in the 
blood and its receptor [110-112]. 
 
VEGF: a key regulator of angiogenesis in tumor 
The vascular endothelial growth factor (VEGF) gene is another O2-sensitive 
checkpoint to maintain the oxygen carrying capacity and tissue oxygenation during hypoxic 
and ischemic challenges. Early reports documented that either hypoxia or hypoglycemia were 
able to up-regulate and stabilize both VEGF mRNA and protein [118-120]. Later, the 
functional HIF-1 binding site in VEGF’s 5’ flanking sequence, required for this hypoxia-
mediated transcriptional response, was being identified by electrophoretic mobility shift 
assays (EMSA) together with protein extracts from hypoxic Hep3B cells [113]. Enhanced 
secretion of VEGF has been implicated in the neovacularization associated with hypoxic 
states such as myocardial ischemia, stroke or cancer. With regard to malignant pathologies, 
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considerable evidence points to the strict requirement of angiogenesis for tumor growth and 
metastasis (reviewed in [12, 13]. For a malignant mass to grow beyond 1-2 mm3, i.e. ∼30 
times the size and more of the initial nodule [13], angiogenesis needs to be initiated to counter 
the increasing diffusion insufficiencies [121, 122]. For solid malignancies, this step is 
considered to be rate-limiting for further development and spreading [13]. Studies on tumor 
vasculature have documented that elevated and secreted VEGF concentrations promoter 
neoangiogensis primarily through endothelial sprouting in pre-existing capillaries. Yet, in 
contrast to normal vasculature, tumor vasculature is notoriously aberrant in structure with 
often elongate, tortuous and blind-ending vessels [4], shows sluggish or erratic perfusion 
(∼85% of all tumor capillaries maintain unstable blood flow) [123, 124] and a great degree of 
heterogeneity in endothelial cell proliferation and pericyte coverage of blood vessels [125]. 
Moreover, VEGF signaling also induces vascular permeability and facilitates leakage of 
plasma protein. Although angiogenesis is evoked to improve already failing O2 supply, the 
disordered architecture of tumor vasculature often leads to insufficient tumor perfusion. 
Therefore, cell-autonomous bioenergetic adaptations need to occur as added strategies, to 
improve the cells’ survival odds.  
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Part A Co-regulatory effect of HIF/USF on human genes containing HRE 
and E-Box palindromes 
 
5 Background 
 
5.1 HIF and glucose metabolism 
To generate ATP as energetic pre-requisite for cell growth, cell motility and 
macromolecular syntheses, glucose is metabolized in two ways. One way is glycolysis in 
which glucose is fermented to pyruvate in the cytosol. This linear substrate flux has a net 
production of 2 moles ATP per mole glucose consumed. The other way is composed of the 
tricarboxylic acid (TCA) cycle in conjunction with the oxidative phosphorylation of delivered 
reduction equivalents (NADH) in the electron transport chain (ETC). Both, the cyclical TCA 
and the linear 4-complex containing ETC reside in the mitochondrium. Oxygen serves as the 
final electron acceptor in the ETC. The energy released through the exergonic electron 
transport from the NADH reduction equivalents onto O2 is temporarily stored in form of an 
electrochemical proton gradient across the inner mitochondrial membrane. This gradient, in 
turn, drives ATP synthesis at the ATP synthetase (complex V) for a net production of 36 
moles ATP per mole glucose oxidized. During oxygen limitation of the mitochondrial ETC, 
pyruvate, or rather its decarboxylated C2 acetyl derivative, will no longer be used as initial 
substrate of the TCA, but instead converted to lactic acid by the cytosolic lactate 
dehydrogenase A. This reduction does nothing to improve the poor energy balance of 
fermentative glucose utilization during hypoxic challenges (2 moles ATP net/mole glucose). 
Due to this inefficient ATP production from anaerobe glycolysis, cells need respond with a 
much larger throughput of glucose import and glucose-to-lactate breakdown, to at least 
maintain energy production under anaerobic conditions. This so-called Pasteur effect was first 
reported by Louis Pasteur in 1861 on yeast cells [126]. Pasteur could show that oxygen 
inhibited fermentation and that glucose consumption was inversely proportional to oxygen 
availability, i.e., that glycolysis was positively regulated by hypoxia. Today we know that the 
elevated substrate flux in hypoxic cells is achieved through the coordinated induction by HIF-
1 of whole series of genes encoding glycolytic enzymes [127-131]. In fact, ten of the twelve 
catalytic steps participating in glycolysis are regulated by HIF-1 (Fig.3). These well 
characterized HIF-1 target genes include glucose transporter 1 and 3 (GLUT 1 and 3), 
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involved in glucose uptake [95], aldolase A (ALDA), phosphoglycerate kinase 1, enolase 1 
and lactate dehydrogenase A (LDHA) [87, 88, 93, 100]. It was hypothesized that this 
overwhelming control of the Pasteur effect might well represent HIF’s primordial function, 
which emerged shortly after the transcriptional activity originated in some archetypal 
metazoan [128]. Similar to angiogenesis, however, the Pasteur effect does not represent the 
“be all, end all” means of hypoxic adaptations. As serious drawbacks of this defense strategy, 
high-flux glycolysis can quickly deplete finite stores of fermentable substrate (e.g. glycogen) 
and amass toxic levels of end products (e.g. H+ per ATP hydrolysis) in sensitive and hypoxic 
cells. In the absence of energy expending reductions, anaerobe fermentations fail to meet ATP 
maintenance demands of ionic and osmotic equilibrium and are thus unable to prevent an 
ultimately fatal ATP imbalance in central neurons, renal tubular cells or hepatocytes [132-
135]. 
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 Figure 3 The glycolytic pathway. Enzymes upregulated by HIF-1 are indicated in bold. HK-1,-2: hexokinase 
type 1 and 2; GPI: glucose phosphate isomerase; PFK: phosphofructokinase; ALDA: aldolase A; TPI: triose 
phosphate isomerase; GAPDH: glyceraldehydes 3-phosphate dehydrogenase; PGK: phosphoglycerate kinase; 
PGM: phosphoglycerate mutase; ENO1: enolase 1; PK: pyruvate kinase; LDHA: lactate dehydrogenase A [136] 
 
Many human and animal tumors display, even under aerobic oxygen tensions, a 
significantly increased rate of glycolytic sugar consumption and lactate build-up [137-140], a 
phenomenon known as the Warburg effect. When Warburg described prominent aerobic 
fermentation as unique dedifferentiation-feature of tumor cells some 80 years ago, he saw the 
tumor’s compensatory reprogramming effort to the initial and cancer-causing insult: an 
irreversible injury of respiration [141, 142]. Warburg had, in essence, associated the mutually 
antagonistic relationship between glycolysis (= activated) and respiration (= impaired), as 
formerly formulated by the Pasteur effect (low pO2 ⇒ activated glycolysis ⇒ impaired 
respiration) or Crabtree effect (high glucose concentration ⇒ activated glycolysis ⇒ impaired 
respiration), to the genesis of cancer. His discovery has had a very strong impact on the 
oncological community and, to this day, aerobic up-regulation of glycolysis [139] or a 
predominantly glycolytic metabolism in general [143], which are regarded as near-universal 
property of primary and metastatic cancers and remain associated with tumorigenesis. 
However, it is quite clear now that a strong basal glycolytic capacity, indeed a feature of 
many tumor types, is neither the cause nor a universal characteristic of malignancies [129, 
140]. Rather, it was found that cultured aerobic cancer cells do not exhibit any more 
glycolytic activity than normal ones, and both cell types alike partition their total normoxic 
ATP production into equivalent ~80% oxidative and ~20% glycolytic contributions [144, 
145]. Furthermore, some studies simply contradicted the existence of a causal link between 
glycolytic activity and in vivo tumorigenesis [146], while others reported that prominent 
glycolysis only reflects active proliferation [147] and/or exposure to low pO2 regardless of the 
cells’ cancerous or normal legacy [129]. Thus, cancer cells, on average, are not inherently 
more glycolytic than normal cells and constitutive high-flux glycolysis is not causally tied to 
the malignant transformation of cells. Whether the Warburg effect carries diagnostic and 
therapeutic significance for secondary or metastatic tumor entities remains a matter of debate. 
HIF-1 can also coordinate the up-regulated glucose uptake and glycolytic substrate 
flux with a substantial reduction in mitochondrial activity [148, 149]. As such, HIF-1 is partly 
responsible to orchestrate the switch from oxyregulated to oxyconforming respiration. 
Pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates mitochondrial pyruvate 
dehydrogenese (PDH) and thus inhibits the complex from using pyruvate to fuel the TCA 
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cycle, was determined as a direct HIF-1 target gene during pO2 ≤ pC levels of oxygen scarcity. 
This TCA block was recently shown to actively suppress respiration, redirect both O2 and 
glucose utilization towards cytosolic sinks, and rescue cells from hypoxia-induced apoptosis 
[148-150]. In addition, a study on non-small-cell lung cancers showed that elevated PDK1 
expression might reduce PDH expression even in non-hypoxic tumor cells [151]. As outcome 
of these findings, HIF-1 actively inhibits the oxidative and promotes the fermentative 
metabolism of glucose under hypoxic conditions. 
5.1.1 Interplay between HIF-1 and c-MYC in glycolysis of cancer cells 
Besides HIF-1, c-MYC also plays a key role in the regulation of the glycolytic 
substrate flux. c-MYC, a proto-oncogene, belongs to the family of basic helix-loop-helix 
(bHLH)/leucine zipper (LZ) transcription factors. It heterodimerizes with other transcription 
factors like MAX or MAD and binds to the DNA consensus core palindrome: CACGTG. The 
complex of c-MYC with this palindromic E-box is involved in cell proliferation, 
differentiation and apoptosis [152-154].  
Multiple mechanisms for HIF-1 to counteract c-MYC function in normal cells have 
been reported. In cancer cells c-MYC is frequently overexpressed. It has been shown that 
overexpressed c-MYC is able to synergize with HIF-1 in the regulation of genes that alter 
metabolism and angiogenesis in human cancer. Using human P436-6 Burkitt’s lymphoma 
cells with conditional overexpression of human c-MYC upon tetracycline withdrawal, Kim et 
al. demonstrated that c-MYC and HIF-1 cooperatively enhanced the expression of pyruvate 
dehydrogenase kinase 1 (PDK1), hexokinase 2 (HK2) and VEGF genes. Furthermore, this 
HIF-1/c-MYC cooperativity promoted glycolysis (HK2 induction) while slowing respiration 
and oxidative metabolism (PDK1 induction) in parallel. The authors further surmised that the 
Warburg phenomenon might result from the cooperation between HIF-1 and overexpressed c-
MYC signaling events [98].  
Besides such mutually supportive HIF-1/c-MYC interaction, the antagonism between 
HIF-1 and c-MYC in tumorigenesis has been also evidenced [155]. Displacement of c-MYC 
by HIF-1 is feasible, since the HIF-1 consensus binding site (5’-G/ACGTG-3’) is almost 
identical with the c-MYC E-box (5’-CACGTG-3’). A study by Koshiji and colleagues 
showed HIF-1 was found to antagonize c-MYC targeted p21(cip1) gene, encoding a key 
cyclin-dependent kinase inhibitor. HIF-1α was able to actually activate c-MYC repressed p21 
gene transcription by displacing MYC binding from the promoter and consequently triggered 
cell cycle arrest rather than accelerated proliferation. Additionally, they reported that the HIF-
1α could suppress the c-MYC-activated TERT and breast cancer 1 (BRCA1) gene expression 
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[156]. HIF-1 is also implicated in promoting genetic instability by decreasing the level of 
MutSα, a MSH2-MSH6 complex recognizing DNA mismatches, via counteracting with c-
MYC [157]. Finally, Mazure et al. reported that HIF-1 and c-MYC could competitively 
modulate the activity of the rat α–fetoprotein (afp) gene through targeting the same 5’-
CACGTGGG-3’ site, located at -3625 to -3619 upstream of the transcription initiate site. In 
this case, both transcription factors confer opposite effects regarding afp gene regulation: 
HIF-1 down-regulated, whereas c-MYC up-regulated afp gene transcription in hypoxic human 
hepatoma cells (HepG2) [158].  
5.1.2 Lactate dehydrogenase A (LDHA) 
As elaborated above, most of the ATP in cells is produced through the complete 
oxidation of glucose to CO2 and H2O. However, ATP can also be gained via the incomplete 
breakdown of glucose to pyruvate. Under anaerobic conditions, pyruvate is further reduced to 
lactate by LDHA, with the necessary electrons coming from NADH. This leaves the oxidized 
NAD+ as another product, which in turn, re-fuels the glycolytic pathway as long as a strong 
incoming flux of glucose demands it. Mammalian lactate dehydrogenase (LDH) is composed 
of M(uscle) and H(eart) subunits. While the M subunits are encoded by LDHA, H subunits 
are encoded by LDHB. In this work, we focus on human lactate dehydrogenase A (LDHA), a 
known HIF-1 target and important player in carcinogenesis. Given the mutually antagonistic 
relationship between glycolytic and mitochondrial function, silencing of LDHA by short 
hairpin RNAs was found to stimulated oxidative phosphorylation and to decrease the 
mitochondrial membrane potential as expected [159]. LDHA is also co-targeted gene by c-
MYC and HIF-1. Within the promoter of mouse LDHA there are two conserved functional 
HIF-1 binding sites (-72 to -65 and -81 to -86; position always given in reference to the 
transcription initiate site). Works in the mid-90’s determined the HRE at -72/-65 to act as a 
very strong HIF-1 binding site, whereas the HRE at -81/-86 interacted with HIF-1 rather 
poorly [87, 93].  Later, Shim et al. documented that overexpressed c-MYC was able to 
transactivate the rat LDHA promoter by direct binding to two CACGTG palindrome 
sequences (-78/-83 and -175/-180), which are highly conserved in the 5’ flanks of mouse, rat 
and human orthologs. Mutation of either of these E-boxes abrogated this c-MYC dependent 
activation. Additionally, the authors briefly mentioned that overexpression of upstream 
stimulatory factor (USF), another member of the bHLH/LZ transcription factor family, was 
also able to bind to both E-boxes and stimulate LDHA promoter activity although only half as 
efficiently as overexpressed c-MYC [160]. These results indicated that both c-MYC and USF 
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transcription factors can activate LDHA gene expression and aid in switching cancer cells 
from oxidative to glycolytic sugar consumption [161]. 
 
5.2 HIF-1 and cell survival/apoptosis 
5.2.1 Apoptosis and BCL-2 family proteins 
Apoptosis (programmed cell death) plays an essential role in development and tissue 
homeostasis. The characteristics of apoptosis are cell shrinkage, chromatin condensation and 
DNA fragmentation. Apoptosis is tightly regulated by the activation of the aspartate-specific 
cysteine protease (caspase) pathway. There are two pathways to activate caspases: one is 
dependent on mitochondria (receptor-independent), whereas the other starts through the 
interaction of a death receptor with its ligand (e.g. Fas receptor signaling pathway) [162]. Pro- 
and anti-apoptotic factors of the BCL-2 family regulate the mitochondrial pathway. BCL-2 
was originally discovered as a proto-oncogene in follicular B-cell lymphoma and was later 
identified as the mammalian homolog to the apoptosis repressor CED-9 in C. elegans [163]. 
To date, various BCL-2 family members have been identified in mammalian cells. All these 
members contain between one to four BCL-2 homology domains (BH1-4). According to their 
structure and function, BCL-2 family members are currently classified into 3 categories: 1) 
anti-apoptotic members, such as BCL-2, BCL-XL, BCL-W, MCL-1 and A1, which prevent 
cell death triggered by various stimuli; 2) pro-apoptotic members, such as BAX, BAK, BOK 
and BCL-XS, which all inhibit the activity of anti-apoptotic proteins to promote cell death; 3) 
“BH3-only” pro-apoptotic members including BIM, BIK, BNIP3, BNIP3L with BH3 and 
transmembrane (TM) domains, in contrast, BID, BAD, NOXA with an unusually short BH3 
domain [164, 165].  
Once the intrinsic apoptotic pathway is triggered, two pro-apoptotic factors BAX and 
BAK translocate to the mitochondria to initiate the release of cytochrome c (CYTc) from the 
intermembrane space into the cytosol. CYTc release leads to mitochondrial changes, such as 
the opening of the mitochondrial permeability transition pore (MPTP), a reduction of the 
membrane potential ΔΨm and an increased production of reactive oxygen species (ROS). The 
main apoptotic pathway resumes upon binding of the liberated CYTc to the apoptotic protease 
activating factor 1 (APAF-1) in the cytosol. Next, APAF-1 proteolytically cleaves caspase 9, 
which in turn cleaves and activates caspases 3 and 6, leading to apoptosis [166, 167]. The 
anti-apoptotic proteins BCL-2 and BCL-XL prevent CYTc release from mitochondria and, 
thereby, preserve cell survival whereas pro-apoptotic proteins trigger release of CYTc, MPTP 
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(pore) opening, caspase activation and initiation of apoptosis. That way, abundance and type 
of BCL-2 family members determine whether cells will undergo apoptosis or survive 
exposure to harmful agents or developmental reprogramming decisions. 
5.2.2 Bcl2/adenovirus EIB 19kD-interacting protein 3 (BNIP3) 
The pro-apoptotic mitochondrial protein BNIP3 was first identified in a yeast two-
hybrid screen as interacting partner of the adenovirus E1B19K protein. It contains a single yet 
atypical BCL-2 homology 3 (BH3) domain together with a transmembrane (TM) domain and 
thus belongs to the BH3-only subfamily of BCL-2 protein family. As homodimer, BNIP3 
predominantly localizes to the outer membrane of mitochondria [164]. The TM domain is 
required for the mitochondrial localization of BNIP3, the dimerization and the pro-apoptotic 
activity. Ray et al. reported that BNIP3 could heterodimerize with anti-apoptotic factors BCL-
2/BCL-XL via N-terminal regions and TM domain, which also induces cell death [168, 169]. 
Accumulation and activation of BNIP3 induce a form of cell death that shows features of both 
necrosis and apoptosis (Fig.4). However, unusually for a BH3-only protein, death occurs 
independently of the BH3 domain and is critically dependent on a C-terminal transmembrane 
domain [164]. In hypoxic cells kept at neutral pH, BNIP3 was found loosely attached to 
mitochondria whereas the protein became more tightly associated with the organelle once 
hypoxia was accompanied with acidosis. Under these conditions, BNIP3 sparks DNA 
fragmentation and enhanced formation of the mitochondrial pore transmembrane permeability 
(MPTP) assembly [170]. The BNIP3-induced necrosis-like cell death is associated with 
opening of the MPTP, the complete breakdown of the proton electrochemical gradient and the 
spiking generation of ROS. As such, BNIP3-induced cell death is actually independent of 
CYTc release from mitochondria, caspase signaling and the nuclear translocation of AIF, a 
mitochondrial flavoprotein [171].  
Besides the induction of apoptotic and necrotic-like cell death pathways, there is 
mounting evidence that BNIP3 also plays a critical role in the hypoxia-triggered autophagy of 
cells whereby the protein actually aids in cell survival, not death [172, 173]. To respond to 
stresses, such as nutrient deprivation and hypoxia, autophagy or “self digestion” is a well-
conserved survival strategy across many human cancer cell lines and is in vivo considered as a 
key player of promoting tumor progression [172, 173]. During this “self-digestion”, 
macromolecules and entire organelles are degraded in autophagosomes followed by 
regeneration and recycling of the building blocks for upcoming syntheses which process with 
reduced energy expenditures. Different cells might respond to oxygen deprivation via 
alternate autophagy pathways and some cascades are able to be proceed even in the absence 
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of HIF-1 and BNIP3 [174]. Nonetheless, hypoxia has been worked out to spark autophagy in 
many cells via the HIF-1 mediated induction of BNIP3 and the factors downstream signaling 
onto the highly conserved coiled-coil BH3-only protein BECLIN-1 [175]. A direct physical 
interaction between BECLIN-1 and the anti-apoptotic proteins BCL-2 and BCL-XL normally 
inhibits autophagy and shifts the fate of dying cells towards the ATP-costly apoptosis [176]. 
Several recent studies, however, established hypoxic signaling as necessary stimulus to drive 
cells, through the pronounced and HIF-1 mediated induction of BNIP3 and its homologe 
BNIP3-like (BNIP3L, also known as NIX), into autophagy by way of  releasing BECLIN-1 
from the BCL-2/BCL-XL complexes [172, 177]. BNIP3 and BNIP3L confer this switch due to 
their direct competition with BECLIN-1/BCL-2 and BECLIN-1/BCL-XL complexes for the 
binding of BECLIN-1  [178] (Fig. 4).  
 
  
 
Figure 4 Model for BNIP3-mediated apoptosis and autophagy. BNIP3 is hypoxically induced by HIF-1 and 
stabilized by acidosis. Subsequently BNIP3 homodimerizes, translocates and integrated into the mitochondrial 
outer membrane resulting in mitochondrial dysfunction e.g. the loss of Δψm and increased production of ROS. 
Once BNIP3 signaling is activated, cells may undergo three different fates: a) the main apoptosis pathway in 
which BAX/BAK, CYTc and caspases participate; b) necrosis, characterized through the opening of the MPTP, 
the collapsing electrochemical gradient across the inner mitochondrial membrane (ΔΨm) and the resulting 
generation of ROS and c) autophagy as a survival mechanism during BECLIN-1 is released from the BCL-
2/BCL-XL complexes [179]. 
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5.2.3 Hypoxia and acidosis: triggers for BNIP3-mediated cell death in human cancer cells  
Severe hypoxia is an established stimulus to induce apoptosis by slowing and eventual 
inhibition of the ETC in the inner mitochondrial membrane. This reduction of electron flux 
causes a decrease in the membrane potential, subsequent generation of ROS and a declining 
capacity to produce ATP through the oxidative phosphorylation reactions taking place in the 
ETC. As mentioned above, hypoxic (pO2 < pC) cells will also switch from oxyregulated to 
oxyconforming respiration and from an oxidative to a fermentative (glycolytic) mode of 
metabolism. This switch results in up-regulated import and consumption rates of glucose and 
an elevated production of lactic acid (see section 4.2 HIF and glucose metabolism). Together 
with the pronounced ATP hydrolysis rate (i.e. ATP hydrolysis > ATP production rate) in 
severely hypoxic cells, dissociation of lactic acid to lactate and protons is the main source of 
protons during hypoxic stress. Tumor needs to cope with such ensuing acidification and 
preserve a neutral intracellular pH (pHi) that is compatible with cell growth and survival (see 
[180] for review). Acid export leads to a reduction of extracellular pH (pHe) that it is typical 
for the tumor microenvironment and commonly associates with a more invasive phenotype. 
Additionally, substrate flux through the TCA produces a high amount of CO2 in cancer cells 
which diffuses through the plasma membrane and contributes to a further fall in pHe. Hypoxic 
tumor cells respond to this acidic microenvironment by inducing carbonic anhydrase IX 
(CAIX), again via HIF-1 transactivation. CAIX catalyzes the reversible hydration of CO2 + 
H2O ? HCO3- + H+ in the extracellular space. The resulting bicarbonate ions are imported by 
bicarbonate transporters such as anion exchangers (AEs) and the Na+/HCO3- co-transporter 
and, thus, contribute in neutralizing the intracellular pH, while the CAIX derived protons 
remain outside only to further aggravate the pericellular acidosis [180].  
Outside of cancer, hypoxia and acidosis have also been implicated in ischemic 
myocard. In cardiac myocytes, it was shown that acidosis was required to induce apoptosis 
under hypoxia. Kubasiak et al. reported that hypoxia, when combined with acidosis, triggers 
BNIP3-mediated cell death in cardiac myocytes. In contrast, hypoxia alone did not activate 
cell death in neonatal cardiac myocytes. During the dual insult, hypoxia enhanced the 
expression of BNIP3 mRNA and protein, whereas acidosis was necessary to stabilize the 
BNIP3 protein and increase the association of its homodimers with mitochondria [181]. 
Besides energy deprivation and acidosis, radical formation, in particular, ROS production, 
contributes to hypoxia induced apoptosis as well. ROS are known to activate caspase-9 in a 
CYTc independent manner, which causes hypoxic cell death in epithelial cells [182].  
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When focusing on its pro-apoptotic/pro-autophagic role in cancer, it is worth noticing 
that BNIP3 protein is highly expressed in some tumors, including breast, lung and cervix 
cancers, and undetectable in normal tissue [164]. A strict requirement of HIF-1 to induce 
BNIP3 mRNA and protein levels in O2-deprived cells (see section 4.2.3 HIF-1 target genes), 
was substantiated when Sowter et al. utilized RCC4 renal clear cell carcinoma cells. RCC4 
cells are deficient for VHL, therefore, HIF-1α and HIF-2α are constitutively active. As a 
result, BNIP3 protein is abundantly expressed even in normoxic RCC4 cells. Reintroduction 
of VHL into the RCC4 genome led to the typical profile of a normoxic HIF-1α degradation 
and the subsequent absence of BNIP3 in oxygenated cells [101]. Similarly, treatment of 
chinese hamster ovary (CHO-K1) cells with “hypoxia mimetics”, such as the transition metal 
CoCl2 and the iron chelator deferoxamine mesylate (DFO) (see section 4.2.1 Structure of 
hypoxia-inducible factor and section 4.2.2 HIF-1 signaling pathway), was able to induce NIP3 
expression [183]. Therefore, BNIP3 has clearly been characterized as HIF-1 controlled 
hypoxia-induced target gene in cancer. One of two BNIP3 HRE sites (-246 from translation 
start site) was determined to function as direct HIF-1 binding site by electromobility shift 
assay [90]. Over-expression of BNIP3 in breast cancer cells (MCF7) induces apoptosis by 
binding to and inhibiting the anti-apoptotic proteins BCL and BCL-XL. It has further been 
reported that hypoxia-induced BNIP3 expression inversely correlates with metastatic potential. 
Ductal carcinoma in situ (DCIS) of the breast is an early, non-invasive lesion and the 
prognosis is associated with necrosis and cell death within the tumor. The analysis of DCIS, 
as well as of benign and invasive breast tissue unearthed the correlation between high 
expression of BNIP3 and high-grade necrosis in DCIS [184]. Silencing of BNIP3 with siRNA 
in breast cancer cells was sufficient to evade cell death and enhance metastatic survival [185]. 
5.2.4 Gaining resistance to apoptotic stimuli 
Cells can also acquire resistance to hypoxia-mediated cell death.  As first described by 
Graeber et al. [9], hypoxia can select for the expansion of apoptosis-defective cell variants, 
for example those that acquired loss-of-function mutations in tumor suppressor genes such as 
p53 (reviewed by [186, 187]). P53 has been implicated in controlling apoptosis of hypoxic 
cells due to its ability to stimulate BNIP3L via the recruitment of the coactivator CBP (CREB 
binding protein) [188]. Other than through p53 loss-of-function, acquisition of cell death 
resistance of hypoxic cells can also process either at mitochondrial or cytosolic compartments. 
Regarding mitochondria, the translocation of BAX to these organelles can be suppressed, and 
consequently, less CYTc can be released in resistant cells. Regarding the cytosol, rat kidney 
proximal tubule cells (RPTC) were found to induce the inhibitor of apoptosis protein 2 (IAP-2) 
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during anoxia via HIF-1 independent mechanisms [189]. Such increased concentration of 
IAP-2 in the cytosol can repress the release of CYTc from mitochondria, which again 
facilitates survival of O2 depleted cells [190]. Both alterations of the pathway can therefore 
endow cells to evade incoming apoptotic stimuli. 
Another way to escape apoptosis induced by hypoxia and to gain hypoxia tolerance is 
through inhibiting the expression of BNIP3. Several mechanisms of epigenetic silencing of 
the BNIP3 gene are known. Various studies on pancreatic cancer showed that 
hypermethylation of CpG islands in the region of the transcription start site of BNIP3 
promoter silenced BNIP3 gene expression in the most pancreatic cancer. This CpG 
methylation of BNIP3 contributed to resistance to hypoxia-induced cell death in pancreatic 
cancer cells. Re-expression of BNIP3 by treatment with DNA methyltransferase inhibitor 5-
aza-deoxycytidine (5-aza-dc) was able to restore hypoxia-mediated cell death [191-194]. 
Other studies demonstrated that BNIP3 silencing via DNA methylation occurred not only in 
pancreatic cancer but also in many colorectal, hematopoietic and gastric cancers. In addition, 
the authors showed that histone deacetylation also played a role in silencing BNIP3 [195-197]. 
Beyond epigenetics, several growth factors including epidermal growth factor (EGF) and 
insulin-like growth factor (IGF) can also protect from BNIP3 induced cell death in hypoxic 
epithelial cells [90]. On the other hand, BNIP3 protein level was reported to be dramatically 
increased in breast and lung cancers compared to the equivalent normal tissue. Thus, 
epigenetic silencing of BNIP3 expression occurs cell-/tissue-type specifically and it remains 
an open question how BNIP3 silencing influences the phenotype of these tumors.  
5.2.5 HIFs’ role in apoptosis: crosstalk with p53 
HIFs’ role in controlling cell death appears multifaceted and cell-type specific. 
Carmeliet et al. reported that HIF-1α induces apoptosis in wild-type (HIF-1α +/+) embryonic 
stem (ES) cells [198], whereas Akakura et al. demonstrated boosted survival and proliferation 
of pancreatic cancer cells under hypoxia and glucose deprivation upon the constitutive 
expression of HIF-1α and the enhanced expression of the downstream effectors GLUT-1 and 
aldolase A [199]. HIF-1 can exert control in both p53-independent and p53-dependent ways 
of apoptosis. p53-independent initiation of apoptosis by hypoxic signals commonly involves 
BCL-2 family proteins and other unknown factors [138, 200]. The much debated HIF/p53 
crosstalk was inspired by early reports in which HIF-1α was thought to function as stabilizer 
of p53 and, that way, to contribute in the induction programmed cell death [137]. 
Subsequently, HIF-1α was shown to directly bind to the p53 ubiquitin ligase MDM2 both in 
vivo and in vitro and to exert its stability-enhancing effect on p53 [201]. However, other 
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reports supported a direct interaction of HIF-1α with wildtype, but not tumor derived mutant, 
p53, whereby the  DNA binding region of p53 was in direct contact with the ODD domain of 
HIF-1α [202]. Whether or not HIF-1 truly underlies the oxygen-regulated induction of p53 
has been questioned by Wenger and colleagues, since hypoxia, that activated HIF-1-
dependent gene expression as well as HIF-1α protein, induced neither p53-dependent gene 
expression nor p53 protein [203]. One also has to bear in mind that HIF-1 signaling has 
evolved to sense hypoxic pO2, while the p53 pathway commonly engages at a more severe, 
anoxia approaching, level of O2 depletion [203, 204]. Thus, under physiological or in vivo 
conditions, the two cascades might complement, rather than overlap, one another to regulate 
cellular responses under a wider pO2 spectrum. 
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5.3 Upstream stimulatory factors (USFs) -- bHLH/LZ transcription factors 
5.3.1 Structure and isoforms of USFs 
Upstream stimulatory factor (USF)/major late transcription factor (also called MLTF), 
initially identified from HeLa cell nuclei and purified as heterogeneous complex, consists of 
two USF isoforms with molecular masses of 43 and 44kDa, that were referred to as USF1 and 
USF2a, respectively [205, 206]. USF1 and 2a are products of two different genes and each 
contain a conserved basic helix-loop-helix domain (bHLH) and a leucine zipper (LZ) motif at 
the C-terminal region. Two transcriptional activation domains, located at the N-terminal 
region of USF1 (residues 26-39 and 93-156), are required for full activation [207]. The basic 
region is required to interact with CANNTG E-box core consensus sequence, whereas HLH 
and LZ motif are involved in factor dimerization. The USF-specific region (USR), located N-
terminally from the basic region and highly conserved in USF1 and USF2a, is essential for 
transcription activation [208, 209]. Several additional domains adjacent to the N-terminus are 
less conserved in USF1 and USF2a. These regions include domain M, found only in USF1 
and domains G and O of USF2a (Fig.5) [210].  
A novel splice form of USF1, termed USF1/BD, has been observed. Compared with 
USF1 wild type, USF1/BD lacks the N-terminal transactivation domain due to the excision of 
exon 4. USF1/BD is localized in the nucleus, where it heterodimerizes with wild type USF1. 
Its DNA binding activity, however, repressed the promoter activity of human angiotensinogen 
gene [211]. Another USF2 splice variant, termed USF2b, can heterodimerize with other USF 
proteins. As a heterodimer, USF2b can bind to E-boxes but, due to the missing exon 4 with its 
positive-regulatory domain, fails to activate gene expression. Thus, USF2b contains 
functional USR and the negative-regulatory domain. It functions as a dominant negative 
regulator of USF-mediated gene expression [212]. It has been reported that two truncated 
USF1 and USF2 variants, namely mini-USF1 and mini-USF2, which contain intact 
dimerization and DNA-binding domain (bHLH/ZIP domain), might result from the use of 
internal translation initiators [205, 210]. These mini-USF proteins behave as transdominant 
inhibitors and are expected to down-regulate USF activity [213] (Fig. 5). 
Although USF1 and USF2 are ubiquitously expressed, ratios of USF homodimers or 
heterodimers vary according to cell types [205]. Viollet et al. described that USF1/2a 
heterodimer acts in vivo as main constituent of the cells’ USF binding activity in rat liver 
tissues and human cells (hepatoma cells HepG2, megakaryoblastic cells UT7 and cervical 
cancer cells HeLa) [210].  
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Figure 5 Schematic representation of human USF proteins. The family includes: major late transcription 
factor (MLTF)/hUSF1, two spliced variants hUSF2a and hUSF2b and two truncated USF species: mini-USF1 
and mini-USF2. Percentage indicates the identities among the conserved domains of USF1 and USF2a. Arrows 
define the sequences encoding specific domains in either USF1 or USF2. bHLH-ZIP: basic helix-loop-helix-
leucine zipper [210] 
5.3.2 General functions of USFs 
USFs are ubiquitously expressed and key regulators of gene regulation networks, 
including stress and immune responses, control of cell cycle, cell proliferation and glucid-
lipid metabolism [214]. USFs modulate gene transcription through direct binding to E-box 
cis-elements [215] containing the core sequence CANNTG. In most cases, the two central 
nucleotides NN are either GC or CG. They can seldom be either CA or TG. USFs exert a 
higher binding affinity for the CACGTG palindrome than the CATGTG motif, the latter also 
being referred to as M-box. Additionally, the nucleotides flanking the CANNTG core 
sequence can also contribute to selective recognition of E-box binding protein. Different 
studies on the binding sites of USF1 regulated promoters suggested that the importance of 
3’AC residues are important for USF1 to selectively recognize a CACGTG E-box palindrome 
[216-218]. Modification within the E-box, including methylation at the CpG site (CACpGTG), 
may negatively regulate gene expression. Several observations have shown that USF can not 
only bind to classical E-box elements but also directly to alternative sites, so called 
pyrimidine-rich initiator elements (5’YYCAYYYYY3’) adjacent to the transcription start site 
in various promoters including those of HIV-1 and Ad-ML. This physical interaction with 
initiator elements results in a drastic enhancement of basal transcription level [219, 220].  
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USFs’ physical and functional interaction with other general or cell specific 
transcription factors, such as specificity protein 1 (SP1), polyoma virus enhancer activator 3 
(Pea3) and metal-regulatory transcription factor 1 (MTF1) leads to a cooperative 
transcriptional regulation of several genes including BCL2-associated X protein (BAX), 
metallothionein-I (MT-1) and deoxycytidine kinase (dCK) [221-223]. In addition, USFs are 
known to interact with transcription factors of the basal machinery, including TFII-I, TFIIB, 
TFIID, TFIIE and TATA-binding protein (TBP) associated factor (TAF), upon which a 
synergistic activation of the TATA-box directed transcription unfolds [218, 224, 225]. To date, 
different co-factor models for the transcriptional activity of USF in different cell type are 
considered. Breen and Jordan showed that USF2 activates the mammalian F1F0ATP synthase 
α–subunit (ATPA) gene through an initiator element in the core promoter and that this USF2 
dependent transcriptional activation is mediated by p300 [226]. Activity of the promoter of 
the human telomerase reverse transcriptase (TERT) gene was enhanced by USF in hTERT 
positive immortal cells, again due to recruitment of the co-activator p300 [227].  
The roles of USFs and USF target genes extend beyond adjustments within the general 
transcription machinery. To this end, USF-regulated genes have been implicated in the 
immune response following viral and bacterial infections. Here, USF1 participates in both the 
humoral-antibody response and the cell-mediated non-specific immune response [212, 228]. 
Secondly, USFs are involved in controlling cell cycle through the regulated expression of 
different cyclin and cyclin-dependent kinase (cdk) genes, like CDK4, CYCLN B1 and CDK1 
[229, 230]. Thirdly, USFs regulate mediators of cell proliferation like TERT, TGFβ2 and 
IGF2R [227, 231]. A final important function of USFs lies in the coordinated control of the 
glucid and lipid metabolism through regulating genes encoding insulin growth factor-binding 
protein 1 gene (IGFBP1), glucokinase [232, 233], L-pyruvate kinase gene [213] and fatty acid 
synthase [234]. 
Different signal transduction pathways may modulate USF1 transcriptional activity 
including growth factor stimuli, irradiation by ultraviolet (UV) light, heavy metals, oxidative 
stress, virus infection and DNA damage. For example, phosphorylation of USF1 is required to 
enhance the factors’ transcriptional activity. Several kinase pathways are involved in the 
phosphorylation of USF1. These cascades include the p38 stress activated kinase pathway 
[235], the nitrogen-activated protein kinase (MAPK) kinase and tyrosine kinase pathway 
[236], the protein kinase A and C pathways [237] and the CDK1 pathway [238]. 
Posttranslational phosphorylation increases USF1 DNA binding activity and allows the 
modulation of USF mediated gene regulation. 
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5.3.3 USFs: transcriptional activators and repressors  
USFs were originally identified as activator of the adenovirus major late promoter in 
HeLa cells. Early studies also unravelled these proteins also to act as essential factors for the 
efficiently enhanced transcription from the adenovirus major promoter via binding to the 
GGCCACGTGACC sequence located between positions -63 and -52 relative to the  
transcription start site [218, 239, 240]. Thus, USFs were originally considered as 
transactivating factors. Unexpectedly, more and more evidence suggested that USFs might act 
as transcriptional repressors as well. For example, Carter et al. reported that overexpressed 
USF1 could effectively inhibit immunoglobulin heavy chain (IgH) enhancer activity in mouse 
embryonic fibroblast cells (NIH3T3). According to the authors, this inhibition was correlated 
with the lack of a strong activation domain within USF1 and absence of other IgH enhancer 
E-boxes in the vicinity of the μE3 E-box [241]. Additional studies showed that USF1 is able 
to suppress the transcriptional activity of different genes by competing with positive-
transacting factors. In this regard, USF1, in rat liver nuclear extracts, other than the AhR/Arnt 
(aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator) complex could in 
vitro constitutively bind to the xenobiotic responsive element (XRE) in the promoter of the 
rabbit cytochrome gene P450 1A1 (CYP1A1). Overexpression of USF1 antagonized the 
induction of the rabbit CYP1A1 gene by the AhR/Arnt complex [242]. As possible 
mechanism of such negative effect on a gene’s activity, USF1 and 2a were found to bind to 
two E-boxes within the promoter of the cytochrome P450 family 19 (CYP19) gene, which 
prevents the assembly of a stable transcription complex and inhibits of CYP19 promoter 
activity [243]. Chen et al. showed that a dominant negative USF1 construct, which lacked the 
basic DNA-binding domain but retained the dimerization domain, repressed the promoter 
activity of the aortic preferentially expressed gene-1 (APEG-1). Wild type USF1, but not 
USF2a, transactivated APEG-1 activity leading to differentiation of vascular smooth muscle 
cells [244]. A study on the rat gene encoding the plasminogen activator inhibitor 1 (PAI-1) 
reported that overexpressed USF2a inhibited rat PAI-1 gene expression via direct binding to 
E-box in hepatocytes [245]. 
5.3.4 Differential role of USF1 and USF2 in transcriptional activity 
The homozygous USF-deficient mice models permitted to investigate the differential 
transcriptional role of USF1 and USF2. These studies also clarified the essential role of USFs 
for the embryonic development. Utilizing USF-1-/- and USF2-/- single homozygous as well as 
USF1-/-/USF2-/- double homozygous mice, this work demonstrated that USF-1-null mice are 
viable, fertile and essentially normal, whereas USF2 knockout mice displayed high mortality 
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rate and growth defects. Sirito et al. reported on the asymmetrical cross-regulation of USFs 
proteins in fetal fibroblasts isolated from USF1-/- and USF2-/- mice. According to these 
authors, USF1 null mice exhibited an elevated level of USF2, which might compensate for the 
USF1 defect. In contrast, USF2 knockout mice had a reduced level of USF1 and displayed 
decreased fertility [246]. Two studies by Vallet and colleagues on the differential role of 
USF1 and USF2 in the transcriptional response of liver genes to glucose demonstrated that the 
USF1/USF2 heterodimer represents the major USF activity in hepatocytes that confers the 
glucose-induced expression of the gene encoding the glycolytic L-type pyruvate kinase (L-
PK). In wildtype rodents, both USFs participate in carrying out a regulated normal glucose 
response. In USF1-/- mice, however, a normal transcriptional response of the L-PK gene to 
glucose is sufficiently sustained by the USF2, even though the USF2 homodimer exhibits 
only 40-50% of residual USF binding activity. Conversely, in USF2-/- mice, the USF1 
homodimer was shown be less efficient than the USF1/2 heterodimer for promoting L-PK 
gene expression in response to glucose. The authors suggested that USF dimers per se have 
different transactivating properties as provided by the distinct N-terminal activation domain of 
USF1 and USF2 [247]. Interestingly, this study did not observe altered liver expression of 
USF1 in USF2 null mice or, conversely, altered USF2 gene expression in USF1 null mice 
[248]. A weak transcriptional activity of USF1 was also described by Desbarats et al. [249]. 
These authors suggested that the distance between the E-box and the transcriptional start site 
might influence the transactivation efficacy of USF1. In addition, the different transcriptional 
activity between USF1 and USF2 might stem from their divergent N-terminal transcription 
activation domains [205], which in turn, might result in distinct interactions of USF1 and 
USF2 with other regulatory factors [225, 250-252]. Work by Allen and colleagues on the 
USF1 mediated regulation of PAI-1 in human keratinocytes showed that USF1 transcriptional 
activity might be modified by a transcriptional co-repressor or a co-activator, which, in turn, 
depends on the abundance of TGF-β1 [253]. In addition, USF1 transcriptional effects could 
be not only gene-/and cell- type dependent but also E-box specific. 
5.3.5 Antiproliferative effects of USF on cancer progression 
USFs and c-MYC are both bHLH/LZ transcription factors and target the same DNA 
binding site, the CACGTG E-box palindrome. c-MYC plays an important role in various 
processes of cellular transformation and proliferation whereas USFs often display 
antiproliferative properties. This antagonism between c-MYC and USFs on cellular 
transformation was demonstrated by in vivo experiments with rat embryo fibroblasts. The 
DNA binding and transactivation domains of USFs were required for this antagonism [208, 
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254]. The USF loss of function in many cancer cell lines implied that USFs might suppresses 
tumor progression. This transcriptional effect of USFs is also cell type context dependent. 
Although HeLa cervical carcinoma and Sao-2 osteosarcoma cells had similar endogenous 
USF protein levels und DNA binding activities. USFs in HeLa cells are transcriptionally 
active leading to growth inhibition, while USFs in Sao-2 lack transcriptional activity and do 
not mediate a slowdown in the proliferation rate of these cells [209]. The authors developed a 
model in which USFs’ antiproliferative activity was shown to be controlled by interaction 
with a coactivator via the USF specific domain (USR). In HeLa cells, the USR domain 
exhibits a dual function. It was sufficient for USF2 to show transcriptional activity at a 
promoter containing an initiator element. In case of a promoter lacking such initiator element, 
cofactor binding to the USR triggered a conformational change to expose the activation 
domain in HeLa cells. In Sao-2 cells, however, this cofactor might be missing and thus USFs 
remained inactive [209]. Han et al. confirmed this cell type-dependent USF transcriptional 
activation in their study on human topoisomerase IIIα in HeLa and Sao-2 cells [255]. 
Inactivity of USF2 is not only restricted to Sao-2 cells but also extends to some lines of breast 
cancer cells. Ismail et al. documented that USF1 and 2 exhibited strong transcriptional 
activities in the non-tumorigenic human breast cancer cells, yet were completely inactive in 
transformed breast cancer cells. Loss of USF function in breast cancer cells has been 
implicated during carcinogenesis whereas c-MYC overexpression favors a rapid proliferation 
[256]. IGF2R (mannose 6-phosphate/insulin-like growth factor 2 receptor), a USF2 specific 
target, was transactivated by overexpression of USF2 only in non-tumorigenic mammary 
epithelial cells (MCF-10A) but not in breast cancer cells (MCF7 and MDA-MB231). The 
authors suggested that the defect in USF2 function in breast cancer cell might contribute to 
the down-regulation of IGF2R and some cofactors might be also involved in this regulation 
[257]. 
Besides this antagonism between USFs and c-MYC, both factors can also act in 
concert with regard to gene regulation. USF and c-MYC both up-regulate the promoter 
activity of CXCR4, a coreceptor for T cell-tropic HIV-1 entry [258]. Another example, the 
gene for cell cycle and cell growth control factor CDK4 has been identified as being co-
regulated by c-MYC and USF2. In non-tumorigenic breast epithelial cells, c-MYC and USF2 
cooperatively activate the transcriptional activity of CDK4, whereas expression of this gene is 
independently controlled by both transcription factors in breast cancer cells. The authors 
suggested that this cooperation or co-stabilization of c-MYC and USF at the CDK4 promoter 
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existed only in normal cell but not in cancer cells due to loss of USF function in the latter 
[230]. 
  
5.4 Melanoma: UV signaling in a hypoxic microenvironment 
The incidence of malignant melanoma worldwide is increasing faster than any other 
cancer [259]. Although melanoma accounts for only 10% of all skin cancers, it is the most 
biologically aggressive common skin cancer and leads to 80% of skin cancer related deaths 
[260]. Particularly prone to develop this cancer is fair-skinned Caucasians who freckle or 
sunburn easily without tanning. Consequentially, melanoma incidence peaks in Australia, 
New Zealand, Scandinavia and Northern America [261]. The only effective treatment of 
melanoma is the wide margin surgical excision of the lesion during the early phase of the 
disease. Advanced melanoma is able to metastasize and commonly resistant to conventional 
therapeutic interventions [262]. Triggered by intermittent exposure to the mutagenic qualities 
of the ultraviolet (UV) fraction within the solar spectrum, melanoma can develop via the 
malignant transformation of melanocytes that reside at the dermal-epidermal junction as well 
as in hair follicles (Fig. 6). UV wavelengths range from 200-400 nm and can be further 
subdivided into UVA (320-400 nm), UVB (280-320 nm) and UVC (200-280 nm) bands. 
Unlike UVC, UVA and UVB actually reach the Earth’s surface and harmfully affect exposed 
skin by causing an excess of DNA lesions that overwhelm the cells repair capacity. UVB is 
considered to represent the most carcinogenic waveband and causes two types of DNA lesions: 
pyrimidine (6-4) pyrimidone photoproducts and cyclobutane pyrimidine dimers. Both types of 
lesions can result in genetic mutations such as the C→T or CC→TT transitions. The latter 
transition is the hallmark of UV-induced mutagenesis. Compared with UVB, UVA-induced 
melanoma is not well characterized. However, UVA is also able to mutate DNA, 
predominantly via injuries spawned through the generation of ROS [259].  
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Figure 6 Location of melanocytes in epidermis-dermis junction in the skin.  Melanocytes are cells located in 
the bottom layer (the stratum basale) of the skin’s epidermis and produce dark pigment called melanin to protect 
UV radiation. 
5.4.1 Tanning response: MITF mediated basal and USF mediated UV-induced gene control 
The tanning response of melanocytes is responsible to protect the skin against 
sunburning and UV-induced DNA damage. It centers on the synthesis of the brown-black 
pigment (eu)melanin in specialized organelles termed melanosomes. Mature melanosomes are 
released from melanocytes via exocytosis, transferred to surrounding keratinocytes and 
culminate in the common darkening of the skin during the days following the UV exposure. 
Melanin has a dual photoprotective function in the skin: it absorbs of ultraviolet photons and 
scavenges of ROS. Genes, encoding melanin-synthesizing enzymes, include tyrosinase (TYR), 
tyrosinase-related-protein 1 (TRP-1) and dopachrome tautomerase (DCT) [235]. 
The synthesis of melanin is the result of a complex signaling network involving 
paracrine factors secreted by cutaneous keratinocytes (e.g. α-melanocyte specific hormone, α-
MSH), specific receptors (e.g. melanocortin 1 receptor, MC1R), transcription factors (e.g. i: 
microphthalmia-associated transcription factor, MITF; ii: upstream stimulatory factors, USFs) 
and downstream effector genes directly involved in pigment manufacture (TYR, TRP-1 and 
DCT) [214]. The secreted melanocortin α-MSH, encoded by the pro-opiomelanocortin 
(POMC) gene and liberated through proteolytic processing of the POMC precursor 
polypeptide, is recognized by its cognate heterotimeric G-protein receptor MC1R on the 
surface of melanocytes. This ligand/receptor interaction sets in motion a cAMP signaling 
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cascade which subsequently activates, via the transducing actions of protein kinase A (PKA) 
and the cAMP response element binding protein (CREB), the expression of the melanocyte 
specific form of MITF through activation [263].  
MITF belongs to the bHLH/LZ family of transcription factors. MITF transactivates 
expression of TYR, TRP-1 [263] and DCT genes through binding to M-box (CATGTG) 
sequences in the respective promoter. Therefore, MITF plays a critical role in the basal 
pigmentation of human skin. In addition, it also regulates target genes whose products control 
key aspects of melanocyte differentiation and proliferation, melanosome transport and 
melanoma progression [264]. Recently, the group of Dummer (University Hospital Zurich) 
underscored MITF’s role in supporting tumor expansion by reporting that expression and 
activity of MITF is a key feature in proliferative clones of melanoma cells, while this 
transcription factor was found absent in invasive cohorts of this cancer [265]. Remarkably, 
cAMP signaling is known to stimulate transcription of the HIF-1α gene and some of its 
downstream targets (e.g. VEGF) in a melanocyte-specific and MITF-dependent manner. 
Elevation of HIF-1 abundance is elicited through the binding of MITF to multiple E-boxes 
nestled within the promoter of the human HIF-1α gene. Thus, the presence of a normoxic 
cAMP/MITF/HIF-1/VEGF cascade in melanocytes and melanoma cells might critically 
contribute to aspects of differentiation and progression of these cutaneous neoplasms [266]. 
In contrast to MITF’s control of the basal synthesis of melanin, USFs serve as key 
stress-responsive transcriptional inducers of genes encoding melanin manufacturing enzymes 
(e.g. TYR) in response to UV-stimulation (Fig.7). The UV-induced tanning response in 
melanocytes and melanoma cells is mediated through the p38-stress activated MAP kinase 
pathway. USF1 is phosphorylated at Thr153 by the p38 stress-activated kinase and thus able to 
directly up-regulate POMC, MC1R, TYR, TRP-1 and DCT genes through binding to the same 
E-box as MITF. Indeed, all these genes failed to be activated following UV stimulation in a 
USF-/- melanocyte cell line [267]. However, USF1 function can regulate genes in more than 
one way. Recently, Corre and co-workers identified a novel post-translational modification of 
USF1. They reported that various stimuli including DNA damage, oxidative stress and 
cellular infection, were able to acetylate USF1 on lysine199 in a phospho-T153 dependent 
manner. This two-step post-translational modification of USF1 directs the factor to operate at 
DNA level in a positive or negative fashion. While low level of stress cumulates in the 
phosporylation on Thr153 of USF1 and consequently triggers a positive gene regulation with 
regard to cell cycle control or tanning response. Massive stress results in a phospho-dependent 
acetylation of USF1 in conjunction with a marked down-regulation of targeted genes [268]. 
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Figure 7 Tanning response via MITF and USF-1 signaling pathways in melanocytes. In response to UV 
radiation, USF-1 is phosphorylated on Thr-153 via p38 kinase. Phosphorylated USF1 binds to specific E-box 
within the promoter of TYR, MC1R and POMC leading to gene activation. Besides UV induced melanin 
synthesis, MITF signaling pathway is responsible for basal pigmentation. Binding of the paracrine melanocortin 
α-MSH to MC1R on the surface of melanocytes stimulates a cAMP pathway along with the downstream 
effectors PKA and CREB which together results in the activation of MITF. MITF is key for the basal gene 
expression of TYR, MC1R and POMC, hence responsible for constitutive level of skin pigmentation [214]. 
5.4.2 Oxygen and HIF-1α in skin 
In the skin of mice and humans oxygen levels range from 1.5 to 5% O2 [269-271]. 
Surprisingly, oxygen concentrations even in healthy skin are sufficiently low to stabilize HIF-
1α and result in the up-regulated expression of the HIF-1 targeted carbonic anhydrase IX 
(CAIX) [272] and glucose transporter-1 (Glut-1) marker genes. In clinical and xenografted 
melanoma, even more limited and spatially or temporarily heterogenous oxygen tensions have 
been documented [273]. Hypoxia in these malignant masses often resides in narrow bands of 
cells adjacent to necrotic regions beyond the diffusion capacity of oxygen from blood vessels 
(typically 100–150 μm). Exemplified by the murine B16 cell line, melanoma cells subjected 
to low oxygen levels (1-2% O2/24h) will markedly induce HIF-1α protein and activate HIF-1 
signaling [266]. Moreover, when cultured B16 melanoma cells were exposed to sequential 
rounds of hypoxia and confluence, they progressed from a relatively benign phenotype to a 
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highly malignant and autonomously (i.e. unaffected by serum withdrawal) growing clonal 
variant within weeks [274]. Clearly, deprivation of oxygen in melanomas associates with 
increasingly malignant cell behavior. In this context, the hypoxia/HIF-1α signal is known to 
be required for an efficient melanocyte transformation, particularly in those cases where 
carcinogenesis is driven through a hyperactive AKT oncogene [275, 276]. This line of work 
further elicited the necessity of an active mammalian target of rapamycin (mTOR) kinase for 
the formation of AKT-driven melanomas, potentially through regulation of protein translation 
and HIF-1α activity during mild hypoxia. Conversely, intra-tumoral injection of a HIF-1α 
targeting shRNA-expressing plasmid into B16 intradermal xenografts greatly suppressed the 
growth of this tumor model and linked HIF-1α activity to mass accumulation and progression 
of melanomas in vivo [277]. Victor et al. even noted incidence of migration and invasion of 
wild type uveal melanoma (Mum2B) under normoxic conditions was higher than in HIF-1α 
knockdown Mum2B clones. Therefore, the relative low basal (normoxic) HIF-1α content in 
cells seems to play physiologically important role in contributing to the control of basal 
expression of its target genes including CXCR4, integrin β8 and antiopoietin-like factor [278]. 
5.4.3 Hypoxia/UV crosstalk in melanoma 
Hypoxia and UV induced signaling pathways can interact at DNA level in synergy or 
as antagonists. As elaborated above, hypoxic preconditioning can attenuate UV-induced 
oxidative stress and aid in protecting fibroblasts and keratinocytes against UV induced 
apoptosis [279, 280]. 
Exposure of epidermal keratinocytes to physiological doses of UVB (10-50mJ/cm2, 
equivalent to 0.2-1 minimal erythema doses) identified more than 100 UVB-induced or 
suppressed genes including effectors of angiogenesis, cell cycle, DNA repair, apoptosis and 
many more. For example, a microarray analysis of UVB-regulated genes in normal 
keratinocytes (NHKC) found that VEGF, one of 57 UVB-induced genes, was up-regulated by 
UVB (20mJ/cm2), whereas expression of the angiogenesis inhibitor thrombospondin-1 (TSP-1) 
was suppressed by UVB irradiation [281, 282]. Another study confirmed this finding in UVB 
irradiated HaCaT keratinocytes and proposed that UVB might regulate the balance of 
angiogenesis in keratinocytes by inducing of VEGF expression and repressing of TSP-1 
protein level [283]. Recently, UVB exposure was reported to stimulate HIF-1α expression in 
human keratinocytes. Here, a cytotoxic dose of 200mJ/cm2 of UVB managed to a control 
HIF-1α expression with a biphasic profile--first inhibitory then stimulatory through UV 
mediated ROS generation. The rapid production of cytoplasmic ROS was required for this 
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dramatic decrease of HIF-1α, while the delayed mitochondrial ROS production up-regulated 
HIF-1α. The corresponding UVB induced phosphorylation and accumulation of HIF-1α was 
triggered by p38 MAPK and JNK signaling and mediated through production of 
mitochondrial ROS [284].  
It is worth stressing that skin cells (often keratinocytes) were always subjected to UV 
radiation under non-physiological high oxygen concentrations (air) in gene profiling 
investigations. Not surprisingly, oxidative stress and ROS play a major role in the cellular and 
transcriptomic UV exposure of cells kept in air. Yet, when Matsuda and colleagues subjected 
normal human embryonic fibroblast-like HE49 cells to UVC radiation under physiologically 
hypoxic (5% O2) and artificial normoxic (20% O2) conditions, they found that hypoxic cells 
experienced a lesser build-up of ROS, lesser incidence of apoptosis and enhanced cell 
survival when receiving UV irradiation [279]. Analogously, Xing et al. reported that apoptotic 
rates of UVC irradiated corneal stromal cells were significantly reduced by incubation with 
hypoxia-preconditioned medium compared to normoxic controls. The authors suggested that 
hypoxia preconditioning protected stromal fibroblast and keratinocytes from UV induced 
apoptosis through HIF-1 mediated expression and secretion of protective factors [280]. 
Besides known UV-mediated induction of HIF-1 in keratinocytes, HIF-2α was recently also 
found to be up-regulated via an ATF3 (activating transcription factor 3) dependent pathway in 
human keratinocytes (HaCaT) subjected to UVC (4mJ/cm2) at 21% oxygen. Subsequently, 
loss of function of HIF-2α evidenced that HIF-2α, rather than HIF-1α, mainly contributes to 
the UV-mediated cell death via the triggered activation of caspases 3 and 7 activation [285]. 
Thus, physiological skin-mimicking tanning responses and transcriptomic/proteomic 
programs have not yet been elaborated for UV-irradiated cutaneous keratinocytes and 
melanocytes/melanoma cells. More often than not, studies choose to elicit gene and protein 
responses under highly artificial hyperoxic and genotoxic conditions. 
5.5 Human genes co-targeted by HIF-1α and USFs: PAI-1, TERT, L-PK and P4Hα(I) 
On the molecular level, several human genes have previously been worked out to be 
co-regulated by HIF-1 and USF pathways. To date, this list of co-targeted genes includes 
those encoding the plasminogen activator inhibitor-1 (PAI-1), telomerase reverse transcriptase 
(TERT), L-type pyruvate kinase (L-PK) and Prolyl-4-hydroxylase α (I) (P4Hα(I)).  
The plasminogen activator inhibitor type-1 (PAI-1) is the primary physiological 
inhibitor of tissue-type and the urokinase-type plasminogen activators (tPA and uPA). Both 
tPA and uPA are key fibrinolytic serine proteases which convert the proenzyme plasminogen 
 45
to the active fibrin-degrading protease plasmin. PAI-1 is multifunctional protein which 
modulates proteolytic processes and also participates in cancer metastasis [286]. The group of 
Kietzmann previously reported that the gene for rat PAI-1 (rPAI-1) was flanked by two HRE 
sites (HRE-1 and HRE-2), located at -182/-166 and -168/-152 from the transcription start site 
[287]. They demonstrated by gel supershift assays a high-affinity tethering of USF2a to rPAI-
1 HRE-1 and a weaker attachment to HRE-2. HIF-1, on the other hand, attached preferably to 
the HRE-2 site and this complex was responsible for the enhanced rPAI-1 promoter 
transcriptional activity under mild hypoxia (8% oxygen). USF2a, once docked to the adjacent 
HRE, was able to down-regulate the HIF-1-mediated induction of rPAI-1 in primary rat 
hepatocytes co-transfected with USF2a and HIF-1α expression plasmids under 8% oxygen 
exposure [245]. Additionally, over-expression of USF2a inhibited the expression of rPAI-1 in 
rat hepatocytes, but not in human hepatoma cells (HepG2) [288]. 
The study on human PAI-1 (hPAI-1) documented two canonical E-boxes and one 
HRE site within the promoter of hPAI-1. The HRE site, located at -199/-181 from the 
transcription start site, was elicited as functional HIF-1 binding site [104]. The CACGTG E-
boxes (E4 and E5) were located at -571/-552 and -689/-670 from the transcription start site. 
E4 and E5 served as direct binding sites for USF2a and were strictly required for the USF 
mediated elevation of hPAI-1 expression. Although USFs did not directly bind to the HRE, 
USF/E-box co-occupying complexes were critical for the transactivation of hPAI-1 promoter 
activity during hypoxia. A cautionary note regarding the significance of these cross-talk 
scenarios comes from the obvious cell specificity of the USF2a mediated hPAI-1 control 
[288]. Whereas in human hepatoma cells USF2a induced expression of hPAI-1, the same 
factor directly contributed in the transcriptional down-regulation of hPAI-1 in primary rat 
hepatocytes.  
Telomerase reverse transcriptase TERT, the catalytic subunit of telomerase, is an 
essential component for enzymatic activity of telomerase and responsible for maintaining the 
ends of chromosomes during the division of stem, germ and many cancer cells. The gene 
encoding human TERT (hTERT) contains two functional HIF-α binding motifs (i: -165/-158; 
ii: +44/+51 relative to transcription start site). These two HRE sites are essential for the 
maximal induction of hTERT under hypoxia [107]. Under normoxic conditions, data by 
Yatabe et al. provide evidence for the avid attachment of c-MYC to either HRE motif in both 
in vitro and in vivo settings. The authors also documented a facilitated in vivo binding of HIF-
1 to the TERT promoter when human cervical cancer cells (ME180) were challenged by 
hypoxia. Consequently, HIF-1 controls telomerase activity through transactivation of hTERT, 
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which, in turn, promotes the malignant progression of  cervical cancer [108]. Besides HIF-1 
and c-MYC, USFs are known to also regulate hTERT promoter activity. USFs can also bind 
to either HRE in the hTERT promoter and are known to suppress expression of hTERT in 
certain cancer cells (e.g. oral cancer cells). Thus, USFs might act as transcriptional repressor 
for hTERT in oral cancer cells. Consequently, loss of USF function is associated with an 
increase in hTERT activity, telomere maintenance and oral carcinogenesis [289]. Goueli and 
Janknecht documented the in vitro and in vivo interaction of the USF1/USF2 heterodimer with 
the upstream E-boxes of hTERT in both hTERT positive and negative cells. However, USF 
binding stimulated hTERT expression only in immortalized hTERT positive cells and not in 
non-immortalized hTERT-negative cells. Moreover, this study also revealed a further 
enhancement of the USF-driven hTERT activity by recruitment of the USF/p300 complex to 
hTERT promoter. Recruitment of USF/p300 onto hTERT DNA, in turn, was markedly 
attenuated through inhibition of p38-MAP kinase pathway [227]. 
The third example of a HIF/USF crosstalk converging onto a co-regulated target is the 
gene encoding the glycolytic enzyme L-type pyruvate kinase (L-PK). L-PK catalyzes the 
formation of pyruvate and ATP from phosphoenolypyruvate and ADP. Its gene contains a 
glucose response element (GlcRE) (-165/-149), which is composed of the two imperfect 
CACGGG and CCCGTG E-boxes separated by a 5-nucleotides spacer. Occupation of the 
GlcRE motif is responsible for the induction of L-PK by high glucose. USFs have been 
identified to dock to this GlcRE in vitro and thereby stimulate transcription of L-PK [290, 
291]. Additionally, binding of HIF-1 to this GlcRE within the L-PK promoter was verified by 
EMSA [292]. Although this GlcRE seemed to function as low affinity site for HIF-1, it would 
still be possible that the HIF protein complex could compete with an effective USF/GlcRE 
interaction and disturb the USF-driven glucose dependent activation of the L-PK gene in the 
presence of high glucose and venous pO2 (8% oxygen) [99, 292].  
Lastly, human prolyl-4-hydroxylase α (I) (P4Hα(I)), one subunit of the main collagen 
hydroxylase that modifies proline and lysine residues in these extracellular matrix filaments, 
has been characterized as USF1/2 target gene. According to the report by Chen et al., direct 
docking of USF1/2 to the -135 E-box of this gene positively regulates P4Hα(I) promoter 
activity both in vitro and in vivo [293]. Yet, both mRNA and protein levels of rat P4Hα(I) 
were elevated by hypoxia. The rat P4Hα(I) gene is also flanked by a functional HIF-1 binding 
HRE at -79/-86 on the antisense strand from the transcription start site [106]. 
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6 General objectives 
 
Poor cellular oxygenation, often occurring in form of heterogenous pO2 profiles in 
solid malignancies, aids in promoting tumor growth, virulence and malignant progression, in 
part, via the hypoxia inducible transcription factor 1α (HIF-1α) signaling pathway. Since 
HIF-1α is stabilized and activated under hypoxic conditions, the strategies to inactivate HIF-
1α function through a genetic or pharmaceutical manipulation of the hydroxylation-dependent 
pathway in tumor cells are currently under intense investigation. Another means to modulate 
HIF-1 transcriptional activity in an O2- and hydroxylation-independent manner is thought to 
work through competing transcription factors. This consideration has been supported by 
several publications which had looked at other transcription factors, including c-MYC and 
upstream stimulatory factor (USF) to antagonize HIF-1-mediated gene regulation in cancer 
cells [98, 158, 288, 294].  
We previously utilized the tripartite globin-2 gene (hb2) promoter (phb2) of the 
planktonic crustacean Daphnia magna as luciferase reporter to analyze the responsible motifs 
and factors underlying the prominent hypoxic induction of hb2 in heterologous transfections 
of human cancer cells. Two of the three E-boxes within phb2, placed at -258 and -107, were 
found to act as functional HIF-1 binding sites (i.e. are HREs) and were critically required for 
the maximal hypoxic induction of the phb2 luciferase reporter. The third motif, a CACGTG 
palindromic E-box at -146, interacted with an unknown constitutive transcription factor. 
Mutating this palindrome and disabling the constitutive factor from binding significantly 
increased the HIF-1 load on phb2 and amplified the reporter’s hypoxic induction from 5 to 15 
fold. This finding revealed that the unknown CACGTG factor was able to interfere with the 
hypoxia-driven induction of the phb2 reporter when transfected into human cancer cells (i.e. 
human hepatoma cells Hep3B) [295]. 
CACGTG-palindromes are notably underrepresented in mammalian cells among 
functional HIF elements [88, 100, 296]. Instead, these E-boxes often serve as high affinity 
sites for non-HIF complexes of bHLH factors, e.g. normoxic MYC/MAX heterodimers or 
constitutive ARNT/ARNT homodimers [154, 158, 297, 298]. In addition, CACGTG E-boxes 
are avidly recognized by STRA13/DEC1 [299], ATF-1 and CREB-1 [300] and USF 
complexes [210]. Furthermore, functional CACGTG palindromes have been reported to 
confer hypoxic suppression rather than induction upon target genes [158, 301]. Thus, 
palindrome complexes are predestined to exert a possible fine-tuning of HIF’s transcriptional 
 48
read out. Indeed, multiple interactive mechanisms of HIF-1, either with MYC or USFs, have 
been reported (see sections 5.1.1 and 5.5 for details). 
For all these reasons, the aims of my PhD project included the a) identification of the 
phb2 palindrome binding entity across several human cancer cells and b) analysis of co-
regulatory effects of this factor and HIF-1 on targeted human genes by in vitro and in vivo 
approaches. 
Regarding the first part of this thesis, the unknown constitutive CACGTG binding 
factor, which could significantly suppress the HIF-1/HRE-driven transactivation of the 
globin-2 gene, was identified in an EMSA based supershift survey. For this EMSA survey, 
specific antibodies against above mentioned CACGTG binding factors (USF1, 2a, 2b; ARNT; 
MYC; DEC1; ATF-1) were used along with normoxic nuclear extracts from human hepatoma 
cells (Hep3B), human breast cancer cell (MCF7) and human cervical carcinoma cells (HeLa). 
As a result, upstream stimulatory factors 1 and 2a (USF1 and 2a) were recognized as the main 
phb2-palindrome binding factors across all cell lines tested. The EMSA data were re-
evaluated through independent pull-down assays of Hep3B, HeLa and MCF7 nuclear proteins 
using biotinylated phb2 oligonucleotides that were immobilized onto streptavidin coated 
magnetic beads.  
While the Daphnia hb2 promoter was a valuable model for the initial analysis of the 
crosstalk between E-box binding activities, naturally we wanted to characterize the signaling 
events within the promoter of human HRE/E-box candidate genes, i.e. those containing a 
CACGTG palindrome E-box adjacent to or overlapping with a validated or suggested HRE 
motif.  
To achieve this objective, a human genome-wide computational scan was conducted 
by Dr. Pavel Hradecky (AltraBio, Lyon, France). He searched a 5’-VNVBRCGTG-3’ (V=not 
T; N= any; B=not A; R=A or G) HRE consensus motif [40] and a 5’-CACGTG-3’ palindrome 
E-box within 1000bp upstream of the transcription start site of a promoter of a given gene. 
The distance of both motifs should be less than 100bp. 5’ location and distance of both motifs 
were adopted from the Daphnia hb2 gene, coordinates (i.e. transcription start sites) of the 
human genes were taken from UCSC’s known genes archive (hg18). Hundreds of HRE/E-box 
candidate genes were retrieved in the screen. We selected a few models for future studies, 
provided that the alignment of the homologous human-mouse-rat promoter regions had 
established the respective motifs to be conserved, and thus of likely functional importance. 
Picked promoters with human-mouse-rat conserved cis-elements were cloned as 
luciferase reporter constructs and included four HRE/E-box candidates (i. lactate 
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dehydrogenase A, LDHA; ii. Bcl-2/E1B 19 kDa interacting protein 3, BNIP3; iii. 
Melanocortin 1 receptor, MC1R; iv. 4E-binding protein 1; 4EBP1) along with HIF-1 specific 
(prolyl hydroxylase domain 2, PHD2) and USF specific control targets (tyrosinase, TYR) to 
systematically examine the possible convergence of HIF and USF signaling cascades at DNA 
level. Experimental evaluation of these putative HIF/USF co-targets was carried out in a step-
wise manner. Firstly, we examined which of the HRE/E-box reporters of the human candidate 
genes was responsive to hypoxia. Of the reporters screened, only the LDHA and BNIP3 
constructs were robustly stimulated by low pO2 across all three cell lines tested (Hep3B, HeLa, 
MCF7). Secondly, we assessed any co-regulation of these reporters as a function of over-
expressed HIF-1α and USF1/2a proteins. Thirdly, to evaluate this HIF/USF convergence onto 
BNIP3 and LDHA motifs by an independent approach, we manipulate human cancer cells 
with small-interfering RNAs (siRNAs) in transient Hep3B assays or generated short hairpin 
RNA (shRNA) based stable MCF7 clones to silence the transcription of individual 
components of the HIF-1 (HIF-1α) and USF pathways (USF1, USF2a). Finally, physiological 
binding and interaction of HIF-1 and USFs within the promoter of LDHA and BNIP3 was 
assessed by parallel chromatin immunoprecipitation and EMSA analyses. 
As described in the introduction, melanoma cells and melanocytes are considered to be 
a more physiological model for the gene regulation by HIF-1 and USF cascades. On one hand, 
to respond to an appropriate UV stimulus, USF signaling is key in inducing the sunblocking 
pigmentation that is initiated by the p38 MAP kinase-mediated phosphorylation of USF1. On 
the other hand, the skin of mice and humans display oxygen levels ranging from 1.5 to 5% O2 
[269-271]. Such low levels of cellular oxygenation in normal skin specifically exist at the 
hypovascular junction of epidermis and dermis, i.e. the layer of human skin that houses 
melanocytes and primary melanoma cells. The extent of this chronic hypoxia was found 
sufficient for the stabilization and activation of HIF-1α and several of its targets (GLUT1, 
CAIX) [272, 276]. Of course, even more limited and heterogenous oxygen tension (5-10 
mmHg) in human melanoma xenografts has been documented [273] (see section 5.4.1 for 
detail).  
Therefore, the third part of this thesis focused on the co-regulation of HRE/E-box 
genes by physiologically stimulated HIF-1α (stimulus: hypoxia) and USF (stimulus: UV 
irradiation) signaling pathways in human melanoma cells. Initially, we should establish the 
optimal UV conditions to induce phosphorylation of USF1. For this purpose, we irradiated 
human melanoma cells to different doses and wave-bands (UVB, UVC) of UV and assessed 
different post-irradiation time periods before examining the results by USF1 Western blots. 
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Next, we employed quantitative real time PCR to analyze the impact on various control and 
experimental genes when human melanoma cells were subjected to a dual stimulus set by 1% 
oxygen and UVB irradiation. 
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7 Own research 
 
The following sections summarize the data submitted in the manuscripts enclosed with 
this work. 
 
7.1 Identifying the unknown transcription factor that exerts HIF/HRE-interference     
from the -146 CACGTG E-box within the promoter of Daphnia magna’s globin-2 
gene 
As mentioned above, palindrome CACGTG motifs frequently serve as a strong 
binding sites for several non-HIF bHLH transcription factors including ARNT [154, 298], 
MYC [152, 153], USFs [210], STRA13/DEC1 [299], ATF-1 and CREB-1 [300]. Semenza 
and colleagues were the first to describe that a constitutively expressed factor could recognize 
the same DNA sequence as HIF-1 within the promoter of genes encoding glycolytic enzymes 
and the enhancer of EPO. A decreased binding of HIF-1 in hypoxia protein extract resulted 
from a competition with a binding of the constitutive factor [88, 302].  
Our previous study on the control of the hypoxia inducible globin-2 (hb2) gene of 
Daphnia revealed that the cooperative binding of HIF-1 to two of the promoter’s functional 
HREs was completely required for the enhanced transcriptional activity of the gene’s tripartite 
promoter (phb2) during low pO2. In transfections of human hepatoma cells (Hep3B), we 
noted that the binding of an unknown constitutive factor to the third phb2 motif, a CACGTG 
palindrome at position -146, significantly weakened the HIF/HRE-mediated hypoxic 
induction of the reporter. This finding suggested that a constitutive and cancer cell expressed 
CACGTG-binding factor was able to interfere with the HIF-1/HRE-driven induction of a 
downstream oxygen-sensitive target [295]. 
To identify this unknown HIF-interference factor, an EMSA supershift survey was 
conducted using the -146 CACGTG sequence of the phb2 and different antibodies USF, 
DEC1, MYC, ARNT and ATF-1. Given the constitutive nature of the -146 constituents, the 
survey was carried out with normoxic nuclear extracts from human hepatoma cells (Hep3B), 
human breast cancer cell (MCF7) and human cervical carcinoma cells (HeLa). The screening 
revealed that USF1 and USF2 functioned as main bHLH factors enabling to bind in vitro to 
the phb2 palindrome at -146. In addition, DEC1 participated as a minor addition to this 
constitutive complex. Next, we carried out oligonucleotide-based pull-down assays and were 
able to confirm the avid interaction of USF1, USF2a and USF2b with the oligoucleotide 
housing the wildtype, but not mutant, CACGTG palindrome of the -146 phb2 motif.  
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7.2 Co-regulatory effects of HIF-1 and USFs on human HRE/E-box genes  
The Daphnia globin 2 promoter had served as valuable model for the initial 
exploration of the cross-talk between HIF-1 and USF signaling pathways. Ultimately, 
however, we wanted to learn which human genes feature a similar HRE/E-box configuration 
of adjacent or overlapping candidate HRE and CACGTG palindromes in their promoter and 
thus might be co-responsive to incoming HIF and USF signals. As explained in General 
Objective (section 5) and our manuscript, a human genome-wide computational scan was 
conducted by Dr. P. Hradecky. According to his results, several HRE/E-box and control genes 
were selected and cloned into luciferase reporter plasmid for further analysis. Selection of 
HRE/E-box and control genes was always guided by our own alignments of promoter regions, 
which were established the conservation, hence alleged functionality, of the respective motif 
in a human-mouse-rat matrix of species. The final list of generated luciferase reporter 
constructs included HIF-1 specific (prolyl hydroxylase domain 2, PHD2) and USF-specific 
(tyrosinase, TYR) control promoters as well as the 5’ regulatory DNA of four HRE/E-box 
candidate genes (lactate dehydrogenase A, LDHA; Bcl-2/E1B 19 kDa interacting protein3, 
BNIP3; eukaryotic translation initiation factor 4E binding protein 1, 4EBP1; melanocortin 
receptor 1, MC1R). Of those, the PHD2 and BNIP3 constructs were kindly provided as 
generous gifts provided by other labs (see manuscript for acknowledgments).  
 
Luciferase assay for analysis of co-regulation of these four HRE/E-box candidate genes by 
HIF/USF signaling cascades 
To determine the hypoxia responsiveness of the above HRE/E-box candidate genes, 
Hep3B, HeLa and MCF7 cells were transfected with the luciferase reporter constructs of the 
corresponding promoter. According to these luciferase assays, of the four HRE/E-box 
candidates 4EBP1, LDHA, MC1R and BNIP3, only the LDHA and BNIP3 reporter revealed a 
robust up-regulation by hypoxic conditions (16h, 1% O2) in all three cell lines. We went on to 
analyze the impact of over-expression of a) HIF-1α, b) USF1 and 2a and c) HIF-1α + USFs 
in subsequent luciferase assays. Over-expression of HIF-1α amplified the hypoxic activity of 
the BNIP3 reporter robustly in Hep3B (i.e. 2.8 fold ? 6.6 fold, endogenous 
hypoxia/normoxia (H/N) ratio of relative luciferase activities ? H/N ratio with over-
expressed HIF-1α) and moderately in HeLa cells (H/N: 2.7 ? 3.2 fold). Importantly, this 
potentiated hypoxia response of BNIP3 by exogenous HIF-1α was significantly impaired by 
simultaneous co-transfection with USF1 or USF2a, but not USF2b, in Hep3B and HeLa cells. 
Endogenous and HIF-1α-mediated up-regulation of hypoxic LDHA reporter activity was 
 53
similarly reduced by over-expression of USF1 or USF2a in a dose-dependent manner due to 
the enhanced normoxic transcription from the LDHA promoter.  
Next, we opted to revisit the mutual influence of these pathways on one another by 
using an RNA interference loss-of-function approach in order to gain independence of the 
potentially artificial over-expression of considered HIF-1 and USF factors. For this purpose, 
we generated, and verified, a small hairpin RNA (shRNA)-based stable MCF7 knockdown 
line for USF2a along with equally treated and selected shRNA control clones. We also 
received as generous gift a stable HIF-1α shRNA MCF7 knockdown clone from Dr. D. Stiehl. 
The ~7-fold hypoxic induction by endogenous pathways of the LDHA reporter, was further 
enhanced in the USF2a knockdown clone (H/N: 9.3-fold), due to the significantly reduced 
normoxic reporter activation to ~60% of control cells. HIF-1α shRNA-based loss-of-function 
completely obliterated LDHA induction in low pO2. In USF2a knockdown cells, over-
expressed HIF-1α augmented primarily the normoxic reporter activity, hinting to HIF’s take-
over of the USF-deficient control of the LDHA promoter. Conversely, when adding 
exogenous USF1 and 2a, the LDHA reporter responded again with a marked increase of its 
normoxic and hypoxic activities in HIF-1α knockdown cells. It thus appears that HIF-1 and 
USFs substitute one another in the LDHA promoter and compensate the loss-of-function of 
the other activity. 
Transfection with BNIP3 luciferase reporter construct in these kd MCF7 variants 
revealed that a) HIF-1α loss-of-function again completely abrogated the hypoxic expression 
of the BNIP3 luciferase reporter, thereby confirming the strict requirement of HIF-1α to 
control the induction of the BNIP3 gene in MCF7 during low oxygen and b) USF-HIF 
competition for BNIP3 was indicated in USF2a kd MCF7 through a tenuous increase in the 
hypoxic stimulation of the reporter relative to shRNA control cells. To reveal this competition 
more clearly we resorted to reporter transfections in conjunction with transient siRNA-based 
manipulations of HIF-1α, USF1 and USF2a protein levels in Hep3B cells. Here, the HIF/USF 
competition for BNIP3 was made evident through a significant raise of hypoxic reporter 
activities in cells treated with USF1 siRNA. There also was an increase in the hypoxic 
induction of the BNIP3 reporter in siUSF2a treated cells. 
 
Characterization the in vivo and in vitro binding of HIF-1 and USFs to BNIP3 and LDHA 
promoter DNA 
To examine the in vivo binding of HIF-1 and USFs to the promoter of BNIP3 and 
LDHA, chromatin immunoprecipitation (ChIP) assays were performed in HeLa, Hep3B and 
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MCF7 cells. For BNIP3, ChIP revealed the dominant in vivo binding of HIF-1α to the 
promoter (region assessed: -509/-196 from translation start site) in deoxygenated cells along 
with the weak and constitutive attachment of USF1 and 2a to this DNA. Remarkably, some 
HIF-1α had successfully escaped proteolytic degradation since it was detected, as heterodimer, 
bound to the BNIP3 promoter in normoxic cells. Towards the precise location of bound HIF 
and USF proteins in the regulatory region of the human BNIP3 gene, EMSA screens with a 
single site oligonucleotide (-259 to -236) characterized the BNIP3 E-box as a surprisingly 
poor HIF-1 motif during hypoxia. In contrast, constitutive USF1 and 2a complexes were 
attracted to this site with high-affinity. Thus, the BNIP3 HRE at -251/-246 is in hypoxic cells 
co-targeted by HIF-1 and USFs. 
LDHA ChIP analysis clearly demonstrated the co-occupation of USF1 and USF2a to 
the human LDHA promoter (region: -2533/-2376 from translation start site) in vivo during 
periods of normoxia. Therefore, these data strengthen the role of USFs as physiological 
drivers of aerobic glycolysis in cancer cells (Warburg effect). In contrast, binding of HIF-1 to 
the upstream LDHA DNA under high oxygen levels was negligible in both cell lines (contrast 
to BNIP3 promoter). In low O2, HIF-1 dominates the LDHA promoter in MCF7 cells, while 
both USFs maintain their association with this DNA. DNA-attachment of HIF-1 does not 
appear to displace USFs from the upstream recognition sites of LDHA, in support of the 
notion that maximal LDHA transcription during low pO2 stems from a parallel and 
independent transcriptional control by HIF-1 and USF1/2a. Follow-up EMSA’s disentangled 
the specific binding motifs of HIF-1 and USFs within the LDHA promoter. The palindrome in 
region II of LDHA (-2367 to -2362: 5’-CACGTG-3’) and the E-box in region III (-2353 to -
2345: 5’-GACGTG-3’ on anti-sense strand) functioned in these assays as specific USF2 (reg. 
II) and HIF-1 (reg. III) binding sites, respectively. Region I of the LDHA 5’ flank (-2465 to -
2460: 5’-CACGTG-3’), known to act as MYC binding site at position -175/–180 from the 
transcription start site of the rat LDHA gene [160], represented a weak HIF-1 site and strong 
USF1 and USF2a site. Presence of these distinct, non-overlapping sites in the LDHA 
promoter by HIF-1 and USFs might be an important element for the mutually independent 
influence of either cascade in regulating this HRE/E-box gene (contrast to BNIP3 sites and 
mode of regulation). 
7.3 Study on HIF-1/USFs signaling pathways during hypoxia/UV co-stimulation of 
human melanoma cells.  
Human M000921 melanoma cells: Western blot for phosphorylation of USF1 and real-time 
PCR for target genes expression TYR and MC1R under UV radiation  
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The human M000921 melanoma cell line, directly isolated from a patient, was kindly 
provided by Prof. R. Dummer’s lab (University hospital of Zurich). M000921 cells were 
exposed to three different doses of UVC (254 nm): 2, 4 and 8mJ/cm2. Cells were harvested at 
2h and 6h post- irradiation. 80μg whole cell extract was subjected to Western blot to monitor 
the UV-induced phosphorylation of USF1 as a reflection of the physiological, tanning-like 
activation of USF signaling in cultured melanomas. Results indicated that UVC (8mJ/cm2, 2h) 
induced the appearance of a band of lesser mobility corresponding to 45kDa phosphorylated 
form of USF1 (p-USF1). P-USF1 was made visible using the rabbit polyclonal anti-USF1 (C-
20; sc-229) from Santa Cruz Biotechnology, INC, because the original anti-USF1M antiserum 
used in our manuscript failed to detect the low migrated USF1 band. Extending the post-
irradiation exposure to 6h yielded a visible phosphorylated form of USF1 in all three doses of 
UVC. Repeating the experiment with 4mJ/cm2 UVC at 2h and 6h post-irradiation collection 
of cells confirmed the induction of p-USF1 in M000921 cells (Fig. 8A). To evaluate the 
impact of such UV exposure, M000921 cells were irradiated with these three doses (2, 4, 
8mJ/cm2) of UVC and cell viability was assessed by Trypanblue staining at 8, 24 and 48h 
post-irradiation time points. Growth rates of control and UVC treated M000921 cells at the 
48h post-irradiation time point clearly demonstrated the marked slow-down (2mJ/cm2 UVC) 
or complete arrest of growth (8mJ/cm2 UVC), whereas growth rates of non-irradiated controls 
showed an average 5-6 increase after 48h (data not shown). To minimize the cytotoxic impact 
of UVC radiation on these cells, we choose low doses of UVC (1, 2 and 4mJ/cm2) for further 
gene expression profiling as a function of UVC exposure. 
To examine the UVC response of TYR and MC1R gene expression in M000921, cells 
were exposed to three different doses of UVC, 1, 2 and 4mJ/cm2. Growth arrest and DNA-
damage-inducible, 45 alpha (GADD45a), a DNA damage marker gene, was taken as positive 
control since elevated GADD45a transcription is a known response of melanoma and 
melanocytes to UV [303, 304]. Total mRNA was isolated from M000921 cells according to 
the TRIzol® reagent manual (Invitrogen) after 5h of UVC exposure. Real-time quantitative 
PCR (qPCR) revealed the dose-dependent up-regulation of GADD45a mRNA levels in 
M000921 cells subjected to UVC irradiation (fold induction of GADD45a mRNA by UVC:  
~2.5 fold at 1mJ/cm2; 4 fold at 2mJ/cm2 and 5 fold at 4mJ/cm2; see Fig. 8B). Surprisingly, 
TYR and MC1R mRNA transcripts responded with a dose-dependent down-regulation, not 
induction, in UVC irradiated M000921 cells (TYR / MC1R mRNA levels: reduction to 60% / 
40% of non-irradiated cells, respectively, when M000921 cells had been irradiated with 
4mJ/cm2 of UVC; Fig. 8B). Since we did not observe any up-regulation of TYR and MC1R 
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even at low doses (1 and 2mJ/cm2) of UVC, our finding is at odds with those of Galibert et al. 
[235]. The stimulated transcription of GADD45a even by a low dose of 1mJ/cm2 UVC 
implied ongoing DNA damage throughout all UVC-irradiation protocols of M000921 cells. 
Moreover, UVC wave bands are hardly of physiological relevance, since this quality of 
ultraviolet radiation is absorbed by atmospheric ozone and does not reach the Earth’s surface. 
UVB radiation (312 nm), on the other hand, has clearly pathophysiological significance since 
it is thought to represent the most carcinogenic waveband [259]. Thus, we switched to UVB 
for further tests in M000921. 
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Figure 8 Exposure of M000921 melanoma cells to UV irradiation (A) Western blot analysis for p-USF1 in 
M000921 cells irradiated with three different doses (2, 4 and 8mJ/cm2) of UVC (254nm) and exposed to 
normoxia. Whole cell extracts were isolated at 2h and 6h after irradiation und subjected to Western blot analysis 
with anti-USF1 (C-20, Santa Cruz). (B) Real-time qPCR was performed using total mRNAs extracted from 
normoxic M000921 cells at 5h post-exposure to 1, 2 and 4mJ/cm2 of UVC. Relative mRNA levels of GADD45a, 
TYR and MC1R genes were normalized by L28 mRNA and documented by mean expression  ± SD of two 
independent experiments. (C) Western blot analysis for p-USF1 in M000921 cells which were harvested at time 
points 8, 16 and 24h after irradiation with two doses (80 and 160mJ/cm2) of UVB (312nm) under normoxia. (D) 
Western blot analysis for p-USF1 in M000921 cells harvested at 8h post-UVB (160mJ/cm2). For co-stimulation 
of hypoxia and UV cascades, cells were exposed to 1% oxygen for 16h prior to UVB (160mJ/cm2) and were 
grown for another 8h after irradiation under hypoxia. 
 
To start out, normoxic M000921 cells were irradiated with two 80 and 160mJ/cm2 
doses of UVB (312nm) and subsequently harvested at 8, 16 and 24h post-irradiation time 
points. Immunoblots revealed occurrence of phosphorylated USF1 24h after low dose of UVB 
(80mJ/cm2). A higher UVB dose (160mJ/cm2) could induce p-USF1 even at 8h post-
irradiation (Fig. 8C). En route to the hypoxia/UV exposures, we compared the impact on USF 
signaling under normoxic/UVB and hypoxic/UVB co-stimulation scenarios in M000921 cells. 
Prior to UVB stimulation, cells were exposed to 1% oxygen for 16h, then irradiated with 
UVB (160mJ/cm2) in the hypoxic camber and then grown for another 8h either in air (N, 
normoxic cells) or under 1% oxygen (H, hypoxic cells). Unexpectedly, we observed a similar 
extent in the phosphorylation of USF1 in both non-irradiated and irradiated cells under 
normoxia (Fig. 8D). Further exposures and immunoblots also yielded ambiguous results so 
that a clear and reproducible induction of USF1 phosphorylation never emerged. Since 
M000921 cells had also not yet been characterized for the UV-mediated induction of the 
USF1 cascade, we opted to switch to human melanoma 501mel cells, a well-characterized UV 
response resource.  
 
501mel cells: USF1 phosphorylation and expression of control and HRE/E-box target genes 
under single and dual stimulation regimes  
In adopting previously published protocols, human melanoma 501mel cells were 
exposed to 8, 20, 40 and 80mJ/cm2 doses of UVB radiation and 2 or 5h post-irradiation 
recovery periods until harvest [267, 268]. To exclude any disturbance on the induction of USF 
phosphorylation by varying O2 concentrations, normoxic 501mel cells were UVB-irradiated 
and kept for recovery under normoxia (contrast to treatment of normoxic M000921 cells, see 
above). In 501mel cells exposed to air or 1% oxygen, USF1 was optimally phosphorylated by 
40mJ/cm2 UVB and 2 or 5h post-irradiation response time points (Fig. 9A). As with M000921 
cells, hypoxia/UV dual stimulation of 501mel cells (Fig. 9A) included a 1% O2/16h 
adaptation (HIF-1 activation) period prior to the UVB stimulus. However, subsequent 
 58
experiments with 501mel cells, while revealing a clear UVB induced USF1 phosphorylation 
during normoxic pO2, resulted in unpredictable USF1 activation profiles in hypoxia. In some 
exposures, hypoxia (1% O2/16h) alone yielded USF1 phosphorylation (Fig. 9B left panel).  
To better understand the nature of the observed double banding pattern of USF1 upon 
UV irradiation, we recalled that phosphorylation of USF1 is thought of being exclusively 
mediated by p38 (MAP) kinase in response to UV light [235]. To verify that the lesser 
migrating USF1 band corresponds to the phosphorylated form of USF1 (p-USF1), 501mel 
cells were treated with 10μM or 20μM of the specific p38 inhibitor SB203580 (SB in Fig. 9B) 
for 1h prior to UVB exposure. Unexpectedly, this UVB induced second band of lesser 
mobility of USF1 was completely refractory to SB203580 (Fig. 9B right panel), implying 
either that USF1 phosphorylation in our batch of 501mel cells is carried out by alternative 
kinases, distinct of p38, or that the upper band does not represent p-USF1 but perhaps a 
different UV-induced post-translational modification of USF1.  
For expression profiling, 501mel cells were subjected to four different conditions: air - 
UVB, air + UVB, 1% O2 - UVB and 1% O2 + UVB. For an appropriate co-stimulation of 
hypoxia/UVB signaling and to avoid saturating p38 kinase activation by hypoxia alone (see 
above, Fig. 9B left), the hypoxic exposure prior to UVB (40mJ/cm2) stimulation was reduced 
from 16h to 2h. After UVB exposure, cells were kept for additional 5h in normoxic or 
hypoxic atmosphere followed by total mRNAs extraction. In subsequent qPCRs TYR, MC1R, 
PHD2, LDHA and BNIP3 mRNA levels expression were elucidated for the aforementioned 
conditions. As expected, mRNA level of the HIF-1 target PHD2 was 3-4 fold induced by 
hypoxia. In contrast, transcription of the USF targeted genes, TYR and MC1R, was 
unaffected by oxygen in 501mel cells. Also BNIP3 mRNA was robustly (4-fold) up-regulated 
by hypoxia, while the LDHA transcript only showed a marginal (1.5 fold) hypoxic induction. 
1% O2- UVB and 1% O2+UVB regimes did not alter the original hypoxia response of PHD2, 
LDHA and BNIP3 transcript (Fig. 9C). To our surprise and disappointment, there was no 
transcriptional activation of either TYR or MC1R mRNAs to air + UVB or 1% O2+UVB co-
stimulatory exposures in 501mel cells (Fig. 9C). 
To assess if this lack of TYR or MC1R induction by UV stems from a technical or cell 
related problem, we resorted again to UVC treatment despite the unphysiological nature of 
this signal (see above). Thus, normoxic 501mel cells were irradiated with three different UVC 
doses (1, 2 and 4mJ/cm2). To analyze alteration of GADD45a, TYR and MC1R mRNA levels, 
total RNA was isolated 5h after UVC irradiation and qPCR was performed. Similar to 
M000921 cells, GADD45a mRNA levels in 501mel cells were dose-dependently up-regulated 
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by UVC irradiation, while steady state levels of TYR and MC1R transcripts were reduced by 
UVC exposure (Fig. 9D). The amplitude of this down-regulation was considerable. A dose of 
4mJ/cm2 of UVC decreased TYR and MC1R mRNA levels to 45% and 30% of control levels  
 
 
Figure 9 Exposure of human melanoma 501mel cells to UV irradiation. (A) Western blot analysis using anti-
USF1 antibody (C-20, Santa Cruz) and whole cell extracts of 501mel cells subjected to four different doses (8, 
20, 40 and 80mJ/cm2) of UVB (312nm). Protein was harvested at indicated post-UVB stimulation time points. 
Cells were exposed to air (N) (left panel) and 1% oxygen (H) (right panel), respectively. For combined 
stimulation of hypoxia and UVB, cells were exposed to 1% oxygen for 2h prior to UVB and were grown for 
another 2 and 5h after irradiation under hypoxia. (B) Western blot analysis for p-USF1 in normoxic and hypoxic 
501mel cells exposed to three different doses of UVB as indicated with protein harvests at 5h post-UVB (left 
panel). Normoxic 501mel cells were pre-treated with the p38 family kinase inhibitor SB203580 (at 10μM and 
20μM final concentration, 1h prior to UVB exposure) (right panel). (C) Real-time qPCR was performed for TYR, 
MC1R, PHD2, LDHA and BNIP3 gene expression in 501mel cells exposed to UVB (40mJ/cm2; 5h post-UV 
harvest) and hypoxia (2h ? +UVB ? 5h post-UV harvest). Relative mRNA expression level of these five genes 
was normalized by L28 and recorded as mean expression ± SD of two independent experiments. (D) Real-time 
qPCR for GADD45a, TYR and MC1R transcripts was performed using total mRNAs extracted from normoxic 
501mel cells at 5h after exposure to 1, 2 and 4mJ/cm2 of UVC. Relative mRNA levels were normalized by L28 
and recorded as mean expression ± SD of two independent experiments. 
  
(no UVC exposure) in 501mel cells, respectively (Fig. 9D). This lack of UV response together 
with the resistance of the UV-induced modification of USF1 to the p38 inhibitor SB203580 
(Fig. 9B, right) point either to defects in the UV-induced USF signaling pathway or to UV-
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triggered post-translational alterations of USF1 (= upper band in Western blots) that are 
distinct from a phosphorylation. In this context, various stresses have recently been reported 
to lead to an acetylation of USF1, which, in turn, no longer activates but suppresses the 
transcription of targeted genes [268]. For future work it will be necessary to find out if 
exposure of 501mel and M000921 cells to UVB and UVC under our cell culture conditions 
analogously resulted in USF1 acetylation rather than phosphorylation.   
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8 Conclusions and Outlook 
 
8.1 Conclusions 
Low oxygen partial pressure (hypoxia) is a main characteristic of human solid tumors. 
Control and workings of the hypoxic-inducible factor 1 (HIF-1) are relatively well understood. 
In hypoxic cells, the alpha subunits HIF-1α and -2α are rendered stable, translocate into the 
nucleus and dimerize with HIF-1β aka ARNT to generate the HRE-binding HIF-1 and HIF-2 
heterodimeric complexes that are responsible for promoting tumor growth in various cancer 
settings. The discovery of PHD and FIH-1 class dioxygenases as O2 sensors of the HIF-1/-2 
signaling pathway opens the opportunity to pharmacologically manipulate both abundance 
and transcriptional activity of the HIF cascade. The supply of high-affinity PHD/FIH-1 
substrates or inhibitors and generation of gain-of-function mutant PHD/FIH-1 variants can 
antagonize excessive HIF function in malignant growths. Yet, all the PHD/FIH-based 
interceptions of HIF signaling require oxygen. To effectively target a derailed HIF pathway in 
severely hypoxic or even anoxic cells alternative and hydroxylase-independent means are 
needed. HIF-competing transcription factors might be such a novel approach to modulate or 
interfere with the hypoxic adaptations of neoplastic cells that are governed by HIF-1 and HIF-
2. 
We previously reported on the specific binding of a constitutive, human hepatoma cell 
(Hep3B)-expressed transcription factor to the CACGTG E-box palindrome at position -146 
adjacent to two functional HREs in the promoter of a hypoxia inducible globin2 gene (hb2) of 
Daphnia magna (i.e. phb2). Interaction of this complex with the -146 phb2 palindrome 
counteracted with the HIF-driven induction of a phb2 luciferase reporter [295].  
As mentioned in the 6th and 7th sections, E-box palindromes of the CACGTG type are 
frequently bound by homo- or heterodimeric complexes of several bHLH transcription factors 
including ARNT, MYC, USF, STRA13/DEC1, ATF-1 and CREB-1 [152-154, 210, 298-300]. 
A recent review reported two modes of HIF-mediated hypoxic suppression of MYC 
transactivation of gene expression: one mode is that HIF displaces MYC from the MYC-
activated promoter thereby leading to hypoxic repression of cell cycle and DNA repair genes; 
the other mode is the HIF-driven activation of the expression of MAX interactor 1 (MXI1), 
which is an inhibitor of MYC [294]. In addition, other bHLH/PAS family transcription factors, 
e.g. Single Minded 1 and 2 (SIM 1 and 2), can functionally interfere with HIF-1 
transactivation by sequestering ARNT [305, 306]. 
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To study the precise mechanisms by which the palindrome complex in phb2 interferes 
with the transcriptional activity of HIF-1, the aims of this thesis were twofold: 1) to identify 
this phb2 CACGTG-binding transcription factor and describe its occurrence across several 
cancer cell lines and 2) to investigate the factors interplay with HIF-1α in the control of co-
targeted genes. 
To identify which of the above mentioned bHLH transcription factors are able to bind 
to the -146 CACGTG E-box in phb2, electrophoretic mobility shift assays (EMSA) and 
oligonucleotide pull-down assays were performed with nuclear extracts from Hep3B, HeLa 
and MCF7 cell lines. Both methods consistently and reproducibly (n=2-3 supershifts; n=2-4 
pull-downs per cell line) identified USF1 and USF2a/2b as the main in vitro complex of the -
146 CACGTG-palindrome of phb2 in the nuclear extracts of all three cancer cell lines. 
Furthermore, the oligonucleotide-based pull-down surveys demonstrated the avid tethering of 
USF proteins to the symmetric phb2 E-box whereas the asymmetric TACGTG HRE motifs of 
the Daphnia promoter were found to strongly attract HIF-1. This observation agreed not only 
with several papers describing CACGTG-palindromes as comparatively poor HIF-1/-2 
binding motifs [87, 100, 296] but also with the EMSA results of the various phb2 cis-
elements reported in the earlier publication [295]. Co-immunoprecipitations failed to show 
any direct interaction between HIF-1 subunits and USF2a. Krones et al. provided similar 
evidence that there was no physical direct interaction between HIF-1 and USF in their study 
on the cross-talk of HIF and USF on L-type pyruvate kinase (L-PK) [292]. In conclusion, the 
-146 CACGTG palindrome of Daphnia’s hb-2 promoter functions unequivocally as strong 
docking site for USF1 and 2a in human cancer cells and the USF complex exerts its indirect 
interference onto the HIF/HRE-mediated transactivation of the downstream reporter. 
The Daphnia hb2 gene promoter was considered as technical tool to initiate the 
investigation of the interplay HIF-1/HRE and USF/CACGTG complexes. Ultimately, we 
wanted to learn which human genes, flanked by an adjacent or overlapping HRE/palindrome 
(PAL) motif signature in their promoter, might be co-targeted by HIF and USF signals. As 
explained General Objective (section 6) and in our manuscript, we finally obtained a range of 
luciferase reporter constructs including only HIF-specific (PHD2) and USF-specific gene 
(TYR) promoters as well as 4 HRE/E-box candidate genes: 4EBP1, LDHA, MC1R and 
BNIP3 for further investigation in Hep3B, MCF7 and HeLa cells.  
When assessing hypoxia (1% O2, 16hr) responsiveness of these HRE/E-box reporters, 
only LDHA and BNIP3 construct showed markedly elevated luciferase transcription during 
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low oxygen across all three cell lines. This hypoxic induction of LDHA and BNIP3 
expression was consistent with two previous publications [90, 100].  
Next, the interplay between HIF-1α and USF1/2a in the LDHA promoter was 
evaluated by overexpressing (Hep3B, HeLa) or silencing (MCF7) HIF and USF components 
in the indicated cancer cells. Co-overexpression of HIF-1α and USF1 led to a mutual increase 
in the LDHA promoter activity in Hep3B and HeLa cells, but surprisingly not in MCF7. We 
surmised that in MCF7 an extremely efficient production and/or promoter attachment of 
exogenous HIF-1α completely saturated the LDHA sites even under normoxia (18-fold 
normoxic enhancement of LDHA promoter activity by exogenous HIF-1α), thus rendering 
this DNA no longer accessible for accessory USFs. Short-hairpin RNA-based stable 
knockdown of HIF-1α and USF2a in MCF7 revealed HIF-1 and USFs could compensate the 
silencing of the other activity and further confirmed the mutually supporting effect of both 
signaling pathways on LDHA promoter.  
The following EMSA and chromatin immunoprecipitation (ChIP) analyses allowed to 
reveal the in vivo convergence of HIF and USF pathways onto the LDHA promoter as well as 
to determine the distinct binding sites of these factors within this DNA. According to our 
ChIP results, USF1 and 2a bind to LDHA promoter in oxygen-independent manner whereas 
HIF-1α resides in the promoter exclusively during hypoxic periods. Docking of HIF-1 to the 
LDHA promoter left the USF attachment to this DNA undisturbed. Utilizing the EMSA 
technique, we observed that HIF-1α and USF1/2a could mutually occupy the CACGTG site 
at position -2465, named region I. However, USF1/2 exhibited a much stronger binding 
affinity to this motif than HIF-1α. The other CACGTG element at position -2367, called 
region II, was exclusively bound by USF1/2a whereas the GACGTG (on the antisense strand) 
at position -2353 (region III) turned out to act as specific HIF-1 binding site. Two previous 
studies on rat and mouse LDHA evidenced the occupancy of c-MYC and HIF-1 to the same 
region of the genes’ promoter. Shim et al. reported that the constitutive transactivation of rat 
LDHA gene expression required the direct occupancy of c-MYC at two E-boxes, 
corresponding to regions I and II of human LDHA mentioned above [160]. On the other hand, 
Semenza’s lab validated in 1996 a strong binding HIF-1α binding site in mouse LDHA, 
which corresponded to region III in human LDHA [87]. Both papers reported that c-MYC and 
HIF-1α could transactivate LDHA expression.  
In contrast to LDHA, the mutual control of the BNIP3 luciferase construct occurred 
via a competitive effect between HIF-1α and USF1/2a. It was particularly noticeable when 
Hep3B or HeLa cells were co-transfected with HIF-1α together with a low amount (15ng) of 
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USF1/2a plasmids. Loss-of-function (LoF) approaches to knockdown either HIF-1α or USF 
signaling pathway in Hep3B cells reproduced this competitive effect in the sense that siUSF1 
treatment achieved a significantly potentiated hypoxic BNIP3 activity while siUSF2a 
manipulation yielded a raise in the hypoxic/normoxic ratio of the reporters’ transcription. 
Thus, the HIF-1α-mediated hypoxic induction of BNIP3 can be antagonized by active USF 
signaling.  
Subsequent EMSA and ChIP data for BNIP3 demonstrated the binding of HIF-1 under 
in vitro and in vivo conditions to the HRE site at position -246 of the promoter in line with an 
earlier report by Kothari et al. [90]. Although this HRE site reads as CACGTG E-box 
palindrome, to date, there is no literature available with regard to a competition of HIF-1 with 
other transcription factors for the same BNIP3 site. Our ChIP and EMSA data provided 
convincing evidence that USF 1 and 2a also, yet constitutively, interacted with the -246 
BNIP3 HRE site in vivo and in vitro. In contrast, interaction of a HIF-1/HRE complex formed 
predominantly but not exclusively under hypoxic pO2. Some HIF-1α had obviously escaped 
proteolytic degradation and functioned as transcriptionally competent factor since it remained 
tethered, as HIF-1 heterodimer, to the BNIP3 promoter even in normoxic cells. Moreover, the 
hypoxic dominance of HIF-1 interaction with the BNIP3 HRE did not displace attached USF 
proteins, suggesting that the latter might actually attach to accessory motifs in close proximity 
to the HRE rather than the HRE itself. Interaction of USF1 and 2a with these accessory motifs 
allows for a basal transcription activity of BNIP3 under normoxic condition and perhaps for a 
fine-tuned hypoxic activation of the BNIP3 gene via HIF-1. Activated USF signaling lends 
itself to interfere with the HIF-driven control of BNIP3 in deoxygenated cancer cells. 
During the silencing of USF2a in MCF7 (shRNA-based stable knockdown) and USF1 
or USF2a in Hep3B cells (siRNA-based transient knockdowns), we unexpectedly yet 
reproducibly observed that USF1 protein level was also visibly reduced in USF2a knockdown 
MCF7 and Hep3B cells. A similar asymmetrical cross-regulation of USF1 by USF2a was 
seen in mouse embryonic fibroblasts (MEF) of USF1-/- or USF2a-/- mice [246]. However, this 
finding was challenged by a report of Vallet et al. on USF1 and 2a protein levels from the 
liver of USF1-/- or USF2a-/- knockout mice. They did not observe any alteration of USF1 
protein level in the liver of USF2-/- mice [248]. In our study, used siRNA and shRNA 
recognized the partially conserved region at nucleotides 786-806 of USF2a (i.e. the shRNA 
used for generating the USF2a kd MCF7 clone contained an octamer (nucleotides 787-794: 
CCAGACTG) which is conserved in USF1 and USF2a transcripts). Thus, either the reduction 
of USF1 mRNA in cells transfected by the siUSF2a siRNA/shRNA resulted from the 
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insufficient USF2a specificity of the sequence or USF2a is required to directly or indirectly 
activate USF1 transcription in certain cancer cells.  
Returning to the HIF/USF cross-talk at DNA level, we also aimed to utilize a more 
physiological strategy to study the differential impact of both cascades on the control of 
human HRE/E-box genes. This strategy was to be independent of any overexpression or 
RNAi-based knockdown scenarios to avoid common drawbacks associated with these 
artificial and exaggerated expression manipulations. Here we utilized human melanoma cells 
to investigate the coactivation of HIF-1 and USF signaling through simultaneous exposure of 
the cells to hypoxia and UV irradiation. As described in section 5.4.2, human melanocytes 
and primary melanoma growths reside in a persistently hypoxic microenvironment of the 
epidermis-dermis junction whose cells, even without malignant transformation, exhibit the 
physiological activation of HIF-1 and its downstream gene targets [275, 276, 278, 307]. It is 
within this context that the USF cascade activates the UV-triggered tanning response program 
in melanocytes/melanoma cells [235, 267, 268]. Thus, our pilot project on the convergence of 
hypoxia/HIF and UV/USF signaling events at DNA level in melanoma cells aimed to address 
this crosstalk under physiological conditions. 
To titrate UV conditions (wavebands, energy dose) that would yield an optimal 
activation of USF1 and downstream melanogenesis constituents, we used as readout the UV- 
mediated activation of the stress kinase p38 pathway which is the responsible signal for the   
transcriptional activation of USF1 via phosphorylation in melanoma cells [214, 235]. Beyond 
p38/USF signaling responsible for the UV-induced tanning response, a functional cyclic AMP 
(cAMP) pathway is also essential to mediate a proper melanin pigmentation in melanocytes 
[308]. The paracrine signal to activate the cAMP cascade in melanocytes is the α-MSH 
peptide hormone. α-MSH is one of several cleavage products of a large precursor peptide 
called pro-opiomelanocortin (POMC) that is synthesized in cutaneous keratinocytes. For a 
constitutive pigmentation, secreted α-MSH binds to the simultaneously induced quantities of 
MC1R on the surface of melanocytes [308-310]. This ligand/receptor interaction sets off the 
stimulated production of the cAMP second messenger which leads to the nuclear translocation 
of the microphthalmia-associated transcription factor (MITF) and the MITF-mediated basal 
transcription of TYR and MC1R to keep a steady state of tanning response in melanocytes 
[308]. 
All melanoma cells utilized for this thesis were cultured with a 10% CO2 atmosphere 
and in the presence of 10% non-heated FBS. For our initial experiments we worked with the 
human M000921 melanoma cells, directly isolated from a patient at the Dermatology 
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Department, University Hospital Zurich (group of Prof. R. Dummer). M000921 cells are 
proliferative, non-pigmented human melanoma cells, express both mRNA and protein 
components of key players of the basal (i.e. MITF) or UV induced branch (USFs) of melanin 
synthesis [214].  
To test if this USF1 activation is translated onto the changed expression of USF target 
genes (tyrosinase, TYR; melanocortin 1 receptor, MC1R), we checked by real-time 
quantitative PCR (qPCR) the expression profile of TYR and MC1R mRNAs as a function of  
UVC irradiation. We included with growth arrest and DNA-damage-inducible, 45 alpha 
(GADD45a), a known UV-inducible marker of DNA double-strand breakage [303, 304] to 
parallel assess the severity of any mutagenic UV impact on the cells. Optimally, the UV 
conditions should trigger an activation of the tanning response genes TYR, MC1R while not 
stimulating an elevated expression of GADD45a, since we wanted to keep DNA damage in 
the cells to a minimum. However, the qPCR data demonstrated a dose-dependent increase in 
GADD45a mRNA level when M000921 cells were subjected to 1, 2 and 4mJ/cm2 doses of 
UVC, whereas these quantities of UVC irradiation resulted in decreasing TYR and MC1R 
transcript levels. 
Various publications provided clear evidence that TYR or MC1R mRNA levels were 
up-regulated by UVC [235, 311] or UVB stimulation [267, 312, 313]. Yet, Hara et al. 
observed by reverse-transcription PCR that a marked UVB-triggered induction of TYR 
mRNA levels occurred only in several melanoma cell lines and not in others. This cell 
specific UVB-mediated increase in TYR transcripts was not correlated with melanoma’s 
ability of pigmentation [314]. Ota et al., on the other hand, documented a nearly 2-fold 
increase in TYR mRNA expression after repeated exposure to 5mJ/cm2 of UVB for 7 
consecutive days for three pigmented murine melanocytes, melan-a2, melan-b and melan-s. 
The non-pigmented murine melanocyte line, melan-c, exhibited no TYR response to UVB 
[315]. Further complexity is added in regard to the data by Scott and colleagues who reported 
on a two-step regulation of MC1R mRNA in melanocytes exposed to low (7mJ/cm2) or 
moderate (14mJ/cm2) doses of UVB: a down-regulation of MC1R mRNA level at 6hr and an 
up-regulation at 24hr post-irradiation. The authors proposed that UVB directly induced DNA 
damage as well as stimulated the production of α-MSH. Induced α-MSH, in turn, acted as 
paracrine factor and mediated the effects of UVB on survival of melanocytes [316]. Thus, the 
overall emerging picture for UV-triggered activation of tanning response genes is surprisingly 
heterogeneous. The recent discovery by Corre et al. of a novel 47-kDa USF1 specific band in 
immunoblot analyses in response to prolonged periods of cellular stress, might provide some 
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explanation for these variable outcomes [268]. The authors found that exposure to the above 
stressors (DNA damage, oxidative stress, cellular infection) caused USF1 to be acetylated at 
Lys199 in a manner depending on the prior phosphorylation of Thr153. Remarkably, this 
phospho-acetylated USF1 lost transcriptional activity leading to the marked down-regulated 
expression of several of the genes implicated in pigmentation (TYR, POMC and MC1R) and 
cell cycle progression (CCNB1, CDC2 and TERT) [268].  
Therefore, we hypothesized that UVC irradiated cells may have been stressed too 
much by the completely non-physiological UVC wave-band, which resulted in the reduction 
of TYR and MC1R mRNA levels. In contrast to UVC, UVB wavelengths (290–320 nm) are 
able to traverse the atmosphere and to reach the Earth’s surface. UVB qualities of the 
ultraviolet spectrum are the most effective waveband in eliciting sunburns or melanogenesis. 
At the same time, UVB is also considered the main causative agent of many of the mutagenic 
and transforming effects attributed to UV exposure [259, 281, 317]. For these reasons, we 
next exposed M000921 cells to UVB (312nm). Unfortunately, we did not succeed in 
achieving a reproducible UV-induced USF1 phosphorylation in M000921 cells. A USF1 band 
of lesser mobility was either seen even in non-irradiated cells or remained undetectable in 
UVB treated cells. Even though the group of Prof. Dummer had established basal expression 
of MITF, TYR and DCT in M000921 cells, no validation had been carried out until these 
experiments here in regard to cells’ ability to activate USF signaling upon UV irradiation. 
Thus, for further experiments, we switched to the human melanoma cell line 501mel, a well 
established tool for analyses of UV-triggered gene responses including the robust (3-7 fold) 
induction of POMC and MC1R mRNA levels by UVB irradiation (80mJ/cm2) [267].  
Four different doses of UVB and two post-irradiation time points were investigated in 
normoxic and hypoxic 501mel cells. For combined stimulation of hypoxia and UVB signaling, 
cells were exposed to 1% oxygen for 16h prior to UVB and were grown for another 2 or 5h 
after irradiation under hypoxia. Exposure of 501mel cells to 40mJ/cm2 of UVB yielded the 
induction of a USF1 band with lesser mobility at both time points (2 and 5h post-irradiation) 
and both oxygen concentrations (21% and 1% oxygen 16h). However, this appearance of the 
alleged p-USF1 species in response to UVB (UVB: 40mJ/cm2, 5h post-UVB) displayed a 
considerable variability under normoxia in following immunoblots. Furthermore, hypoxia 
(1% oxygen, 16h) alone seemed to be able to generate p-USF1. There is some literature 
indicating hypoxia as  stimulus for the p38 kinase pathway in human prostate cancer cells 
(LNCaP) [318] or mouse neuroblastoma cells (Neuro2a) [319]. Thus, p38-driven USF1 
phosphorylation triggered by oxygen deprivation is not entirely surprising for some cell 
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backgrounds. Even when we subjected 501mel cells to a shortened hypoxic exposure of 7h 
without any UVB irradiation, we could still observe this more slowly migrating USF1 species 
(data not shown). To further analyze this confounding effect, we applied with compound 
SB203580, a highly specific inhibitor of p38 kinase activity. Treatment of 501mel melanoma 
cells with 10μM SB203580 is known to abrogate the UV-induced phosporylation of USF1 
[235]. To our surprise, 10 or 20 μM final concentrations of SB203580 had no affect on the 
formation of the p-USF1 band, suggesting that the observed “p-USF1” still may not 
correspond with the phosphorylated species of USF1.  
Furthermore, qPCR analyses of TYR, MC1R, PHD2, LDHA and BNIP3 expression 
revealed a profound hypoxic induction of PHD2 and BNIP3 genes and a marginal one for 
LDHA in 501mel cells. Yet, UVB irradiation failed to cause any up-regulation of TYR and 
MC1R mRNAs regardless of the oxygen concentration.  
At this point we had to assess if our batch of 501mel cells was actually capable of any 
UV response, since UVC-mediated up-regulation of TYR mRNA in 501mel cells was 
reported by Galibert et al. [235]. Despite the non-physiological nature of this stimulus, we 
subjected our melanoma cells also to UVC irradiation (UVC: 1, 2 and 4mJ/cm2; response: 5h 
post-UVC) and recorded GADD45a, TYR and MC1R mRNA steady state levels. We 
obtained an overall UVC expression profile very similar to that of M000921 cells. As can be 
seen in Fig. 9D, exposure to the above detailed UVC conditions resulted in an up-regulation 
of GADD45a mRNA and a down-regulation of both TYR and MC1R transcripts in 501mel 
cells. Either cell line is apparently incapable to elicit positive responses of tanning genes when 
facing UVB or UVC challenges. This could stem from a cell-related or a UV-related problem. 
Since it is known that in the absence of the cAMP inducing α-MSH signal, a single irradiation 
of melanocytes with 28mJ/cm2 of UVB leads to a decrease, rather than increase, of TYR 
activity as well as protein levels [320], defects in either the p38 or cAMP cascade in our 
melanoma lines could underlie the failure to induce tanning components (TYR, MC1R) in 
response to UVB/UVC signals. 
Therefore, addressing the following key questions will be of vital importance to still 
make this line of work a successful endeavor: 
a) Is the observed down-regulation of TYR and MC1R mRNAs in UVB/UVC-
exposed M000921 and 501mel cell lines associated with the acetylated form of USF1, which 
switches the factor from trans-activator to trans-inactivator [268]? 
b) Are our batches of M000921 and 501mel cell lines defective in either the p38/USF-
mediated or the α−MHC/guanylate cyclase/cAMP-mediated pathways that are known to work 
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side by side for an appropriate tanning response in melanoyctes/melanoma cells (details 
below)? If so, which cell lines are better tools in regard to these signaling mechanisms and 
UV-triggered gene responses? 
Answers to both questions can be obtained by any of the following approaches:  
i) The appearance of the true p-USF1 species is associated with the auto-
phosphorylation of p38 itself, yielding p-p38, in response to UV radiation [235]. Thus, one 
needs to test intact p38 signaling in UV irradiated melanoma cells by measuring the p-
p38/total p38 ratio as indicator of the functionality of this cascade in melanoma cells. Specific 
antibodies for phosphorylated and total p38 are commercially available [321]. As additional 
readout for a functional p38 cascade, treatment of cells with p38 kinase inhibitor SB203580 
should reverse the appearance of a lesser-mobility USF1 band.  
ii) Our suspicion that the observed USF1 species of lesser mobility in SDS-PAGE gels 
did not correspond to the phosphorylated form of the transcription factor stems mainly from 
the complete resistance of the signal to the specific p38 kinase inhibitor SB203580. Thus, 
attempts should be made to isolate the upper USF1 band from preparative gels and conduct 
mass spectrometric determinations of its peptide masses in order to reveal the nature of its 
post-translational modification. In parallel, one should treat cells with specific deacetylase 
inhibitor trichostatin A [268] to see if this drug causes an increase in the upper USF1 band 
signal. If so, this would lend strong credibility to the notion that the UV-induced species is the 
acetylated repressing, and not the phosphorylated inducing form of USF1.  
iii) Other melanoma lines need to be screened for an UV-conferred up-regulation of 
TYR and MC1R mRNA levels, and if affirmative, also for the appearance of a p-USF1 
species (reversal by SB203580 treatment). Those cell lines which both criteria characterized 
the existence of an intact UV-induced tanning response cascade will be subjected to HRE/E-
box reporter (LDHA, BNIP3) transfections in conjunction with hypoxia-only, UV-only and 
hypoxia/UV dual exposure regiments. 
iv) To test the USF-specific impact on HIF-driven LDHA or BNIP expression can be 
done by co-transfecting cells, prior to hypoxia/UV dual exposures, with the dominant-
negative A-USF variant which contains USF heterodimerization domain but lacks of USF-
specific region [209], and determining if the modified reporter response converts back to its 
normal hypoxic activity.  
  v) In addition, even those melanoma cells that remain unresponsive to UV signals as 
judged by the criteria in (iii), may not be completely non-informative, since the suspected 
defects in p38 signaling can be circumvented through transfections with a constitutively 
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active USF1 mutant (T153E) which has been generated in Galibert’s lab in 2001 [235]. That 
way, the transcriptional impact of a phosphorylation-independent USF1 construct on HRE/E-
box promoters can still be assessed in hypoxic, HIF-1 positive melanoma cells (to be 
validated). Similarly, suspected defects in the cAMP pathway (e.g. α-MHC application yields 
no TYR/MC1R mRNA response and no MITF nuclear translocation) can also be addressed 
since cAMP signaling is mimicked through 10μM of forskolin [321]. This surrogate 
treatment should be used to recover TYR or MC1R responsiveness in cells with suspected 
defects in the cAMP cascade.  
 
8.2 Outlook 
Our current data on human cancer cells revealed the agonistic and antagonistic 
interactions of HIF-1 and USFs on the promoters of the human LDHA and BNIP3 genes. The 
relevance of this finding lies within the potential to gain mechanistic insights into the 
crosstalk of hypoxia- and UV-signaling components and apply this research to the biology of 
human melanoma cells. Melanocytes and primary melanoma cells reside in a chronically 
hypoxic cutaneous microenvironment and carry out the UV-induced tanning response during 
which the natural sun-blocking pigment melanin is synthesized to protect the skin from any 
mutagenic insult by intermittent or persistent ultraviolet radiation. 
Based on the data obtained in this pilot study with human melanoma cells, a follow-up 
project is required to further optimize the conditions leading to a robust, reproducible and 
USF-dependent induction of tanning response effector genes by UV irradiation (i.e. pursue 
experimental answers to issues raised in points i-v, above). At the same time, conditions 
should be selected for a minimal DNA breakage. Once these irradiation conditions have been 
worked out, subsequent focus should lie on investigating the crosstalk between hypoxia/HIF-1 
and UV/USF cascades in HRE/E-box-reporter transfected melanoma cells that will be 
subjected to hypoxia-only, UV-only and hypoxia/UV-dual stimulation regimes. Thus, the 
main tasks of the follow-up work will be:  
1) to establish the optimal UV irradiation conditions using the following readouts: a) 
TYR, MC1R mRNA induction and formation of p-USF1 species; b) Trypan blue viability 
assay for assessment of UV-mediated cytotoxicity; c) GADD45a mRNA and p53 protein 
induction for assessment of UV-mediated DNA damage.  
2) to carry out a genome-wide comparison of hypoxia-only, UV-only and 
hypoxia+UV exposed melanoma cells to reveal hypoxia-regulated genes which are also 
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susceptible to UV signals. How widespread are HIF/USF cooperative or antagonistic inter-
relationships and which genes are affected and which way?  
So far, UVB or UVA -induced alterations in gene expression profiles have been 
elaborated by cDNA microarray and real-time qPCR human keratinocytes or melanocytes 
[281, 282, 303, 322]. Consequently, there is hardly any available data about UV-regulated 
transcriptome profiles, including the responses of tanning effector genes, for human 
melanoma cells. Worse, the transcriptomic/proteomic studies existing to date for the 
elucidation of UV-responsive genes recorded these profiles under non-physiologically 
hyperoxic, hence genotoxic, conditions. Thus, systematic and physiologically meaningful 
screens of the UV-mediated expression profiles in deoxygenated, HIF-1 positive and tanning 
competent cell systems, are urgently needed.  Hypoxia/UV co-responsive genes found by the 
approach in (2) will be validated by real-time qPCR and ChIP approaches using both wild 
type and stable knockdown HIF-1α or USF1 clones of the transcriptome-screened melanoma 
cell line. 
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Part B Hypoxia-mediated myoglobin expression in human breast cancer 
 
9 Background 
 
Myoglobin (Mb) and hemoglobin (Hb) are two well known members of the family of 
globin proteins. Globins are heme-binding proteins which can reversibly bind oxygen and 
other diatomic gases via the iron atom in the centre of the porphyrin chromophore. The 
heterotetrameric Hb (human HbA1 = α2β2) transports oxygen in the blood, whereas 
monomeric Mb temporarily stores and transports oxygen within vertebrate heart and skeletal 
muscle cells [323]. Mb is a cytoplasmic hemoprotein, exclusively expressed in cardiac 
myocytes and oxidative skeletal muscle fibers. Besides Mb and Hb, two other family 
members, neuroglobin (Ngb) and cytoglobin (Cgb), have recently been discovered. Ngb is 
mainly expressed in the cytoplasm of neuronal (brain and retina) cells, whereas Cgb is 
primarily expressed in fibroblasts and fibroblast-related cell types in a broad variety of organs 
including liver, heart, muscle, gut, kidney, lung and pancreas. Both globins bind oxygen 
reversibly and may be involved in cellular oxygen homeostasis [324-326]. 
 
9.1 Structure and function of myoglobin 
The three-dimensional structure of sperm whale myoglobin was first delineated by 
Kendrew and his colleague over 50 years ago [327, 328]. Since then, a number of works 
continually refined the tertiary structure of Mb. Collectively, these studies established that Mb 
is a single polypeptide chain consisting of eight α-helices. These α helices wrap around a 
central pocket containing a prosthetic protoheme group which is bracketed by two histidine 
residues (His64 and His93). The iron interacts with six ligands, four of which are provided by 
the nitrogen atoms of the four pyroles of the porphyrin ring system. The imidazole side chain 
of His93 provides the fifth ligand for stabilization of the heme group. The sixth ligand position, 
which is unoccupied in deoxymyoglobin, acts as the binding site for O2, and for other gaseous 
ligands such as carbon monoxide (CO) or nitric oxide (NO) [329, 330].  
Similar to hemoglobin, binding of O2 to Mb does not oxidize the central iron ion. 
Rather, binding of O2, known as oxygenation, can switch deoxyMb (Mb) to oxyMb (MbO2) 
without change in the valency of the ferrous iron atom (i.e. MbFe2+ + O2 ? MbFe2+O2). 
Oxidation of the iron from a ferrous (Fe2+) to a ferric ion (Fe3+) found in the so-called Met 
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form of the protein can occur during oxidative insults (e.g. ischemia-reperfusion) and renders 
Mb or Hb incapable to bind any more O2. To prevent a pathological build up of Met-Mb or 
Met-Hb, cytochrome b5/b5 reductase systems (i.e. Met-Hb reductase) have evolved to reduce 
ferric into ferrous iron within the heme of the protein. Thus, a ferrous iron (Fe2+) is critical for 
the reversible binding of the O2 or CO ligand. 
In diving mammals (e.g. sperm whale, seals), concentrations of Mb of 4-5 mM 
expressed in the cardiac and skeletal muscles aid as temporary O2 store during the breath-hold 
period of the dive [329, 331]. This wealth of the protein helps to postpone or alleviate tissue 
hypoxia when no ambient O2 can be acquired. Striated muscle in humans, on the other hand, 
contains on average 200 μM of Mb. Here the alleged main function of Mb has shifted more 
towards the facilitation of oxygen diffusion from the periphery of the cell to the mitochondria. 
However, unlike tetrameric Hb with its sigmoid-shaped oxygen equilibrium curve that 
illustrates the cooperativity of binding the ligand by all four subunits, monomeric Mb has a 
single O2-binding site and thus exhibits a hyperbolic O2 equilibrium curve characteristic of 
normal Michaelis-Menten enzyme kinetics (Fig. 10) [330]. The oxygen-binding curves of Mb 
and Hb also indicate the completely different oxygen binding affinities of both hemoproteins. 
While human HbA1 has a P50 (i.e. oxygen partial pressure at 50% saturation) of 
approximately 27mmHg, in contrast, human Mb displays a much stronger binding of O2 (P50 
of 3mmHg) [332]. During normal exercise, 40-70% of Mb will remain saturated with 
dioxygen (Mb+O2↔MbO2) [331]. 
 
 
Figure 10 Oxygen-binding curves of myoglobin (Mb) and hemoglobin (Hb). Mb and Hb function as oxygen 
transporter. Myoglobin displays a hyperbolic-shaped oxygen-binding curve, in contrast, hemoglobin displays a 
sigmoidal-shaped oxygen-binding curve [330]. 
 
 The oxygen-binding curve implies further that Mb-bound oxygen starts to significantly 
dissociate from the protein only when intracellular pO2 < 10mmHg, i.e. during severe hypoxic 
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conditions. Animals, which live in low oxygen environments, adapted various means to better 
survive hypoxia, including increased capillary densities, Mb concentration and volume 
densities of mitochondria. That way, oxygen can still adequately be delivered to the 
mitochondria and aerobic metabolism be maintained, while the organism encounters markedly 
reduced levels in ambient oxygen. 
As stated above, Mb has been proposed to function in the facilitated oxygen diffusion 
in human cardiomyocytes by J. and B. Wittenberg [323]. However, this function still is rather 
controversially discussed. Based on measurements and calculation of oxygen transport by Mb 
in skeletal muscle, various studies suggested that contribution of myoglobin to intracellular 
oxygen transport in intact red muscle was of minor importance [333, 334]. An additional role 
of Mb is the proteins’ regulation of NO bioavailability within the cardiomyocyte. MbO2 can 
rapidly and effectively scavenge NO through the following diffusion-limited reaction: MbO2 
+ NO ? Met-Mb + NO3- (oxymyoglobin +NO ? ferric iron met-myoglobin + nitrate) [335]. 
Furthermore, cardiomyocytes expressed Mb functions as a scavenger not only of NO but also 
of ROS and thus participates in protecting the heart from these highly reactive radicals [336]. 
To understand the in vivo role of Mb in striated muscle, Mb-/- mice were generated by 
two laboratories via the deletion of exon 2 of the single copy Mb gene. Exon 2 encodes the 
heme-binding domain including both coordinating histidines, and thus is essential for a 
functional protein. Experiments with these knockout survivors showed that Mb-deficient mice 
can grow normally, are fertile and exhibit normal exercise capacity as well as a normal 
ventilatory response to low oxygen levels [337]. However, these Mb-/- mice developed several 
important compensatory adaptations in the heart to support and uphold an O2 delivery during 
exercise despite the lack of this O2 carrier. These compensations included increased capillary 
densities and blood O2 carrying capacity as well as elevated hematocrit values [338]. 
Subsequent studies of skeletal muscles in Mb-/- animals also showed these compensation 
mechanisms. Additionally, the work by Grange et al. demonstrated a fiber type transition 
(from slow myofibers (type I) to fast myofibers (type II) in soleus), augmented expression of 
HIF-1α and -2α, of stress proteins such as heat shock protein 27, of the angiogenic vascular 
endothelial growth factor and of enhanced nitric oxide metabolism in response to Mb 
deficiency in muscle and cardiomyocytes [339, 340]. These findings were critical in 
enhancing our understanding of the workings of Mb as oxygen transporter and regulator of 
NO and ROS homeostasis in striated muscle. 
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9.2 Hypoxia mediated myoglobin expression  
For a long time we have known the impacts of exercise and hypoxia on Mb expression 
in oxidative muscle fibers (reviewed in:[341]). For example, Vogt et al. reported that 
endurance training promoted development of tissue hypoxia in human skeletal muscle and, 
subsequently, elevated Mb mRNA steady state concentrations in conjunction with increasing 
level of HIF-1α transcripts [46]. The study by Fraser and colleagues on Mb in the hypoxia-
tolerant carp, however, expanded occurrence and hypoxia-responsiveness of Mb even to non-
muscle tissues. One of two carp myoglobin transcripts, Myg-1, was expressed not only in 
muscle but also in liver, kidney, heart and gills of the fish. Moreover, Myg-1 mRNA and 
protein was strongly induced by hypoxia in these tissues. In contrast, expression of Myg-2 
was restricted to brain and independent on oxygen [342]. Additionally, a study on a long-term 
(for 3 weeks) response to severe hypoxia in zebrafish revealed a robust myoglobin induction 
in the gills [343]. 
Outside of striated muscle, human Mb was recently shown to be expressed in 
epithelial tumors which had faced intermittent periods of hypoxia and oxidative stresses 
during cancer progression. In contrast to normal breast epithelial cells (MCF-10A), de novo 
mRNA and protein Mb expression was shown for breast cancer cells (e.g. MCF7). 
Furthermore, this Mb protein expression in MCF7 cells was confirmed to be induced in 
response to 48h/1% O2 exposures. Immunohistochemistry confirmed this induction of Mb in 
other human carcinomas as well. Moreover, Mb expression was also induced by several other 
stimuli, such as oxidative stress and mitogenic signals (epidermal growth factor) [344]. 
Galluzzo et al. reported that Mb was able to attenuate the hypoxia-mediated cancer 
progression by enhancing the oxygenation of the resulting xenografts when Mb was 
overexpressed in A549 human lung carcinoma cells and MDA-MB435 human breast cancer 
cells by transferring an Mb expressing lentiviral construct. In this system, Mb expression 
yielded a marked reduction of tumor angiogenesis and significantly inhibited tumor growth as 
well as metastatic spreading [345].  
Despite the evidence above for an O2-responsive transcriptional control of the Mb 
gene, sequence comparison by Wystub et al. failed to detect conserved HREs when 
comparing the upstream flanks of human, mouse and rat Mb genes. Rather, the authors 
noticed conserved mRNA stabilization signals within the 3’ untranslated regions (utr) of the 
Mb gene [346]. A recent study on hypoxia mediated Mb expression in cultured mouse C2C12 
myoblasts and whole animals documented that hypoxia alone could not stimulate the 
induction of the Mb gene. Analysis of 10-kb of upstream DNA of mouse, human and rat Mb 
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genes failed to show any conserved HRE site for HIF-1 complex. This study reported that the 
hypoxic induction of Mb operates independently of HIF-1. Rather, levels of low oxygen 
would trigger a calcium signaling event, which in turn activates the calcineurin/NFAT 
pathway that underlies the hypoxia-mediated Mb expression [347].  
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10 General objectives  
 
Recently, Flonta et al. reported that Mb was strongly detectable in different epithelial 
human breast tumors and cell lines, but not in cells of normal breast tissue. The authors also 
showed for MCF7 breast carcinoma cells that hypoxia is able to induce Mb protein levels 
[344]. As part of a larger collaborative effort we aimed to further extend our understanding of 
the expression, regulation and function of Mb and of the proteins’ prognostic impact in human 
breast cancer. Our immunohistochemical survey involved analysis of Mb in human breast 
cancer specimens (n=917) and revealed endogenous expression in 71% of invasive breast 
carcinomas, preferentially of luminal-type. Mb positivity correlated with expression of the 
estrogen receptor alpha (ERα) and a favorable patient prognosis. A positive correlation of the 
hemoprotein with hypoxia-inducible factor 2α (HIF-2α) and carbonic anhydrase IX (CAIX) 
suggested oxygen to regulate Mb in breast carcinomas. Indeed, Mb mRNA and protein levels 
were robustly induced by prolonged hypoxia in different breast cancer cell lines, thus 
confirming this set of data of the Flonta’s study. 
The aim of my part of this project was therefore to clarify whether the hypoxia-
induced Mb expression in cultivated MDA-MB-468 and MCF7 human breast carcinoma cell 
lines is HIF-dependent. 
Main research objectives included: 
1) to determine the kinetics of the hypoxia-mediated induction of Mb protein at 1% 
oxygen 
2) to investigate the requirement of HIF for this induction of Mb by using transient 
knockdown approaches with siRNAs directed against HIF-1α, HIF-2α or both;  
3) to generate stable short hairpin RNA (shRNA)-based Mb knockdown MDA-MB-468 
clones for further characterization of potential respiratory and tumorigenic properties 
of Mb in human breast cancer cells. 
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11 Own research 
 
The following section summarizes my own contribution included in the manuscript 
“myoglobin in breast cancer” enclosed in this dissertation. 
 
11.1 Hypoxia-induced myoglobin protein levels in MDA-MB-468 and MCF7 breast 
cancer cell lines 
Our collaborators could provide solid evidence for the mRNA level activation of Mb 
gene transcription by prolonged hypoxia (1% O2) in human MDA-MB-468 and MCF7 breast 
cancer cell lines. Mb protein level response to hypoxia was analyzed for the same cells 
subjected to 72h normoxia or 4, 8, 24, 48 and 72h hypoxia (1% O2). In SDS PAGE analyses, 
breast cancer cell expressed Mb protein showed identical mobility relative to muscle 
expressed Mb (biopsied material). In agreement with RNA expression data, both cell lines 
induced Mb protein between 3.4 and 5.1-fold following a hypoxia exposure of 48h or longer. 
In addition, the HIF response was transient in hypoxic MCF7 cells. Here, induction of the 
predominant species, HIF-1α, peaked at 4h hypoxia, followed by a steady decline of the 
protein content thereafter. In contrast, hypoxic MDA-MB-468 cells expressed preferably HIF-
2α whose induction persisted for up to 72h of 1% O2. 
 
11.2 Involvement of HIF-1α and -2α in Mb induction in MDA-MB-468 subjected to 
prolonged deprivation of oxygen 
To study the role of HIF in the hypoxic induction of Mb, we utilized siRNA 
oligonucleotides specifically directed against nucleotides 1380-1400 of HIF-1α mRNA 
(Entrez accession number: AF304431.1) and nucleotides 1260-1280 of HIF-2α mRNA 
(Entrez accession number: NM_001430.3), respectively. To gain the optimal knockdown 
efficacy in MDA-MB-468 cells, two different final concentrations of siRNA oligonucleotides 
(100nM and 200nM for single siRNA; 50/50nM and 100/100nM for combined siRNAs) and 
two hypoxic exposures (24h + 48h/1% O2, starting at 18h post-siRNA transfection) were 
tested. Subsequently, changes in HIF-1α and -2α protein level were detected by Western blot.  
Maximal knockdown efficacy of HIF-1α or 2α was achieved at 48h hypoxia exposure with 
final concentrations of 200nM for single siRNAs and 100nM for each siRNA for the 
combined targeting of HIF-1α and -2α. As negative control, MDA-MB-468 cells were 
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transfected with a non-targeting siRNA pool of scrambled sequences (siControl) at a final 
concentration of 200nM.  
Since induction of Mb protein levels was robustly detected from 48h hypoxia onwards, 
the siRNA assay focused on control and HIF-1α (= siHIF-1α), -2α (= siHIF-2α) and 
combined knockdown effects (= siHIF-1α/2α) after 52h to 96h of exposure to 1% O2. A 
maximal ~7-fold induction of Mb protein was reached at 72h hypoxia during the siControl 
transfections. This 72h-peak induction was reduced to ~4-fold upon single HIF-1α or -2α 
siRNA treatment. Moreover, the combination of both siRNAs, with ~30% residual content of 
either HIF factor remaining, significantly attenuated the Mb induction to ~1.7 fold at 72h 
hypoxia. Therefore, this data implied both HIF-1 and HIF-2 in participating in the peak 
stimulation of Mb during prolonged periods of low oxygen. 
 
11.3 Stable Mb knockdown MDA-MB-468 clones  
To demonstrate a functional relevance of Mb in breast cancer cells, stable knockdown 
Mb MDA-MB-468 clones were generated using short hairpin RNAs (shRNA) that target the 
mRNA of human myoglobin at nucleotides 284-304 (constr. 83), 483-503 (constr. 84), 340-
360 (constr. 85) and 415-435 (constr. 86) (positions in accordance to GenBankTM accession 
number NM_203377). Inserted into the mammalian expression vector pLKO.1-puro, these 
four shRNA constructs, were purchased as bacterial glycerol stock from Sigma-Aldrich 
(Basel, Switzerland). Stable shRNA Mb knockdown MDA-MB-468 cells were established by 
overnight calcium phosphate transfection followed by selection and maintenance in 
0.75μg/ml puromycin containing medium. Mb protein levels in knockdown and control cells 
were analyzed by Western blot as described above. Myoglobin level in clones 83#4, 83#8, 
83#9, 84#31 and 86#13 was strongly suppressed, whereas Mb level in clones 84#2, 84#5, 
84#20, 85#14 and 85#18 remained unaltered. Densitometry of β-actin normalized Mb band 
intensities from 3 independent analysis showed that the Mb protein level was most strongly 
reduced in 3 individual clones 83#4, 83#8 and 84#31 with residual contents at 20%, 20% and  
30%, respectively. Clones 84#5, 84#20 and 85#14, which had been subjected to the same 
transfection/selection procedure but where Mb remained unaltered, were taken as negative 
controls. Due to unexplainable technical problems, clones 83#8 and 84#31 lost knockdown 
effect in later passages. Ultimately, clone 83#4 was taken as stable knockdown Mb for further 
functional tests. 
 80
13 Conclusion and outlook 
 
Since Ray Lankester’s [348] first identification, Mb is commonly thought to solely 
occur at milli- to micromolar concentrations in cardiac myocytes and type I and IIa skeletal 
muscle fibers of mammals. In myocytes, the monomeric hemoprotein is widely accepted to 
function as  temporary “store” for oxygen and able to buffer short phases of exercise-induced 
increases in O2 flux during which it supplies the gas to mitochondria [330]. Another, more 
controversially discussed role is Mbs’ facilitation of oxygen diffusion within muscle cells 
[333, 334]. Mb knockout mice which were generated by two laboratories in the late 90’s [337, 
338] exhibited normal exercise capacity and no signs of compromised cardiac energetics due 
to multiple systemic compensations [338]. However, follow-up studies stressed the 
importance of functional myoglobin in maintaining nitric oxide (NO) homeostasis in muscle 
through either scavenging [336] or producing the NO molecule [349]. That way, Mb might 
participate in tuning vasodilatory responsiveness and protecting the cytochrome c oxidase in 
the respiratory chain from inhibition by elevated NO concentrations [341, 350].  
Work on the common carp and zebrafish recently revealed an unexpected multiplicity 
of Mb genes and protein expression in non-muscle tissues, such as liver, brain and gills (see 
[341] for review). Furthermore, in these fish species expression of certain Mb isoforms was 
strongly up-regulated by reduced tissue oxygenation in the liver and gills of these fish [342, 
343, 351]. In humans, the single-copy Mb gene synthesizes the protein at concentrations of 
~200-300 μM in striated muscle, whose expression is highly responsive to chronic muscular 
activity or hypoxia [330, 352]. In human skeletal muscle, Mb in mitochondria rich oxidative 
myofibers shows elevated synthesis in response to exposure to high altitudes [352] or intense 
endurance training under reduced oxygen pressures [46, 330, 352]. Striated muscle of mice 
shows in vivo induction of the Mb gene by chronic hypoxia. The master regulator of cellular 
O2 homeostasis HIF-1 has been implicated in the mouse for this transcriptional activation 
[353]. The possibility that HIF-1 might generally be involved in the induction of Mb is 
supported by two observations. First, stimulation of the HIF-1 pathway in muscle is triggered 
by exercise with or without hypoxia and mechanical stress (stretching) [46, 354, 355]. 
Second, the HIF-1/Mb system is colocalized in oxidative skeletal myofibers (type I and IIA 
fibers) [330, 356]. Therefore, the link between hypoxia/HIF signaling and Mb production can 
reasonably be extended onto neoplastic tissues. The logical next step is to provide 
experimental proof for this supposition. 
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Our own collaborative breast cancer study (see manuscript for detail) initially looked 
at the in vivo and in vitro abundance of Mb products. Mb mRNA expression was upregulated 
in nine of ten matched (same patient) normal/tumor tissue samples with a median tumor-to-
normal up-regulation of 352 fold. With regard to breast cell lines, Mb mRNA was not 
detectable in benign MCF12A epithelial cells, while ten breast cancer cell lines (incl. MDA-
MB231, MCF7) expressed detectable but low amounts of Mb mRNA. Three breast cancer cell 
lines, including the MDA-MB-468 line, contained abundant quantities of the Mb transcript. 
When using tissue microarrays and a validated monoclonal Mb antibody, our survey detected 
Mb protein in normal breast tissue (n=56 cases), intratumoral ductal carcinoma in situ (DCIS; 
n=155) and invasive breast cancer (n=917). In normal breast tissue, staining was observed in 
secretory luminal epithelial cells, but not in myoepithelial cells. In invasive carcinoma, the 
number of Mb positive or negative cases was markedly higher than in normal tissue. 
Increased expression of Mb in breast carcinomas occurred independently of rhabdomyoid 
tumor differentiation. With increasing transformation and aggressiveness (normal tissue ? 
DCIS ? invasive carcinoma) the proportion of Mb negative and strongly positive tissues both 
gained in frequency. 
In invasive breast carcinomas Mb expression was associated with better histological 
tumor differentiation and with estrogen (ERα) and progesterone receptor (PgR) positivity. 
High Mb expression was also significantly associated with longer overall patient survival 
(five-year survival rate of Mb-pos. cases 83% vs. 75% in Mb-negative cases). Positive 
correlations of presence of Mb were found to the hypoxia-inducible factor 2α (HIF-2α) 
(correlation coefficient, cc=0.257, p=0.001), carbonic anhydrase IX (CaIX; cc=0.361, 
p=0.001), cytoglobin (Cygb; cc=0.361, p=0.001) and E-cadherin (E-Cad; cc=0.207, p=0.001). 
In contrast, no significant correlation was found with HIF-1α, glucose transporter 1 (GLUT1), 
the proliferation indicating Ki-67 marker and microvessel density. 
To study the responsiveness of the Mb gene, the effect of hypoxia (1% O2; 4, 8, 24, 48, 
72h) was analyzed by quantitative real-time PCR (qPCR) in four different cell lines: the 
benign breast cell line MCF12A, the ERα-negative breast cancer cell lines MDA-MB-231 
(low basal Mb expression) and MDA-MB-468 (high basal Mb expression), and the ERα 
positive cell line MCF7 (medium basal Mb expression). Whereas transcription of the Mb gene 
was unaltered by hypoxia in the benign MCF12A cells, normalized steady state levels of Mb 
mRNA increased 3-4 fold in hypoxic MDA-MB-468, MDA-MB-231 and MCF7 cells. In all 
cases, a robust activation of the Mb gene required at least 24h or 48h of hypoxia to take effect. 
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Activation of the Mb gene by prolonged hypoxic exposure MCF7 cells was also noted in the 
study of Flonta et al. [344]. 
Thus, the aim of my contribution to the “Mb in breast cancer”-project was to analyze 
the control of hypoxia over Mb synthesis at the protein level and to examine whether this 
hypoxic induction of Mb requires the activity of HIF-1 or HIF-2. To tackle this task, I worked 
with two human breast carcinoma cell lines: MDA-MB-468 and MCF7. I also generated 
stable shRNA-based Mb knockdown clones of MDA-MB-468 cells. 
  I found the Mb protein, in agreement with the RNA expression profiling, 3-5 fold up-
regulated during prolonged hypoxia in both MDA-MB-468 and MCF7 breast carcinoma cells, 
although MDA-MB-468 cells displayed a much higher basal level of Mb protein than MCF7 
cells. Other colleagues in the team were able to quantitate that the amount of Mb protein in 
106 normoxic MDA-MB-468 cells as ~65 ng or 4 pmol by using a commercial 
chemiluminescence based Mb-assay.  
Towards the control of this induction, distinct HIF-gene preferences and stabilization 
kinetics became apparent in these two breast cancer cells. The HIF response was transient in 
hypoxic MCF7 cells where the predominant species, HIF-1α, peaked at 4h hypoxia, followed 
by a steady decline of the protein content thereafter. In contrast, hypoxic MDA-MB-468 cells 
expressed preferably HIF-2α whose induction persisted for up to 72h of 1% O2. Similar 
patterns of transient HIF-1α versus persistent HIF-2α induction profiles during maintained 
hypoxia were previously reported for human lung endothelial cells or human hepatoma cells 
(Hep3B) [357]. These kinetic distinctions between the HIF-α subunits are difficult to 
reconcile with a common PHD and/or FIH control mechanism. 
To our surprise, the most effective suppression of the 7-fold induction of Mb protein 
levels occurred in MDA-MB-468 cells subjected to 72 h hypoxia, when cells were 
simultaneously transfected with siRNAs directed against HIF-1α and -2α. This double 
silencing of both HIF subunits significantly attenuated the Mb induction from 7 to ~1.7 fold. 
The residual gene activation or protein stabilization must use HIF-independent mechanisms.  
In contrast to that, silencing of either HIF-1α or -2α alone did not significantly attenuate the 
hypoxia-triggered elevation of Mb in MDA-MB-468 cells. It thus becomes clear that both 
HIF-1 and HIF-2 actively participate in the peak stimulation of Mb at 72h of hypoxic 
exposure. Before and after this time point, the impact of any siRNA-HIF treatment resulted in 
hypoxic response time-courses of Mb that were indistinguishable (52-56h hypoxia), or 
insignificantly reduced (96h hypoxia), compared to siControl experiments. Transactivation of 
the Mb gene in breast cancer expressed apparently proceeds in HIF-dependent and -
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independent signaling waves. During these experiments we also noted, as did other studies on 
MCF7 cells before us [358], that single siRNA treatments against one HIF-α resulted in a 
reciprocal surplus accumulation of the other factor during periods of low pO2 (e.g. HIF-2α 
knockdown potentiates HIF-1α accumulation in hypoxia to 1.6-fold higher stead state levels 
as siControl transfections).  
Posttranscriptional controls might participate in the hypoxic stimulation of some Mbs, 
because several hypoxia inducible mRNA stabilization signals have been discovered in the 3’ 
untranslated regions (UTR) of human and rodent sequences [346]. The standard promoter of 
the Mb gene that is driving the expression in striated muscle cells has been characterized in 
1984 by Weller et al. for the human and in 1986 by Blanchetot et al. for the mouse Mb gene 
[359, 360]. This TATA box promoter contains no candidate HRE [346]. Consequently, 
expression of the standard Mb transcript (Mb-s) was found in our team effort to be not 
affected by O2.  
However, we also noted the hypoxia-activated transcription of a non-canonical Mb 
mRNA (alternative transcript: Mb-a), transcribed from a promoter that is located proximal to 
the 5’ UTR exon -1. EST evidence and our own comparison of the copy numbers of the 
alternative versus standard Mb mRNAs expressed in MDA-MB-468 cells suggested that Mb-a 
can tentatively be regarded as a cancer-specific transcript due to its ~300 fold higher 
expression level relative to Mb-s. Discovery of the O2-responsiveness of Mb-a, in conjunction 
with the found HIF-1/-2-driven transactivation of the Mb gene during hypoxia (above), 
prompted the search for candidate HREs as potential regulatory sites for the alternative 
transcript. Scanning the complete genomic region of human and mouse Mb genes for HRE 
motifs yielded a candidate HRE, which consists of two inverted HIF-1 binding sites at an 
interval of 6 bp, embedded in a conserved stretch of 53 bp. The 53bp stretch of the Mb-HRE 
has 93% sequence similarity to an upstream promoter region from the human heat shock 
protein HSPB1 gene that encodes the Hsp27 protein. Interestingly, promoter assays had 
already suggested that this observed HRE of HSPB1 is indeed functional in mediating HIF-1 
responses [361]. Based on these findings, breast cancer cells induce the Mb gene in response 
to longer periods of low oxygen via an alternative and perhaps tumor specific promoter whose 
enhanced activity depends, in part, on the binding of HIF-1/-2 to the HRE located 2.7 kb 
upstream from the ATG codon. We thus are beginning to obtain a mechanistic rationale for 
the significant positive correlation of Mb protein with HIF-2α and CAIX in breast carcinomas 
(see manuscript for detail). Logical follow-up studies of this discovery and to better 
understand the mechanism of the hypoxic induction of Mb transcripts and proteins in human 
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breast cancer cells, would be to a) evaluate occurrence of Mb-a in breast tumors and the 
transcripts association with regional tumor hypoxia; b) repeat Mb-a/Mb-s copy number 
assessment for matched tumor/healthy breast tissue sample; c) engineer a fluorophore-labeled 
Mb-a antisense RNA to detect and inhibit Mb expression in situ and d) examine whether the 
Mb-HRE functions as direct HIF-1/2 binding site in vivo and in vitro. 
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Abstract 
 
A constitutive CACGTG binding activity in human cancer cells was previously found to interfere with 
the HIF-driven hypoxic activation of a Daphnia globin gene promoter construct (phb2) from adjacent 
HIF-1 binding hypoxia response elements (HREs). Using gel supershift and pull-down assays we now 
identify upstream stimulatory factor (USF) 1 and 2 as the primary phb2 CACGTG-binding entity in 
human hepatoma (Hep3B), cervical carcinoma (HeLa) and breast carcinoma (MCF7) cell lines. A 
genome-wide computational scan for HRE and CACGTG motifs co-occurring adjacently in upstream 
sequences retrieved multiple O2-sensitive human genes. Luciferase (LUC) reporter of the human 
HRE/CACGTG bibox promoter constructs LDHA/LUC (lactate dehydrogenase A/LUC) and 
BNIP3/LUC (Bcl-2/E1B 19 kDa interacting protein 3/LUC) showed robustly elevated luciferase 
activities in transfected Hep3B, HeLa and MCF7 cells during hypoxia. Chromatin 
immunoprecipitation confirmed the in vivo convergence of HIF-1α, USF1 and USF2a onto LDHA and 
BNIP3 promoters. Hep3B and HeLa cell co-transfections of LDHA or BNIP3 reporter with HIF-1α 
and USF1/2a expression plasmids or specific siRNAs directed against each transcription factor 
revealed clear evidence for cooperative (LDHA) or competitive (BNIP3) crosstalk modes between 
HIF and USF pathways. Thus, USF signaling might operate to fine-tune or restrain cell type-
specifically HIF-mediated gene expression in hypoxic nuclei. 
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Introduction  
 
The key regulators of cells’ responses to inadequate oxygenation (hypoxia) are the hypoxia inducible 
transcription factor 1 and 2  (HIF-1 and -2) (44, 60). Relaying minutes-to-hours of hypoxia onto the 
level of DNA via HIF is a highly conserved signalling event across the animal kingdom (1, 17). 
During low oxygen partial pressures (pO2), the mammalian HIF-1 complex controls the activity of 
numerous genes as heterodimer composed of HIF-1α and HIF-1β subunits (12, 59). Whereas HIF-1β, 
also known as ARNT (aryl hydrocarbon receptor nuclear translocator), is constitutively present, the 
activity of the HIF-α subunits is regulated as a function of pO2. Homologs of prolyl hydroxylase 
domain 1-3 (PHD1-3) dioxygenases in both C. elegans and mammalian cells were identified to act as 
oxygen sensors of HIF (10, 26, 27). In the presence of oxygen and 2-oxoglutarate, the Fe (II)-
dependent hydroxylation of two proline residues in HIF-1α and -2α is catalyzed by PHDs. 
Subsequently, this hydroxylated HIF-α is recognized by the von Hippel-Lindau tumor suppressor 
protein (VHL) and rapidly degraded via the ubiquitin-proteasome pathway (26, 32). A second, O2-
requiring post-translational modification of HIF-1α/-2α occurs at an asparagine residue within the C-
terminal trans-activation domain. Hydroxylation of this particular Asn is catalyzed by asparaginyl 
hydroxylase called factor inhibiting HIF (FIH) to prohibit HIF-α/co-activator interaction and to block 
trans-activation of genes under high oxygen (35, 36). During hypoxia, both PHD and FIH reactions are 
inhibited, leading to α/β-subunit dimerization in the nucleus and binding to hypoxia response element 
(HRE) within target genes. HIF-1/-2 execute their transcriptional activity by recruiting co-activators 
such as p300/CBP (9, 28). Being members of canonical CANNTG E-box motifs, HREs consist of a 
mandatory consensus 5’-VNVBRCGTG-3’ (62) (V=not T; N= any; B=not A; R=A or G). To date, 
several hundred potential (38) and more than 70 validated hypoxia-responsive gene targets of HIF-1 
have been identified. Through this transcriptional outflow, HIF-1 is able to reprogram cellular 
metabolism, growth, apoptosis, and O2 supply in response to declining pO2 (62). 
 
Our previous work utilized the globin-2 gene (hb2) promoter (phb2) of the planktonic crustacean 
Daphnia magna, housing two functional HREs at position -258 and -107 and one CACGTG E-box 
palindrome (PAL) at -146, as luciferase reporter to analyze the responsible motifs and factors 
underlying the prominent hypoxic induction of hb2 in heterologous transfections of human cancer 
cells. An unknown constitutive CACGTG factor in human cancer cells was found to be able to 
interfere with the HIF-1-driven induction of the phb2 luciferase reporter (16). Here, we report on the 
identification of the primary phb2 CACGTG factor across several cancer cell lines as a complex of O2-
independently acting upstream stimulatory factors 1 and 2 (USF1, USF2). 
 
To launch a comprehensive analysis of the capacity of USF signaling to generally fine-tune or 
interfere with HIF’s transcriptional outflow, we implemented a genome-wide computational scan to 
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identify candidate human genes that have adjacent or overlapping HRE and PAL motifs in their 
upstream sequence. Our results suggest the occurrence both of competitive (BNIP3 promoter) and 
cooperative (LDHA promoter) crosstalk modes when HIF-1/USF signalling pathways were over-
expressed or silenced. This study, therefore, points to the potential of the oxygen-independent USF 
pathway to influence, and even inhibit, HIF-mediated gene expression in human cancer cells. 
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Materials and methods 
 
Cell culture: Human hepatoma cells (Hep3B), human cervical cells (HeLa) and human breast cancer 
cells (MCF7) were maintained in high glucose (4.5g/l) Dulbecco’s modified Eagle’s medium (DMEM) 
as described earlier (4). Cells were cultured at 37°C in incubators ventilated with room air in a water-
saturated, 5% CO2 containing atmosphere, which corresponds at sea level to a partial oxygen pressure 
of 141.6 mmHg or 18.6% O2 (“normoxia”). Hypoxic cells were subjected to 1% O2/5% CO2/balance 
N2 for 16h in a HERA Cell240 incubator (Heraeus). 
  
Antibodies: Mouse monoclonal anti-ATF-1 antibody (25C10G: sc-270) was purchased from Santa 
Cruz Biotech, INC. Rabbit polyclonal anti-USF1M, anti-USF2F, anti-USF2G, anti-USF2Z and anti-
USF2aO antibodies were kindly provided by Prof. B. Viollet (58). Generous additional antibody gifts 
included: a) rabbit anti human DEC1 (CW27) (56); b) rabbit anti human MYC (55); c) rabbit anti 
mouse ARNT (anti-mARNT R-1 lgG) (24); d) rabbit anti human ARNT (anti-hARNT C34) (51); e) 
rabbit anti human USF full length antibody (USF FL) (29). 
 
Computational sequence scan: Repeat-masked human genome sequence in FASTA format (hg18, 
build 36.1 finished human genome assembly by International Human Genome Project of March 2006) 
was downloaded from the UCSC Genome Bioinformatics Site 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/, database accessed on October 2, 2006). 
Sequence coordinates of the annotated features on the genome assembly (transcriptional and coding 
sequence start and end) were obtained from the same source (http://genome.ucsc.edu/cgi-bin/hgTables, 
database accessed on October 3, 2006). The computational scan was implemented as a PERL script 
and performed for individual chromosomes, using as input the genomic sequence and the list of 
feature coordinates. We searched within 1000 nucleotides upstream of the annotated 5`end of the 
transcript for the co-occurrence of a consensus HRE motif (62) and a CACGTG palindrome (PAL), 
and permitted, as seen in phb2, a maximal motif-motif distance of 100 nucleotides. Identifiers of these 
putative bibox (HRE+PAL) genes fulfilling the search criteria, together with the motif coordinates and 
their relative position with respect to the gene, were written into an output file. 
 
Luciferase reporter: Genomic DNA, isolated from HeLa cells using TRIzol Reagent ™ (Invitrogen, 
Basel, Switzerland), was used as template for the amplification of the promoter region surrounding the 
HRE, E-box palindrome (PAL) or bibox (= HRE + PAL) motifs via nested PCR (for primers, see 
Supplement Table ST 1). The 3’-end of any given amplicon always extended into the first exon of the 
respective gene. In detail, we amplified and cloned the following promoter regions (start/end always in 
regard to translation start ATG codon): a) human 4EBP1 gene, -518/+403; b) human MC1R gene, -
880/+9; c) human LDHA gene, -2617/+530; d) human TYR gene, -400/+108. The PCR products were 
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TOPO-cloned into the pCRII-TOPO vector (Invitrogen). Following a KpnI/XhoI digestion for 
4EBP1/pCRII and TYR/pCRII, a XhoI/HindIII digestion for MC1R/pCRII, and a HindIII/HindIII 
digestion for the LDHA/pCRII construct in accordance to a preceding re-amplification of the construct 
with a reverse primer carrying an extra HindIII site (see Table ST 1), the liberated insert was ligated 
into pGL3-basic luciferase vector (Promega AG, Dübendorf, Switzerland) to generate the luciferase 
reporter constructs. The BNIP3/pGL3-basic luciferase reporter vector was kindly provided by Prof. J. 
Okami (42). PHD2 luciferase reporter plasmid (P2P (-607/+3) wt) is a truncated version of the 
previously published human PHD2 promoter (40). HIF-1α expression plasmid (i.e. pcDNA3.1-hHIF-
1-PK tag) was a generous gift from Prof. P. Maxwell’s lab. All USF expression plasmids (pCR3-USF1, 
pCR3-USF2a and pCR3-USF2b) were kindly given to us by Prof. B. Viollet (41).  
 
Electrophoretic Mobility Shift Assay (EMSA): Nuclear protein extracts of Hep3B, HeLa and MCF7 
cells were isolated as previously reported (16). Protein concentrations of the extracts were measured 
by the BioRad method (Bio-Rad Laboratories, Reinach BL, Switzerland). Analysis of in vitro protein-
DNA interaction by EMSA was done as described earlier (16). All oligonucleotide sequences used as 
probes are shown in Supplement Table ST 2. For gel supershifts, 1.5 μl rabbit anti-USF1M, rabbit 
anti-USF2G or 1.0 μl mouse anti-HIF-1α (mgc3) were added into the reaction, respectively, followed 
by a 30 min pre-incubation at room temperature. Negative supershift controls included 1.5 μl pre-
immune serum from the same rabbit to be immunized against USF1M or USF2G, as well as 1.0 μl 
rabbit anti-human IgG (code: 309-005-003 Jackson Immuno Research). 
 
Pull-down assay: Wildtype and mutated phb2 -146 palindrome or -107 HRE oligonucleotides (see 
Supplement Table ST 2), biotinylated at the 5’ end and PAGE purified, were annealed into double 
stranded DNA and immobilized on streptavidin-coated magnetic beads (Dynal Biotech, Oslo, 
Norway). The pull down assay was adopted from a previous protocol (18).  
 
Western blot: Proteins were resolved in 10% SDS acrylamide gels and transferred onto a nitrocellulose 
membrane (Whatman GmbH, Dassel, Germany). The membrane was incubated with primary 
antibodies diluted in 5% milk TBS-T: (a) anti-HIF1α (mgc3) (1:500) or (b) anti-USF-1M or anti-USF-
2G (1:750) at 4°C overnight. The signal was detected with horseradish peroxidase-conjugated goat 
anti-mouse or anti-rabbit diluted 1:5000 and luminol substrate (100mM Tris-HCl pH8.5, 9% H2O2, 
1.25mM Luminol (in DMSO), 0.225mM p-coumaric acid (in DMSO)).  
 
Co-immunoprecipitation: 150 μg nuclear protein was diluted with a Tris buffer (50 mM Tris-HCl, 
pH7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM sodium vanadate and 0.5 mM PMSF) and 20 
μl mouse anti-HIF-1α or 0.75 μg anti-mARNT or 2.5 μl USF antiserum were added. The nuclear 
extract/antibody mix was rotated at 4°C over night. The next day, 40 μl of sepharose G beads were 
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added into the mix and incubated at 4°C for another 2.5h. The nuclear extract/antibody/sepharose 
beads mix was collected by centrifugation (3300xg, 1min), the pellet boiled at 95°C in 1×SDS sample 
buffer for 10min and the supernatant analyzed by Western blot. 
 
Transient reporter transfection: Half-confluent Hep3B, HeLa and MCF7 cells seated in ∅6cm plates 
were transfected overnight using the calcium phosphate method with different luciferase reporter 
constructs and β–galactosidase plasmid to normalize luciferase activity to varying transfection 
efficiencies. To carry out co-transfections, 15-500ng HIF-1α plasmid and/or 15-100ng USF1, USF2a 
or USF2b plasmid were added. In each transfection, pUC18 plasmid was used as filler DNA for a total 
of 2-3μg DNA. On the following day, each batch of transfected cells was split into two for parallel 16h 
normoxia (N) and hypoxia (H) exposure. After 16h N/H exposure cells were lysed and luciferase 
activity was measured using a commercially available Luciferase Assay System (Promega AG) and a 
SIRIUS Luminometer (Berthold Technologies, GmbH &Co. KG, Bad, Wildbad, Germany). 
Luciferase activity was normalized by β-galactosidase activity (β-galactosidase enzyme assay kit; 
Promega AG) and relative luciferase activity expressed in percent (% RLA) of the total activity of all 
normoxic and hypoxic reactions of a given assay. 
 
Reporter transfections and siRNA transient knock down of HIF-1α, USF1 or USF2a: The specific 
siRNA HIF-1α and siRNA USF1 oligonucleotides were selected based on previous publications (3, 11, 
25). siRNA USF2a oligonucleotides targeted nucleotides 786-806 of human USF2a mRNA. All 
siRNA sequences (see Supplement Table ST 3) were synthesized by Dharmacon Research Inc. 
SiCONTROL non-targeting siRNA pool #2 was used as scrambled siRNA control (Dharmacon). Half-
confluent Hep3B cells were transfected with a total of 200nM of siRNAs using Oligofectamine™ 
reagent (Invitrogen). In the combined USF1+USF2a siRNA transfection targeting both USFs, 100nM 
of each siRNA were added to the cells. To perform siRNA manipulation together with a BNIP3 
promoter luciferase reporter assay, Hep3B cells were transfected 30h post-siRNA transfection with 
150ng BNIP3/LUC reporter construct and 40ng β-galactosidase plasmid in a total amount of 500ng 
DNA per well using Invitrogen’s Calcium Phosphate Kit followed by parallel 16h normoxia and 
hypoxia exposure and luciferase assay as above. 
  
Stable HIF-1α and USF-2a knockdown MCF7 clones: To generate stable HIF-1α and USF2a 
knockdown MCF7 cells, we used MISSION shRNA bacterial glycerol stocks of the shRNA lentiviral 
plasmid (pLKO.1-puro) kit (Sigma-Aldrich, Basel, Switzerland). The HIF-1α and USF2a kits are both 
composed of five individual shRNAs each, that target HIF-1α (accession number NM_001530) and 
USF2a (accession number NM_003367), respectively at different mRNA sections. 1×106 MCF7 cells 
were transfected either with 3μg of each of the 5 shRNA HIF-1α plasmids using polyethyleneimine as 
described earlier (52), or with 6μg of each of the 5 shRNA USF2a plasmids using the calcium 
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phosphate method. 48h post-transfection, single clones were selected in medium containing 1.0 μg/ml 
puromycin followed by Western blot analysis. 
 
Chromatin Immunoprecipitation (ChIP) assay: ChIP assays were  performed in human Hep3B, HeLa 
and MCF7 cells subsequent to a 4h exposure to normoxic (air) or hypoxic (1% O2) atmospheres as 
described in (23). In brief, genomic DNA was crosslinked with bound proteins using 1% 
formaldehyde in 1× phosphate-buffered saline (PBS) for 10min at room temperature and sonicated in a 
Bioruptor™ UCD-200 (Diagenode sa, Liège, Belgium) or a Sonifier cell disruptor B15 (Branson) into 
fragments with an average length of 500-1000bp. For immunoprecipitation of the DNA/protein mix, 
4.5 μl rabbit polyclonal anti-HIF-1α IgG (ab2185, Abcam, Cambridge, UK), 10 μl rabbit polyclonal 
anti-USF1M or anti-USF2G was added into the chromatin solution. 10 μl pre-immune rabbit 
antiserum and 2.5 μl rabbit anti-human IgG were used as negative controls. The purified DNA was 
amplified by PCR using the ChIP primer pairs shown in Supplement Table ST 4. 
 
Statistics: Using the STATA 10.0 software package (Stata™ 10.0; StataCorp, College Station, USA) 
we compared the mean relative luciferase activity (RLA) data shown in the individual panels in 
Figures 3 and 6 for each reporter assay and within the same oxygen category (either normoxic or 
hypoxic results). Significance of RLA differences between samples was calculated in two ways, i.e. 
for a) control transfections without overexpressed HIF/USF versus experimental co-transfections with 
overexpressed HIF/USF (i.e. endo/exo tests, used symbols: asterisk, circle), and b) control co-
transfections with overexpressed HIF-1α versus co-transfections with overexpressed combinations of 
HIF-1α and USF proteins (i.e. hif/combi tests, used symbols: plus, diamond). Each population of 
normoxic or hypoxic reporter assay results was assessed for normality and for equal variances between 
compared samples. Next, statistical significance (i.e. p value < 0.05) was calculated in accordance 
with these tests by i) one-way Anova modelling and post-hoc Sidak corrections when assumptions of 
normality and variance equality were maintained (e.g. Fig. 3B, C; when p-value < 0.05, used symbols: 
circle, diamond), and ii) non-parametric Kruskal-Wallis tests plus Wilcoxon rank-sums for pairwise 
RLA comparisons when assumptions were violated (e.g. Fig. 3A, D; for p-value < 0.05, used symbols: 
asterisk, plus). Respective symbols are shown in gray within the RLA bar for a given endo/exo or 
hif/combi test. 
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Results 
 
CACGTG palindromic E-boxes often serve as binding sites for several basic helix-loop-helix (bHLH) 
transcription factors, including ARNT (53, 54), MYC (21, 22), USFs (58), STRA13/DEC1 (56), ATF-
1 and CREB-1 (34). To identify the factor(s) responsible for the HIF-interfering constitutive activity at 
the -146 CACGTG element within the promoter of the hb2 gene (phb2) of Daphnia magna (16), along 
with the factor(s) occurrence across different cancer cells, we conducted an EMSA survey using 
normoxic nuclear extracts from human hepatoma (Hep3B), cervical carcinoma (HeLa) and breast 
carcinoma cells (MCF7). Since HeLa and MCF7 EMSA screens yielded compatible results, Figure 1A 
presents Hep3B data only (Fig. 1A). The protein components within the constitutive complex (cc) of 
the -146 phb2 activity were identified using specific antibodies directed against USFs, DEC1, MYC, 
ARNT and ATF-1. Of these five factors screened by supershifts (ss), only USF1 and USF-2 were 
recognized as main in vitro binding factors of the -146 phb2 palindrome (Fig. 1A, lanes 3, 5, 7, 9, 11) 
while all other factors either failed (MYC, ATF-1) to bind to this motif or interacted (DEC1) with it 
only as minor contribution (Fig. 1A, lane 15; ~5-10% of total pool). Increasing volume of anti-USF1M 
(left) and anti-USF2G (right) antiserum in the binding reaction nuclear extracts from normoxic (N) 
and hypoxic (H) Hep3B reduced the intensity of the CACGTG complex in a dose-dependent manner 
(Suppl. Fig. S1A). This dose-dependent reduction additionally underscores the specific participation of 
USFs in the CACGTG complex, because addition of the same maximal volume of pre-immune serum 
(PI-1M and PI-2G) left the complex’s intensity unaffected. Moreover, binding of USF proteins to the -
146 phb2 E-box is clearly oxygen-independent (Suppl. Fig. S1A). Based on Viollet et al.’s work on 
the characteristic of USFs to homo- or heterodimerize to a different extent according to cell type (58), 
we were furthermore able to delineate the slightly different mobility of bands within the CACGTG-
bound constitutive complex (cc) as USF1/2 heterodimers (i.e. USF1/2a, USF1/2b, fast complex, “1/2”), 
1/1 homodimers (medium complex, 1/1) or 2/2 homodimers (slow complex, 2/2) (Suppl. Fig. S1A).  
 
We re-evaluated our EMSA results through independent pull-down assays of Hep3B, HeLa and MCF7 
nuclear proteins using biotinylated phb2 oligonucleotides, bound to streptavidin coated magnetic 
beads. In a representative assay with HeLa normoxic (N) and hypoxic (H) nuclear extracts (Fig. 
1B+C), wildtype biotinylated oligonucleotides (w-bio), containing the -146 CACGTG phb2 E-box, 
were able to pull down 43 kDa USF1 (Fig. 1B), 44 kDa USF2a and 38 kDa USF2b proteins regardless 
of pO2 (Fig. 1C). The specificity of this USF binding reaction was confirmed due to the markedly 
reduced (50× comp.) or abolished (m-bio) binding of any USF to the phb2 E-box either upon addition 
of 50 fold molar excess of competing wildtype oligonucleotides (50× comp.) into the reaction or when 
using beads coated with -146 mutant (m-bio) E-box motifs (5’-CAATGT-3’). Similar results were 
obtained with extracts from Hep3B and MCF7 cells (not shown). Based on these mutually 
corroborating and reproducible data in Fig. 1, we concluded that USF1 and USF2 complexes are the 
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main phb2 CACGTG binding factors in three different cancer cells (Hep3B, HeLa, MCF7). 
Subsequent co-immunoprecipitation experiments demonstrated the interactive precipitation of HIF-1α 
by ARNT proteins and vice versa, but failed to reveal any physical contact between USF2a and either 
subunit of HIF-1 (HIF-1α, ARNT) (see Suppl. Fig. S2). Thus, the USF-HIF interference in phb2 is 
indirect and DNA context dependent (19). 
 
While the Daphnia hb2 promoter was a valuable model for the initial analysis of the crosstalk between 
E-box binding activities, naturally we wanted to characterize the signaling events within the promoter 
of human bibox candidate genes, i.e. those containing a CACGTG palindrome E-box adjacent to a 
validated or suggested HRE motif. To achieve this objective, a computational scan of  human genome 
sequence was conducted, in which we checked within 1000 nucleotides upstream of the transcription 
start site for the presence of a 5’-VNVBRCGTG-3’ HRE consensus motif (62) and a 5’-CACGTG-3’ 
palindrome E-box with a motif-motif distance of ≤100bp. 5’ location and distance of both motifs were 
adopted from the Daphnia hb2 gene, coordinates (i.e. transcription start sites) of the human genes 
were taken from UCSC’s known genes archive (hg18). According to these criteria, some 383 genes 
fitted the bibox definition and included with VEGF-C (vascular endothelial growth factor C), LDHA 
(lactate dehydrogenase A), PGM2 (phosphoglucomutase 2), BNIP3L (Bcl-2/E1B 19 kDa interacting 
protein 3-like) and BAX (Bcl-2–associated X protein) several known hypoxia induced expressions 
(Excel file: “Human bibox candidate genes” with total of 383 entries of annotated human 
HRE/CACGTG candidate genes is available as Supplement). From this list, different bibox candidate 
genes were selected for future studies, provided that the alignment of the homologous human-mouse-
rat (hmr) promoter regions had established the respective motifs to be conserved, and, thus, of likely 
functional importance (Suppl. Fig. S3). Comparing the hmr alignments of the promoters of BNIP3L 
with those of its close relative, the known HIF-1 target BNIP3 (Bcl-2/E1B 19 kDa interacting protein 
3), yielded a remarkably conserved HRE region for the latter gene, prompting us to study the 
transcriptional control of BNIP3 rather than of BNIP3L itself (Suppl. Fig. S3). 
 
The respective promoter regions were amplified from genomic DNA, cloned, sequence confirmed and 
inserted into basic pGL3 luciferase reporter plasmids. That way, we either received as generous gifts 
(i.e. BNIP3 and PHD2), or generated ourselves (all others), a set of luciferase promoter reporters that 
ranged from HIF-1 specific (prolyl hydroxylase domain 2, PHD2) (52) to USF specific targets 
(tyrosinase, TYR) (15) and included four bibox candidates (4EBP1, LDHA, MC1R, BNIP3) to 
examine the possible interaction of HIF and USF signalling cascades at DNA level (see Table 1 for 
relevant cis-elements and adjacent or intermittent DNA). Initially, we set out to examine the hypoxia 
responsiveness of these bibox candidate promoters. Respective reporter transfections of Hep3B, 
MCF7 and HeLa cells included negative control reactions with empty pGL3 basic luciferase vector 
(Fig. 2, “bVec”) which, indeed, lacked a hypoxia response in any of these cells. In contrast, the HIF-1-
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driven PHD2 luciferase construct was induced approximately 3-fold in Hep3B, 8-fold in MCF7 and 4-
fold in HeLa in response to a 16h exposure at 1% O2 (Fig. 2). Luciferase assays with the four bibox 
candidates 4EBP1, LDHA, MC1R and BNIP3 revealed only for LDHA (~2 fold) and BNIP3 (4-7 fold) 
a robust up-regulation by hypoxic conditions in Hep3B, MCF7 and HeLa cells. The 4EBP1 and 
MC1R constructs, in contrast, lacked any O2 sensitivity in any of the cell lines (Fig. 2). 
 
Next, we investigated the possible co-regulation of BNIP3 and LDHA by HIF and USF cascades in 
response to the co-transfection of these bibox reporters with HIF-1α and USF1, 2a or 2b expression 
plasmids. Efficacy of these co-transfections was stereotypically compared to endogenous reporter 
expression (Fig. 3; leftmost H/N double-bar in each particular reporter transfection; no numbers 
underneath). In pilot studies (not shown), we had carefully titrated for each cell line the amount of 
HIF-1α plasmid needed for an optimal hypoxic induction of either reporter (i.e. minimal normoxic 
gene activation by over-expressed HIF-1α, achieved with 15ng plasmid for BNIP3 and 100ng plasmid 
for LDHA construct), and of any USF plasmid needed for an optimal specific activation of either 
reporter construct (i.e. minimal non-specific binding of over-expressed USFs to pGL3 backbone; 
achieved with 15ng of any USF plasmid) (see Fig. 3). Transfected TYR reporter yielded, regardless of 
O2 tension, a 4-7-fold increased activity upon co-transfection of USF1, and an up to 20-fold elevated 
activity upon over-expression of USF2a. Over-expression of HIF-1α did not impact TYR expression 
(Fig. 3A). On the other hand, a 2.7 fold induced PHD2 reporter activity, which entirely depended on 
the presence of a functional wildtype HRE in the PHD2 promoter as seen in Table 1 (i.e., transfection 
data with HRE-mutant PHD2 constructs, not shown), was increased up to 3.8 fold upon HIF-1α over-
expression. The impact of over-expressed USFs on the PHD2 reporter was either negligible (USF1) or 
within the range of the non-specific stimulation that the over-expressed factor exerted on the vector 
backbone (USF2a). Therefore, both control reporters responded specifically to the over-expression of 
their respective transcriptional driver(s) (Fig. 3A).  
 
As mentioned above, the promoter activity of LDHA was induced by endogenous hypoxia signals 
almost 2-fold in Hep3B (Fig. 3B). Co-transfection of cells with 20, 40 or 100ng of USF-1 plasmid 
elevated the activity of LDHA luciferase dose-dependently as a function of the USF1 level. Over-
expressed USF2a and 2b were even more able to activate the LDHA promoter. Yet, any over-
expressed USF augmented LDHA luciferase activity predominantly under normoxia, thereby reducing 
the original hypoxic induction to an almost constitutive expression pattern in Hep3B (Fig. 3B) and 
MCF7 cells (not shown). Similarly, over-expressed HIF-1α (100ng plasmid) stimulated the LDHA 
promoter under normoxic and hypoxic pO2. However, when Hep3B cells were simultaneously co-
transfected with HIF-1α and USF1 (2x100ng plasmid; Fig. 3B), LDHA expression levels superseded 
those of any over-expression scheme of the individual transcription factors. Convergence of co-active 
HIF-1 and USF signals on the LDHA promoter are mutually supportive in driving the gene. 
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 The BNIP3 reporter was nearly 3-fold induced by endogenous (HIF-1) hypoxic signalling pathways in 
Hep3B (Fig. 3C) and HeLa cells (Fig. 3D). Co-transfection with USF1 and 2a, or with USF2b, 
enhanced BNIP3 promoter activity in both cell lines particularly under normoxia and consequently 
weakened the hypoxic induction of the reporter to 1.5-2.4 fold. Over-expression of HIF-1α amplified 
the hypoxic activity of the BNIP3 reporter robustly in Hep3B (6.6 fold; Fig. 3C) and moderately in 
HeLa cells (3.2 fold, Fig. 3D). Importantly, this potentiated hypoxia response of BNIP3 by exogenous 
HIF-1α was significantly impaired by simultaneous co-transfection with USF1 or USF2a, but not 
USF2b, in Hep3B and HeLa cells (Figs. 3C+D: see ? arrows). Increasing the added amount of 
USF1/2a plasmids further (15?100ng plasmid), eventually converted the hypoxic trans-activation of 
the reporter into an increasingly constitutive response, especially in Hep3B cells (Fig. 3C). These data 
suggest that HIF-1α and USF1 or USF2a compete dose-dependently with each other for the control of 
the BNIP3 promoter. 
 
For further inspection of a physiological interaction of HIF-1 and USFs with the promoter of BNIP3 
and LDHA, we performed chromatin immunoprecipitation (ChIP) assays in Hep3B, HeLa, and MCF7 
cells. No DNA was amplified in the IP lane when either a non-specific lgG or a pre-USF 
immunization serum was used. Regarding the promoter of LDHA (Fig. 4A; left panel: Hep3B; right 
panel: MCF7), the ChIP data indicated a hypoxia-specific interaction of the amplified 159bp region 
with HIF-1α that contrasted with a comparatively weak, constitutive interaction with USFs. The 
notion that USFs target (MCF7) or even dominate (Hep3B) the LDHA promoter in oxygenated cells is 
in accord with our co-transfection assays. In the BNIP3 ChIP assay (Fig. 4B), specific precipitates 
suggested that the BNIP3 E-box in Hep3B (left) and MCF7 cells (right panel) can switch in its 
occupancy from a HIF-1 site during hypoxia to a cis-element for a mixed collection of factors, 
including USFs and, surprisingly, HIF-1 complexes during normoxic pO2. The fact that USF1/2 
complexes remained attached to the BNIP3 314bp promoter fragment, even when HIF-1 overtook the 
occupancy of the -251/-246 E-box (Tab. 1) in deoxygenated cells, suggests the presence of non-
canonical USF cis elements in or adjacent to this HRE. In this regard, note the occurrence of two 
conserved CACGCN motifs, each being separated from the BNIP3 HRE by a triple-nucleotide spacer 
sequence (Suppl. Fig. S3).  
 
To elucidate the precise location of HIF-1 and USF1/2 sites in the LDHA and BNIP3 promoter, we 
opted to carry out additional EMSA screens with Hep3B, HeLa and MCF7 normoxic and hypoxic 
nuclear extracts. Representative results are shown for LDHA (MCF7 nuclear extracts, Fig. 5A) and 
BNIP3 (Hep3B nuclear extracts, Fig. 5B) in Figure 5. The wildtype CACGTG-motif in region I of the 
LDHA promoter (Fig. 5A: reg.I wt) was avidly bound by constitutive proteins (cc) which could be 
supershifted (ss) by anti-USF2G (lanes 9-10), and to a lesser extent, anti-USF1M antibodies (lanes 6-
 110
7). The region I wt oligonucleotide also formed a tenuous hypoxia-regulated complex which could be 
supershifted by the specific anti-HIF-1α IgG mgc3 (Fig. 5A, lane 4). Another radiolabeled 
oligonucleotide, spanning the wildtype region II and III (reg.II/III ww) was tightly bound both by HIF-
1α and USF1/2 (Fig. 5A, lower panel; detection of HIF-1α ss: lane 4; USF1 ss: lanes 6+7; USF2 ss: 
9+10). When using a reg.II/III double site oligonucleotide carrying a mutation in region II and an 
unaltered wildtype sequence in region III (reg.II/III mw), only the hypoxia inducible complex, 
supershifted by anti-HIF-1α (mgc3) IgG, was detected in conjunction with a complete loss of the 
constitutive binding activity by USFs (Fig. 5A: reg. II/III mw). The reverse sequence alteration in 
region III but not II (reg. II/III wm) left the oligonucleotide attachment by the constitutive USF 
complex undisturbed, but erased any interaction with HIF-1. It thus appears that region I of the LDHA 
promoter is, in vitro, mutually occupied by HIF-1 and USF complexes. However, the affinity of HIF-1 
to this region seems to be much reduced compared to USFs. On the other hand, region II acts as 
exclusive, high-affinity site for USFs, whereas region III functions to attach HIF-1 to the LDHA 
promoter in deoxygenated nuclei. Corresponding BNIP3 EMSAs confirmed the mutual binding of 
HIF-1 and USF1/2 to the -259/-236 DNA that contains the HRE at -251/-246 (Supplement Table ST 2) 
(Fig. 5B). Specific supershifts were able to positively identify HIF-1α (ss: lane 4) as constituent of a 
hypoxic activity (lane 2), and USF1 (ss: lanes 6+7) and USF2 (ss: lanes 9+10) as participants of a 
constitutive complex (cc; lanes 1+2) of the BNIP3 promoter (Fig. 5B). 
 
The important observation of a competitive effect between over-expressed HIF-1 and USF 
constituents on the BNIP3 promoter activity in Hep3B cells (see Fig. 3C), warranted a re-examination 
of BNIP3 reporter transfections, this time into cells where either signalling cascade had been silenced 
through the prior use of specific siRNAs. While the steady state abundance of HIF-1α, USF1 and 
USF2a proteins remained unaffected in cells transfected with scrambled siRNA (siContr., compare 
signals to non-transfected (non-TF) cells), exposing Hep3B cells to siRNAs specifically directed 
against HIF-1α (siHIF-1α), USF1 (siUSF1), USF2a (siUSF2a) or the combination of both USFs 
(siUSF1/2a) resulted in a drastically diminished expression of the respective factor. Additionally, cells 
subjected to a USF1 knockdown (siUSF1), left the USF2a expression unaltered. In contrast, absence 
of USF2a (siUSF2a) was accompanied by a strong reduction of USF1 protein level (Fig. 6A, USF1 
signal in siUSF2a). The knockdown effect of any siRNA was stable up to 72h post-siRNA transfection. 
 
Transfection of scrambled siRNA (siContr.) had no effect on the 4-fold hypoxic induction of the 
BNIP3 reporter. In stark contrast, subjecting Hep3B cells to HIF-1α siRNA completely abrogated this 
induction to baseline (Fig. 6B). When examining whether USF1 or/and USF2a silencing could 
influence the hypoxic response of BNIP3, we found that absence of USF1 resulted in a significantly 
increased BNIP3 promoter activity under hypoxia in comparison to siContr measurements. Although 
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suppression of USF2a raised fold hypoxic induction from 4.4 (siContr) to 5.7 (siUSF2a), data variance 
prohibited this difference to reach the level of significance (Fig. 6B). 
 
In addition to transient knockdowns, we also evaluated the convergence of HIF-1 and USF1/2 
pathways at the level of DNA using stable shRNA-based HIF-1α and USF2a knockdown clones in 
MCF7 cells. Beyond the expected specificity of the respective knockdown effect, the stable 
knockdown clones also confirmed: a) the marked reduction of USF1 protein levels upon the USF2a 
knockdown (Supplement Fig. S4A); b) the absolute USF2a requirement to exert a constitutively 
stimulated expression of the TYR reporter (Fig. S4B); c) the absolute HIF-1α requirement to exert a 
hypoxia-inducible expression of the PHD2 and LDHA reporter (Fig. S4C+D); d) the USF2a 
involvement in transactivating the LDHA promoter during periods of high oxygen (Fig. S4D); and e) 
the capacity HIF-1 and USFs to mutually substitute one another in the trans-activation of LDHA 
should the other activity be impaired or eliminated by a genetic or molecular loss-of-function event 
(Fig. S4D).  
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Discussion 
 
One way to fine-tune, or inhibit, HIF’s transcriptional outflow independently of hydroxylase activities 
could be through competing transcription factors. We reported (16) on a constitutive hepatoma cell 
(Hep3B) transcription activity that specifically bound to the E-box like CACGTG palindrome at 
position -146 in the hypoxia responsive globin 2 promoter (phb2) of Daphnia magna. Binding of this 
Hep3B factor was found to counteract the HIF-driven induction of the phb2 reporter from HREs at 
adjacent -258 and -107 positions. Whatever the binding entity to CACGTG motifs among candidate 
transcription factors is, these palindrome occupying complexes can evidently engage in positive or 
negative crosstalk with nearby HIF/HRE complexes (30, 37, 39). A more physiological understanding 
of hypoxic signalling requires to analyze transcriptional control mechanisms not just as a function of 
the stability/activity of HIF-1 per se, but as a function of the interplay that governs the hierarchy by 
which HIF-1 and related complexes gain access to DNA and regulate expression. In this context, the 
main objectives of the current study aimed to 1) identify the phb2 CACGTG-binding entity in human 
cancer cells and 2) investigate the factors interplay with HIF-1α in the control of co-targeted genes. 
 
To determine which of the non-HIF bHLH complexes listed in the Results section is capable of 
binding the phb2 CACGTG palindrome in vitro, we employed EMSA supershifts and oligonucleotide 
pull-down assays (Fig. 1). Both methods consistently and reproducibly identified USF1 and USF2a/2b 
as the main phb2 CACGTG-complex in nuclear extracts from Hep3B and HeLa (Fig. 1) or MCF7 cell 
lines. Our pull-down assays also documented the opposite binding preferences of HIF-1 and USFs to 
phb2 cis-elements (Suppl. Fig. S1B+C). While HIF-1 exerted a measurably higher affinity to the 
asymmetric -107 phb2 HRE than to the symmetrical -146 phb2 palindrome (Suppl. Fig. S1B, 50x 
comp. lanes), USF factors displayed avid in vitro adherence to the -146 phb2 palindrome and an easily 
competed, lower affinity to the -107 phb2 HRE (Suppl. Fig. S1C, 50x comp. lanes). Thus, the single 
base substitution within the hexameric core of both these phb2 E-boxes (i.e. -107 HRE: 5’-TACGTG-
3’; -146 palindrome: 5’-CACGTG-3’), and presumably additional changes in neighboring nucleotides, 
are important contributors to confer the vastly differing affinities of HIF and USF transcription factors 
to these motifs. This observation fits well with the general perception that CACGTG-palindromes tend 
to attract non-HIF bHLH factors (39, 51, 53, 54), and, consequentially, are notably underrepresented 
as functional HIF elements (14, 46, 61). Our co-immunoprecipitations further confirmed the lack of 
any physical protein-protein interaction between HIF-1 subunits and USFs (Supplement Fig. S2). Thus, 
USF1/2a/2b were considered the main and constitutive protein factors which indirectly interfere with 
the HIF/HRE-driven induction of hb2 globin gene (16) by binding to the phb2 CACGTG palindrome 
in HeLa, Hep3B and MCF7 cancer cells.  
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Upstream stimulatory factors (USFs) belong to the basic-helix-loop-helix-leucine zipper (bHLH/ZIP) 
family of transcription factors and exist, in human cells, as three different, ubiquitously expressed 
isoforms, USF1, USF2a and 2b, with molecular masses of 43, 44 and 38kDa respectively (49, 50, 58). 
Physiologically, USFs have been implicated in conferring the UV-induced tanning response in 
melanocytes and are key players in immune response, cell cycle and glucid-lipid metabolism gene 
regulation networks (5). In line with a possible fine-tuning of HIF’s transcriptional read out by 
competing palindrome complexes, three human genes have been examined to date for their co-
regulation by HIF and USF pathways: the genes encoding plasminogen activator inhibitor-1 (PAI-1) 
(8, 13, 43), the catalytic subunit of the telomerase, the telomerase reverse transcriptase (TERT) (2, 20, 
63) and the glycolytic enzyme L-type pyruvate kinase (L-PK) which catalyzes the formation of 
pyruvate and ATP from phosphoenolypyruvate and ADP (33). 
 
 The Daphnia hb2 gene promoter had served as initial tool to narrow down the investigation of such E-
box interference to the responsible players. Ultimately, we wanted to learn which human genes feature 
a similar bibox configuration of adjacent candidate HRE and CACGTG palindromes (PAL) in their 
promoter and thus might be co-responsive to incoming HIF and USF signals. As explained in the 
result section, we selected four human candidate genes which contained closely adjacent or over-
lapping CACGTG PAL and HRE motifs within their promoter for further investigation in Hep3B, 
HeLa and MCF7 cells. Figure 2 revealed that only the LDHA (~2 fold) and BNIP3 (3.5-7 fold) 
reporter yielded a robust up-regulation by hypoxic conditions across all three cell lines. These results 
are consistent with previous studies which had already demonstrated for human LDHA and BNIP3 to 
be hypoxia-inducible HIF-1 target genes in HeLa and MCF7, respectively (14, 31). 
 
When assessing the control of the LDHA reporter in Hep3B cells, our data showed the preferential 
stimulation of this promoter under high rather than low oxygen levels by over-expressed USFs. Co-
transfecting increasing amounts of USF1 into Hep3B cells revealed a dose-dependent up-regulation 
followed by a saturated expression of LDHA, in particular under normoxia (Fig. 3B). A previous study 
had already described rat LDHA as a MYC targeted gene and further noticed the weak up-regulation 
of the gene by USFs under normoxia (47). Over-expression of HIF-1α similarly accentuated the 
LDHA reporter activity above endogenous levels. The fact that over-expressed HIF-1α is known to 
saturate the proteolytic machinery of the cell might explain why the normoxic trans-activation of the 
LDHA reporter increased equally efficient under the regime of surplus HIF-1α (H/N ratios 1.9?1.8). 
The combinatorial overproduction of exogenous HIF-1α and USF1 factors (Fig. 3B, 100ng each 
plasmid) in Hep3B cells yielded LDHA expression levels that superseded those of any over-expression 
scheme of the individual factors. Hence, this data suggests that coproduction of exogenous HIF-
1α/USF1 results in a cooperative transcriptional activation of the LDHA reporter. 
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To follow up whether HIF-1 and USF1 or USF2a indeed engage in the coordinated control of the 
LDHA target, we conducted chromatin immunoprecipitation analyses. As a result, this ChIP data 
clearly documented the in vivo co-occupancy of endogenous HIF-1α, USF1 and USF2a to the LDHA 
promoter (region: -2533/-2375 from translation start site; 159bp amplicon) in hypoxic Hep3B (Fig. 4A, 
left panel) and MCF7 cells (Fig. 4A, right panel). USF1 and USF2a clearly stayed attached to the 
LDHA promoter during periods of normoxia in either cell. In additional gel shift assays we aimed to 
disentangle the occupancy of the three potential LDHA binding sites (region I-III, Tab. 1). Two of 
those three sites, namely the palindrome at reg. II (-2367 to -2362 from translation start site: 5’-
CACGTG-3’) and the asymmetric E-box at reg. III (-2353 to -2345; 5’-GACGTG-3’ on anti-sense 
strand) are highly conserved in mouse, rat and human (Supplement Fig. S3) and have been reported to 
act as HIF-1 binding sites in mouse LDHA promoter (14, 45). Subsequently, Shim et al. showed that 
both E-box sites at region I and II within rat LDHA promoter serve to tether MYC to the gene (47). In 
our hands, the region II palindrome and region III asymmetric E-box functioned in vitro as USF1/2 
(reg. II) and HIF-1 (reg. III) binding site, respectively (Fig. 5A lower panel). Region I of the 5’ flank 
of the LDHA gene (-2465 to -2460; 5’-CACGTG-3’), represents a weak HIF-1 site and strong USF1, 
USF2a sites as well (Fig. 5A upper panel). 
The role of USFs’ in transactivating LDHA in oxygenated cells implies the factors as physiological 
drivers of aerobic glycolysis in cancer cells (Warburg effect). A MYC- or USF-mediated trans-
activation of LDHA might, perhaps, shift the reversible interconversion between lactate and pyruvate 
in favor of the latter product. The cell would gain from the continued fuelling of mitochondria with 
NADH stemming from this reaction. In contrast, binding of HIF-1 to the upstream LDHA DNA under 
high oxygen levels was negligible in both Hep3B and MCF7 cells. In low O2, HIF-1 dominates the 
LDHA promoter in MCF7 cells, while both USFs maintain their association with this DNA. DNA-
attachment of HIF-1, therefore, does not appear to displace USFs from the upstream recognition sites 
of LDHA, in support of the notion that maximal LDHA transcription during low pO2 results from the 
parallel and cooperative transcriptional control by HIF-1 and USF1/2a (Fig. 3B+4A). The presence of 
distinct, non-overlapping sites in the LDHA promoter thus might be a key feature for the mutually 
cooperative regulation of this gene by HIF-1 and USF pathways. 
 
Co-transfection of Hep3B and HeLa cells with HIF-1, USF1 and 2a revealed that USF1 or 2a activity 
can dose-dependently interfere with the HIF-1-mediated BNIP3 induction during low oxygen (see ? 
arrows, Fig. 3C+D). Conversely, transient knockdown of USF1 function in Hep3B cells resulted in a 
significantly augmented BNIP3 promoter activity during hypoxia (Hx-siCon vs. Hx-siUSF1 kd; p < 
0.05) (Fig. 6B). We also noted an increase, albeit not statistically significant, in the hypoxic induction 
of the BNIP3 reporter when Hep3B cells were treated with anti-USF2a siRNA (Fig. 6B: H/N = 4.4 
fold, siContr ? 5.7 fold, siUSF2a). The HRE at the position -251/-246 in the promoter of human 
BNIP3 gene was first identified by Kothari et al. to function as a direct binding site for HIF-1, which, 
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in turn, was found necessary for the transcriptional activation of the gene under hypoxia (31). Our 
ChIP data for Hep3B (Fig. 4B, left panel) and MCF7 cells (Fig. 4B right panel) reveal the dominant in 
vivo binding of HIF-1α to the BNIP3 promoter (region assessed: -509/-196 from translation start site) 
in deoxygenated cells along with the weak and constitutive tethering of USF1 and 2a to this DNA.  
 
Remarkably, and in contrast to the LDHA regulation, we noticed some HIF-1α had successfully 
escaped proteolytic degradation since we detected it bound, as heterodimer, to the BNIP3 promoter in 
normoxic cells (Fig. 4B; Hep3B and MCF7 cells). Contrary to common perception, HIF-1α is not 
necessarily depleted entirely from oxygenated cancer cells - some might actually survive bound to 
DNA. The relevance, however, of functional HIF-1 in oxygenated cancer cells, that had not received 
the common trigger for enhanced alpha subunit translation by virtue of increasing cytokine/growth 
factor concentrations (see (7) for review), remains unclear. Moreover, HIF-1 also does not control the 
activity of its targets in form of a simple one-site/one-factor ON/OFF switch. Rather, transcriptional 
activity of co-regulated genes like BNIP3 results from a highly dynamic binding equilibrium, where, 
for example, expression and activity of USF factors determines to what extent HIF-1 actually can bind 
and control the considered promoter. Control of BNIP3 expression switches from a HIF-dictated 
(hypoxia) to a HIF/USF competed mode (normoxia). These findings demonstrate the capacity of 
activated USF factors to modulate or disturb HIF-1 signalling on several key tumor-promoting genes 
in different cell backgrounds.  
 
Our EMSA screen with a single site oligonucleotide (-259 to -236; Suppl. Table ST 2) characterized 
the BNIP3 E-box as a surprisingly poor HIF-1 motif during hypoxia (Fig. 5B, lanes 2-4). In contrast, 
constitutive USF1 and 2a complexes (cc) were attracted to this site with high-affinity (Fig. 5B, lanes 5-
7 and 8-10). Thus, the BNIP3 HRE at -251/-246 is in hypoxic cells co-targeted by HIF-1 and USFs, 
yet predominant in vivo binding occurs via HIF/HRE complexes (Fig. 4B). We hypothesize that USFs 
are able to either directly displace bound HIF-1α from the BNIP3 E-box at the position -251/-246 or 
prohibit effective binding of the hypoxia inducible factor to this site from the immediately adjacent and 
conserved CACGCN motifs (Supplement Fig. S3). In any event, the fact that USF1/2 complexes 
remained attached to the BNIP3 promoter fragment even in deoxygenated cells suggests that both 
basal (normoxic) and inducing (hypoxic) activities of HIF-1 are under surveillance of palindrome 
factors. 
 
Given that HIF and USF signalling pathways evidently converge in vivo onto the promoter of the 
LDHA and BNIP3 genes in MCF7 cells (Fig. 4), we chose a second loss-of-function (LoF) approach 
by generating two stable MCF7 shRNA knockdown (kd) lines for HIF-1α and USF2a (Supplement. 
Fig. S4A). To our surprise, USF1 levels were visibly diminished in the chosen shRNA-based stable 
MCF7 USF2a knockdown clone (Supplement Fig. 4A, lower panel), as was seen in siUSF2a-treated 
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Hep3B cells (Fig. 6A). Similar cross-talk between USF gene products has been observed by some (48), 
but not others (57), to occur in mouse embryonic fibroblast (MEF) cell lines of USF1-/- or USF2a -/- 
mice, where USF1-/- MEFs showed an enhanced USF2 expression, while those of USF2 knockout mice 
exhibited a significant reduction of USF1 protein level (48). Such carry-over knockdown of USF1 in 
USF2a kd cells may reflect the necessity of USF2a for the optimal production of USF1 (USF2a ? 
USF1), while the reverse transcriptional and/or translational autoregulation (USF1 ? USF2a) does not 
seem to operate in the cancer cells used here. Reporter transfections of these shNA MCF7 clones left 
little doubt on the specific USF2a requirement to constitutively drive the TYR reporter (Fig. S4B), and 
of HIF-1α to exert the hypoxia-inducible expression of the PHD2 and LDHA constructs (Fig. S4C+D). 
Endogenous USF2a was indeed engaged in transactivating the LDHA promoter during periods of high 
oxygen (Fig. S4D: H/N 7.0 fold, wt cells ? 9.3 fold in USF2a kd cells) while over-expressed HIF-1α 
and USFs were found to mutually compensate for the LoF of the other activity in support of the 
cooperative trans-activation of LDHA by either pathway (Fig. S4D; see ? arrows).  
 
Collectively, the shown over-expression and siRNA/shRNA based manipulations of HIF-1α vs. USF1 
and USF2a transcription factors are in line with mutually cooperative and antagonistic interactions in 
regard of the transcriptional control of LDHA and BNIP3 target genes, respectively. Our evidence for 
this crosstalk includes both in vitro and in vivo data and was sampled across a diverse panel of cancer 
cell lines (i.e. Hep3B, HeLa, MCF7). Two different models are considered to account for these 
observations in our study (Fig. 7). An LDHA-type pathway convergence represents a mutually 
supportive regulation of USFs by HIF-1, and vice versa, when bound to closely adjacent yet distinct 
motifs. This cooperation becomes particularly noticeable when using over-expressed factors, i.e. when 
both pathways are activated in parallel (Fig. 7A). Conversely, the BNIP3-type model conveys our 
observations that an oxygen-independent activation of USF signalling is able to counteract HIF-1-
driven transactivation by displacing bound or blocking incoming HIF-1 from occupying the BNIP3 
HRE/palindrome composite motif (Fig. 7B). The HIF/USF competition for the BNIP3 promoter thus 
emphasizes the extent of fine-tuning and dynamics that is possible when different pathways converge 
upon the same gene. Generally speaking, it appears that a gene’s capacity to attract HIF-1/-2 is a multi-
level coordinated response, where accessory factors are also engaging to precisely tailor or disrupt HIF’s 
transcriptional outflow independently of hydroxylase activities and in accordance to the specific needs 
of the cell. Future work should assess the genome-wide implications of the tuning or inhibitory impact 
by activated USF transcription factors on the HIF-1 mediated gene activation in human cancer cells. 
 117
Acknowledgements 
 
We are grateful to Prof. Benoit Viollet (Institut Cochin INSERM, Universite Paris Descartes Dpt 
Endocrinology, Metabolism and Cancer, Paris France) for his generous gifts of USF antibodies and 
expression plasmids, for reading the manuscript and for his unwavering willingness to act as expert 
sounding board throughout the project. We also thank the following colleagues for their kind 
contributions of various materials as mentioned in the paper: Prof. Adrian L. Harris (John Radcliffe 
Hospital, Oxford, UK); Dr. Makoto Tsuneoka (Kurume University, Fukuoka, Japan); Prof. Richard S. 
Pollenz (University of South Florida, Tampa); Prof. Kazuhiro Sogawa (Tonoku University, Sendai, 
Japan); Prof. Robert G. Roeder (the Rockefeller University, New York, USA); Prof. P. Maxwell 
(University College London, London, UK) and Prof. J. Okami (University of Michigan). We thank Ms. 
Kristin Wollenick (Institute of Physiology, University of Zurich) for generating the short version of 
PHD2 luciferase reporter plasmid and Mr. Kristian Reveles Jensen for his motivated help in the 
project while being a BUSS-2008 summer student at the University of Zurich. Further thanks go to 
Prof. L. Poellinger, Dr. K. Gradin and X. Zheng who all provided a great opportunity for one of us (JH) 
to learn the chromatin immunoprecipitation (ChIP) technique at Karolinska Institute, Stockholm, 
Sweden. This work was made possible by funding from the EU’s 6th framework programme (Euroxy 
consortium; partners: MG, TAG) and a grant from the Swiss National Science Foundation (MG). 
 118
References 
 
1. Centanin, L., T. A. Gorr, and P. Wappner. 2009. Tracheal remodelling in response to hypoxia. J 
Insect Physiol., in press; doi:10.1016/j.jinsphys.2009.05.008. 
2. Chang, J. T., H. T. Yang, T. C. Wang, and A. J. Cheng. 2005. Upstream stimulatory factor (USF) as 
a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. 
Mol Carcinog 44:183-92. 
3. Chen, L., Y. H. Shen, X. Wang, J. Wang, Y. Gan, N. Chen, J. Wang, S. A. LeMaire, J. S. Coselli, 
and X. L. Wang. 2006. Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream 
stimulatory factors. J Biol Chem 281:10849-55. 
4. Chilov, D., T. Hofer, C. Bauer, R. H. Wenger, and M. Gassmann. 2001. Hypoxia affects expression 
of circadian genes PER1 and CLOCK in mouse brain. Faseb J 15:2613-22. 
5. Corre, S., and M. D. Galibert. 2005. Upstream stimulating factors: highly versatile stress-responsive 
transcription factors. Pigment Cell Res 18:337-48. 
6. Corre, S., A. Primot, E. Sviderskaya, D. C. Bennett, S. Vaulont, C. R. Goding, and M. D. Galibert. 
2004. UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is 
dependent on the p-38-activated upstream stimulating factor-1 (USF-1). J Biol Chem 279:51226-33. 
7. Dery, M. A., M. D. Michaud, and D. E. Richard. 2005. Hypoxia-inducible factor 1: regulation by 
hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37:535-40. 
8. Dimova, E. Y., and T. Kietzmann. 2006. Cell type-dependent regulation of the hypoxia-responsive 
plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 281:2999-3005. 
9. Ema, M., K. Hirota, J. Mimura, H. Abe, J. Yodoi, K. Sogawa, L. Poellinger, and Y. Fujii-
Kuriyama. 1999. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response 
to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. Embo J 18:1905-14. 
10. Epstein, A. C., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. 
Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. 
Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. 
2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF 
by prolyl hydroxylation. Cell 107:43-54. 
11. Esteban, M. A., M. G. Tran, S. K. Harten, P. Hill, M. C. Castellanos, A. Chandra, R. Raval, S. 
O'Brien T, and P. H. Maxwell. 2006. Regulation of E-cadherin expression by VHL and hypoxia-
inducible factor. Cancer Res 66:3567-75. 
12. Fandrey, J., T. A. Gorr, and M. Gassmann. 2006. Regulating cellular oxygen sensing by 
hydroxylation. Cardiovasc Res 71:642-51. 
13. Fink, T., A. Kazlauskas, L. Poellinger, P. Ebbesen, and V. Zachar. 2002. Identification of a tightly 
regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 
99:2077-83. 
14. Firth, J. D., B. L. Ebert, and P. J. Ratcliffe. 1995. Hypoxic regulation of lactate dehydrogenase A. 
Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270:21021-
7. 
15. Galibert, M. D., S. Carreira, and C. R. Goding. 2001. The Usf-1 transcription factor is a novel target 
for the stress-responsive p38 kinase and mediates UV-induced Tyrosinase expression. Embo J 20:5022-
31. 
16. Gorr, T. A., J. D. Cahn, H. Yamagata, and H. F. Bunn. 2004. Hypoxia-induced synthesis of 
hemoglobin in the crustacean Daphnia magna is hypoxia-inducible factor-dependent. J Biol Chem 
279:36038-47. 
17. Gorr, T. A., M. Gassmann, and P. Wappner. 2006. Sensing and responding to hypoxia via HIF in 
model invertebrates. J Insect Physiol 52:349-64. 
18. Gorr, T. A., C. V. Rider, H. Y. Wang, A. W. Olmstead, and G. A. LeBlanc. 2006. A candidate 
juvenoid hormone receptor cis-element in the Daphnia magna hb2 hemoglobin gene promoter. Mol Cell 
Endocrinol 247:91-102. 
19. Gorr, T. A., T. Tomita, P. Wappner, and H. F. Bunn. 2004. Regulation of Drosophila hypoxia-
inducible factor (HIF) activity in SL2 cells: identification of a hypoxia-induced variant isoform of the 
HIFalpha homolog gene similar. J Biol Chem 279:36048-58. 
20. Goueli, B. S., and R. Janknecht. 2003. Regulation of telomerase reverse transcriptase gene activity by 
upstream stimulatory factor. Oncogene 22:8042-7. 
21. Grandori, C., S. M. Cowley, L. P. James, and R. N. Eisenman. 2000. The Myc/Max/Mad network 
and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16:653-99. 
22. Grandori, C., J. Mac, F. Siebelt, D. E. Ayer, and R. N. Eisenman. 1996. Myc-Max heterodimers 
activate a DEAD box gene and interact with multiple E box-related sites in vivo. Embo J 15:4344-57. 
 119
23. Gustafsson, M. V., X. Zheng, T. Pereira, K. Gradin, S. Jin, J. Lundkvist, J. L. Ruas, L. Poellinger, 
U. Lendahl, and M. Bondesson. 2005. Hypoxia requires notch signaling to maintain the 
undifferentiated cell state. Dev Cell 9:617-28. 
24. Holmes, J. L., and R. S. Pollenz. 1997. Determination of aryl hydrocarbon receptor nuclear 
translocator protein concentration and subcellular localization in hepatic and nonhepatic cell culture 
lines: development of quantitative Western blotting protocols for calculation of aryl hydrocarbon 
receptor and aryl hydrocarbon receptor nuclear translocator protein in total cell lysates. Mol Pharmacol 
52:202-11. 
25. Holmquist-Mengelbier, L., E. Fredlund, T. Lofstedt, R. Noguera, S. Navarro, H. Nilsson, A. 
Pietras, J. Vallon-Christersson, A. Borg, K. Gradin, L. Poellinger, and S. Pahlman. 2006. 
Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in 
neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10:413-23. 
26. Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, 
and W. G. Kaelin, Jr. 2001. HIFalpha targeted for VHL-mediated destruction by proline 
hydroxylation: implications for O2 sensing. Science 292:464-8. 
27. Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. 
Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. 
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl 
hydroxylation. Science 292:468-72. 
28. Kallio, P. J., K. Okamoto, S. O'Brien, P. Carrero, Y. Makino, H. Tanaka, and L. Poellinger. 1998. 
Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 
coactivator by the hypoxia-inducible factor-1alpha. Embo J 17:6573-86. 
29. Kaulen, H., P. Pognonec, P. D. Gregor, and R. G. Roeder. 1991. The Xenopus B1 factor is closely 
related to the mammalian activator USF and is implicated in the developmental regulation of TFIIIA 
gene expression. Mol Cell Biol 11:412-24. 
30. Kim, J. W., P. Gao, Y. C. Liu, G. L. Semenza, and C. V. Dang. 2007. Hypoxia-inducible factor 1 
and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic 
switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27:7381-93. 
31. Kothari, S., J. Cizeau, E. McMillan-Ward, S. J. Israels, M. Bailes, K. Ens, L. A. Kirshenbaum, 
and S. B. Gibson. 2003. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is 
inhibited by growth factors EGF and IGF. Oncogene 22:4734-44. 
32. Krek, W. 2000. VHL takes HIF's breath away. Nat Cell Biol 2:E121-3. 
33. Krones, A., K. Jungermann, and T. Kietzmann. 2001. Cross-talk between the signals hypoxia and 
glucose at the glucose response element of the L-type pyruvate kinase gene. Endocrinology 142:2707-
18. 
34. Kvietikova, I., R. H. Wenger, H. H. Marti, and M. Gassmann. 1995. The transcription factors ATF-
1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. 
Nucleic Acids Res 23:4542-50. 
35. Lando, D., D. J. Peet, J. J. Gorman, D. A. Whelan, M. L. Whitelaw, and R. K. Bruick. 2002. FIH-1 
is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible 
factor. Genes Dev 16:1466-71. 
36. Lando, D., D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw. 2002. Asparagine 
hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-61. 
37. Lendahl, U., K. L. Lee, H. Yang, and L. Poellinger. 2009. Generating specificity and diversity in the 
transcriptional response to hypoxia. Nat Rev Genet 10:821-832. 
38. Manalo, D. J., A. Rowan, T. Lavoie, L. Natarajan, B. D. Kelly, S. Q. Ye, J. G. Garcia, and G. L. 
Semenza. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. 
Blood 105:659-69. 
39. Mazure, N. M., C. Chauvet, B. Bois-Joyeux, M. A. Bernard, H. Nacer-Cherif, and J. L. Danan. 
2002. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma 
cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia 
inducible factor-1 and c-Myc. Cancer Res 62:1158-65. 
40. Metzen, E., D. P. Stiehl, K. Doege, J. H. Marxsen, T. Hellwig-Burgel, and W. Jelkmann. 2005. 
Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional 
hypoxia-responsive element. Biochem J 387:711-7. 
41. North, S., X. Espanel, F. Bantignies, B. Viollet, V. Vallet, P. Jalinot, G. Brun, and G. Gillet. 1999. 
Regulation of cdc2 gene expression by the upstream stimulatory factors (USFs). Oncogene 18:1945-55. 
42. Okami, J., D. M. Simeone, and C. D. Logsdon. 2004. Silencing of the hypoxia-inducible cell death 
protein BNIP3 in pancreatic cancer. Cancer Res 64:5338-46. 
43. Samoylenko, A., U. Roth, K. Jungermann, and T. Kietzmann. 2001. The upstream stimulatory 
factor-2a inhibits plasminogen activator inhibitor-1 gene expression by binding to a promoter element 
adjacent to the hypoxia-inducible factor-1 binding site. Blood 97:2657-66. 
 120
44. Semenza, G. L. 2009. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 
(Bethesda) 24:97-106. 
45. Semenza, G. L., B. H. Jiang, S. W. Leung, R. Passantino, J. P. Concordet, P. Maire, and A. 
Giallongo. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A 
gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529-
37. 
46. Semenza, G. L., P. H. Roth, H. M. Fang, and G. L. Wang. 1994. Transcriptional regulation of genes 
encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757-63. 
47. Shim, H., C. Dolde, B. C. Lewis, C. S. Wu, G. Dang, R. A. Jungmann, R. Dalla-Favera, and C. V. 
Dang. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc 
Natl Acad Sci U S A 94:6658-63. 
48. Sirito, M., Q. Lin, J. M. Deng, R. R. Behringer, and M. Sawadogo. 1998. Overlapping roles and 
asymmetrical cross-regulation of the USF proteins in mice. Proc Natl Acad Sci U S A 95:3758-63. 
49. Sirito, M., Q. Lin, T. Maity, and M. Sawadogo. 1994. Ubiquitous expression of the 43- and 44-kDa 
forms of transcription factor USF in mammalian cells. Nucleic Acids Res 22:427-33. 
50. Sirito, M., S. Walker, Q. Lin, M. T. Kozlowski, W. H. Klein, and M. Sawadogo. 1992. Members of 
the USF family of helix-loop-helix proteins bind DNA as homo- as well as heterodimers. Gene Expr 
2:231-40. 
51. Sogawa, K., R. Nakano, A. Kobayashi, Y. Kikuchi, N. Ohe, N. Matsushita, and Y. Fujii-Kuriyama. 
1995. Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional 
regulation. Proc Natl Acad Sci U S A 92:1936-40. 
52. Stiehl, D. P., R. Wirthner, J. Koditz, P. Spielmann, G. Camenisch, and R. H. Wenger. 2006. 
Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for 
an autoregulatory oxygen-sensing system. J Biol Chem 281:23482-91. 
53. Swanson, H. I., W. K. Chan, and C. A. Bradfield. 1995. DNA binding specificities and pairing rules 
of the Ah receptor, ARNT, and SIM proteins. J Biol Chem 270:26292-302. 
54. Swanson, H. I., and J. H. Yang. 1999. Specificity of DNA binding of the c-Myc/Max and 
ARNT/ARNT dimers at the CACGTG recognition site. Nucleic Acids Res 27:3205-12. 
55. Tsuneoka, M., F. Nakano, H. Ohgusu, and E. Mekada. 1997. c-myc activates RCC1 gene expression 
through E-box elements. Oncogene 14:2301-11. 
56. Turley, H., C. C. Wykoff, S. Troup, P. H. Watson, K. C. Gatter, and A. L. Harris. 2004. The 
hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues 
and tumours. J Pathol 203:808-13. 
57. Vallet, V. S., M. Casado, A. A. Henrion, D. Bucchini, M. Raymondjean, A. Kahn, and S. Vaulont. 
1998. Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver 
genes to glucose. J Biol Chem 273:20175-9. 
58. Viollet, B., A. M. Lefrancois-Martinez, A. Henrion, A. Kahn, M. Raymondjean, and A. Martinez. 
1996. Immunochemical characterization and transacting properties of upstream stimulatory factor 
isoforms. J Biol Chem 271:1405-15. 
59. Wang, G. L., B. H. Jiang, E. A. Rue, and G. L. Semenza. 1995. Hypoxia-inducible factor 1 is a 
basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 
92:5510-4. 
60. Webb, J. D., M. L. Coleman, and C. W. Pugh. 2009. Hypoxia, hypoxia-inducible factors (HIF), HIF 
hydroxylases and oxygen sensing. Cell Mol Life Sci. 66:3539-54. 
61. Wenger, R. H., and M. Gassmann. 1997. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 
378:609-16. 
62. Wenger, R. H., D. P. Stiehl, and G. Camenisch. 2005. Integration of oxygen signaling at the 
consensus HRE. Sci STKE 2005:re12. 
63. Yatabe, N., S. Kyo, Y. Maida, H. Nishi, M. Nakamura, T. Kanaya, M. Tanaka, K. Isaka, S. 
Ogawa, and M. Inoue. 2004. HIF-1-mediated activation of telomerase in cervical cancer cells. 
Oncogene 23:3708-15. 
 
 121
Legend  
 
Fig. 1 EMSA supershifts and pull–down analysis to identify CACGTG complex in phb2. (A) 
EMSA supershift screen to identify factor(s) which bind to the -146 CACGTG motif in phb2. The 
following antibodies were added into the binding reactions with Hep3B normoxic nuclear extracts. 
Lane 1: no antibody; lane 2: non-specific IgG; lane 3: anti-USF1 full length IgG; lane 4: pre-immune 
serum from same rabbit used to generate anti-USF1M antibody (=PI-1M); lane 5: anti-USF1M IgG; 
lane 6: PI-2F; lane 7: anti-USF2F IgG; lane 8: PI-2G; lane 9: anti-USF2G  IgG; lane 10: PI-2Z; lane 
11: anti-USF2Z IgG; lane 12: PI-2aO; lane 13: anti-USF2aO IgG; lanes 14, 16, 18, 20 and 22: non-
specific IgG; lane 15: anti-DEC1 IgG; lane 17: anti-MYC IgG; lane 19: anti-hARNT IgG; lane 21: 
anti-mARNT IgG; lane 23: anti-ATF1. cc: constitutive CACGTG complex; ss: supershifted CACGTG 
complex. (B+C) Pull-down analysis with beads coated with -146 phb2 E-box-carrying 
oligonucleotides (5’-CACGTG-3’) and HeLa normoxic and hypoxic nuclear extracts. Binding 
specificity was assessed either through beads coated with -146 mutant (m-bio) E-box motifs (5’-
CAATGT-3’) or with binding reactions containing 50-fold molar excess of free wild type 
oligonucleotide as competitor (50×comp.). Immunoblot of bound factors with (B) anti-USF1M and (C) 
left panel: anti-USF2G antibody; right panel: anti-USF2aO antibody. Staining of non-specific (ns) 
proteins indicated as loading control. N: air; H: 1% O2 16h. 
 
Table 1. E-box palindromes and HRE sites in promoters of human genes. HIF-1 and USF co-
regulated candidate genes: 4EBP1, LDHA, MC1R and BNIP3; control genes: TYR and PHD2. 
Translation start site ATG as +1 (in brackets). 5’ flanking region upstream of ATG is given for human 
TYR, PHD2, 4EBP1, LDHA, MC1R and BNIP3 genes. HRE and E-box palindromes are capitalized. 
Conserved hmr HREs: bold + underlined; variable HREs: bold only. Conserved hmr palindromes: E-
boxes: italicized + underlined; variable E-box: in italics only. For conservation: see alignments in 
Suppl. Fig. S3. 
 
Fig. 2 Endogenous response of human PHD2, 4EBP1, LDHA, MC1R and BNIP3 luciferase 
reporter. Hep3B (A), MCF7 (B) and HeLa (C) cells were transfected with 2.0μg of 4EBP1, LDHA 
and MC1R or 1.5μg of PHD2 or BNIP3 luciferase reporter plasmid in a total of 3μg plasmid. After 
16h hypoxic (1% O2) exposure (H, black bars) or normoxic (air) exposure (N, white bars), relative 
luciferase activity was determined and normalized with β–galactosidase activity (%RLA, as mean ± 
SD). Plasmid-free transfections (null) and transfections with the empty pGL3 basic vector (bVec) were 
used as negative controls. N: air; H: 1% O2 16h. Mean H/N-fold inductions of each reporter are 
indicated above the respective pair of columns.  
 
Fig. 3 Regulation of BNIP3 and LDHA luciferase activity by over-expressed HIF-1α and USFs. 
(A) Hep3B transfections of USF and HIF-1 control reporter using either 1.5μg TYR plasmid or 0.5μg 
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PHD2 plasmid. (B) Hep3B transfections with 0.3μg LDHA reporter plasmid. (C) Hep3B or (D) HeLa 
transfections with 0.3μg BNIP3 reporter plasmid. For reporter regulation by over-expressed HIF-1α 
and USFs, ng amounts of HIF-1α and USF expression plasmids used are indicated underneath the 
respective co-transfection. Relative luciferase activity is given as in Fig. 2 (mean ± SD %RLA; n = 3 
independent experiments). N: air; H: 1% O2 16h. Mean H/N-fold inductions of each reporter are 
indicated above respective pair of columns. Statistics done in regard to same O2 category (i.e. N or H): 
a) endo/exo test = endogenous controls (reporter alone; no overexpressed HIF/USF) versus reporter 
co-transfection (reporter with exogenous HIF/USF); b) hif/combi test: reporter + exogenous HIF1α 
versus reporter + exogenous (HIF1α + USF1/2a); symbols for p < 0.05 for i) non-parametric 
Wilcoxon rank-sum tests (endo/exo = ?; hif/combi = ?); ii) Anova/Sidak tests (endo/exo = ?; 
hif/combi = ?) (see Material & Methods for details). 
 
Fig. 4 Chromatin immunoprecipitation determination of in vivo HIF-1 and USF binding to 
LDHA and BNIP3 promoters. ChIP assay was performed in Hep3B (left panels) and MCF7 (right 
panels) cells using indicated antibodies or pre-immune serum and non-specific antibody IgG as 
negative controls. Purified DNA was subjected to PCR using LDHA primer (panel A: 159bp amplicon) 
or BNIP3 primer (panel B: 314bp amplicon). N: air; H: 1% O2 4h. PI-2G pre-immune serum for anti-
USF2G; neg. PCR with H2O. 
 
Fig. 5 EMSA supershifts with LDHA and BNIP3 E-box oligonucleotides. Gel supershift using 
LDHA HRE and E-box palindrome oligonucleotides together with MCF7 nuclear extracts (panel A) 
and BNIP3 HRE oligonucleotides together with Hep3B nuclear extracts (panel B). All 
oligonucleotides used in this EMSA are listed in Suppl. Table ST 2. For HIF-1α or USFs gel 
supershifts, 1μl of the indicated specific antibody was used in comparison with pre-immune serum 
(PI-1M or PI-2G) or non-specific lgG as negative control. N, H, cc, ss: as above. 
 
Fig. 6 Transient siRNA knockdown of HIF-1α, USF1 and USF2a and the regulation of BNIP3 
promoter activity in Hep3B cells. (A) Western blot analysis to display knockdown efficiency for 
HIF-1α, USF1 and USF2a. Cells were harvested at two post-siRNA transfection time points: 48h and 
72h, corresponding to 6h and 30h hypoxia exposure (1% O2), respectively. As negative controls, 
transfections with scrambled siRNA (siContr.) and non-transfected cells (non-TF) were used. (B) 
BNIP3 Luciferase assay (0.15μg plasmid) in Hep3B cells treated with siRNAs. %RLA value, 
normalized to β–galactosidase activity, is mean ± SD of 4 independent experiments. N: air; H: 1% O2 
16h. Mean H/N-fold inductions of each reporter are indicated above respective pair of columns. 
Statistics were done in regard to same O2 category (i.e. N or H) as detailed in Material & Methods. 
Pairwise comparison of BNIP3 relative luciferase activity (RLA) values treated with siContr RNA 
versus any BNIP3-RLA of the HIF-1α, USF1, USF2a or USF1/2a siRNA treatments (=siTF, siRNA 
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against named transcription factor) was carried out using a non-parametric Wilcoxon rank-sum tests. 
Significant siContr/siTF RLA differences (p < 0.05) are indicated by black (normoxic data) or white 
asterisks (hypoxic data) before gray background. 
 
Fig. 7 Models for convergences of HIF and USF signals onto HRE and E-box palindrome 
containing bibox promoter. A LDHA-type (A) and BNIP3-type (B) model of the HIF/USF crosstalk 
as indicated. See text for discussion.  
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Table 1 
Gene Sequence 5’-3’ Ref. 
 
hTYR 
          -183   -178                  -91   -86 
gaaaagtcagtCATGTGcttttca---gccaagaCATGTGataat---aggaaga(atg)  
 
(6) 
 
hPHD2 
        -413  -408 
gccgtggtgTACGTGcagagcgcgcagagcgagt---gccgccgccgcc(atg)  
 
(40) 
 
h4EBP1 
        -179  -174                   -120   -115 
ggggatccCACGTGgaagc--caaatcccaggGGCGTGgggcgg--gagacc(atg)  
 
 
 
hLDHA 
     -2465 -2460           -2367 -2362     -2353   -2348 
cagcgCACGTGgagcg--actcaCACGTGggttcccgCACGTCcgccggc--aat(atg)  
 
(45); 
(47) 
 
 
hMC1R 
      -742   -737                 -461  -456 
acgttgaCAGCTGagttgctg--ccccggCATGTGgccgccct--ggacaggact(atg) 
 
(6)  
 
Figure 1 
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Supplement: 
 
Supplement Fig. S1: USFs bind preferentially to the -146 palindrome and HIF-1 to the -107 HRE of 
Daphnia’s hb2 promoter  
 
Additional evidence for the interaction of USFs with the -146 phb2 CACGTG palindrome was obtained by 
adding increasing volumes of anti-USF1M (left) and anti-USF2G (right) antiserum into the binding reaction with 
nuclear extracts from normoxic (N) and hypoxic (H) Hep3B cells. The intensity of the constitutive CACGTG 
complex (cc) was observed to be reduced in a dose-dependent manner. In contrast, addition of the maximal 
volume of pre-immune serum (PI-1M and PI-2G) left the complex’s intensity unaffected. As can be seen, 
binding of USF complexes to the -146 phb2 E-box is oxygen-independent (Fig. S1A). An earlier work had 
established the following isoform-specificity of each of the anti-USF antisera used: anti-USF1M serum 
recognizes USF1 (domain M), anti-USF2G recognizes USF2a or 2b (domain G) and anti-USF2aO recognizes 
USF2a (domain O) (7). Equipped with this knowledge, we were able in additional supershift experiments (not 
shown) to delineate the slightly different mobility of bands within the CACGTG-bound constitutive complex 
(Fig. S1A; cc) as summarized here: USF1/2 heterodimers (i.e. USF1/2a, USF1/2b, fast complex, “1/2”), 1/1 
homodimers (medium complex, “1/1”) or 2/2 homodimers (slow complex, “2/2”) (Fig. S1A; see also (7)) 
 
Our initial report on the regulation of Daphnia globin gene 2 (hb2) had shown that the asymmetric TACGTG 
elements at positions -258 and -107 of the promoter were absolutely necessary for the hypoxic induction of the 
hb2 gene (2). To test whether these two sites indeed comprise avid HIF binding sequences (i.e. are HREs), we 
applied the pull-down assay with beads coated either with wildtype -107 HRE or -146 E-box oligonucleotides 
for a relative comparison of HIF’s in vitro binding affinity. As can be seen in Fig. S1B, the amount of pulled 
HIF-1α protein left attached to the beads in the competed reactions (50× comp.) clearly demonstrates HIF’s 
hypoxia-induced, high-affinity interaction with the -107 HRE and low-affinity interaction with the -146 
palindromic E-box. In contrast, USFs display opposite in vitro binding behavior, with a tight interaction of 
USF2a and 2b to the -146 E-box and a weak, easily competed one to the -107 HRE (note 50x comp. lanes in Fig. 
S1C). The pull-down assay thus demonstrates the opposite binding preferences of USF1/2 (primarily to 
CACGTG motif) versus HIF-1 complexes (primarily to TACGTG HRE) within the phb2 DNA in confirmation 
of our previous observations (2). 
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Suppl. Fig. S1: Dose-dependent USF supershift analysis (A) and pull-down assay (B, C) with -107 HRE 
and -146 E-box of phb2 promoter (A) Dose dependent gel supershift with normoxic and hypoxic nuclear 
extracts from Hep3B cells by applying increasing volume of anti-USF1M or USF2G IgGs into the binding 
reaction as indicated. Representative PIs were used as negative controls. cc: constitutive CACGTG complex; ss: 
supershifted CACGTG complex. (B and C) Pull-down analysis either with -107 HRE wild type oligonucleotides 
(-107 HRE: 5’-TACGTG-3’) or with -146 E-box wild type biotinylated oligonucleotides (-146 E-box: 5’-
CACGTG-3’) using HeLa normoxic and hypoxic nuclear protein. (B) HIF-1α detection with anti-HIF-1α 
antibody (mgc3); (C) USF2a/2b detection with anti-USF2G antibody. Staining of non-specific (ns) proteins 
indicated as loading control. N: air; H: 1% O2 16h. 
 
 
Supplement Fig. S2: Co-immunoprecipitation between HIF-1 subunits and USF factors  
 
To assess whether the observed (2) USF-HIF interference in phb2 results from a direct or indirect contact 
between these transcription complexes, we conducted bidirectional co-immunoprecipitation (Co-IP) experiments. 
Positive Co-IP controls clearly confirmed precipitation (IP lanes), hence physical contact, between HIF-1α with 
immobilized ARNT (Fig. S2A), or conversely, ARNT with immobilized HIF-1α upon the subunits accumulation 
in hypoxic (H) extracts (Fig. S2B). As expected, the minuscule amount of HIF-1α present in normoxic (N) 
extracts is reflected by a small quantity of pulled ARNT protein (Fig. S2B left). However, neither 
immobilization scheme for the HIF-1α or HIF-1β (ARNT) subunit resulted in any detectable precipitation of 
USF2a (Fig. S2A and B right). Lack of co-immunoprecipitation suggests the absence of any physical interaction 
between HIF-1α or ARNT with USFs. Rather, the USF-HIF interference seems to be DNA context dependent. 
 
 
Suppl. Fig. S2 Co-immunoprecipitation with HeLa normoxic and hypoxic nuclear extracts (A) HIF-1α (left) 
or USF2a (right) Western blot of extracts immunoprecipitated (IP) by anti mouse ARNT IgG compared to non-
precipitated supernatants (SN). (B) ARNT (left) or USF2a (right) Western blot of extracts imunoprecipitated (IP) 
by anti HIF-1α IgG compared to non-precipitated supernatants (SN). Input: only nuclear extract (25μg); SN: 
supernatant from IP; IP: immunoprecipitation fraction, N: air; H: 1% O2 16h. 
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Supplement Fig. S3: Human genes selected for HIF or USF control and HIF+USF co-targeted reporter 
constructs 
 
Sequence analysis (see text, Table 1) and promoter alignment revealed human-mouse-rat (hmr) conservation of 
HREs and/or E-box palindromes in the promoters of the following control (a+b) and bibox candidate genes (c-f)  
lignment examples are presented here only for TYR, PHD2, LDHA and BNIP3 promoter regions (Fig. S3):  A
 
a) human tyrosinase (TYR): USF specific target gene with two hmr conserved CATGTG E-boxes (-183/-178 and 
-91/-86). E-box (-183/-178) validated as direct binding site for USF1 (1).  
 
b) human prolyl hydroxylase domain 2 (PHD2): HIF-1 specific target gene with hm conserved HRE (-413/-408) 
as functional HIF-1 binding site (4). 
 
c) human 4E-binding protein 1 (4EBP1): contains hmr conserved E-box palindrome (-179/-174) and non-
conserved HRE candidate (-123/-115). 
 
d) human lactate dehydrogenase A (LDHA): contains distinct, hmr conserved CACGTG palindrome (region II -
2367/-2362) and CACGTC site (region III -2353/-2348; reads as reverse-complement: GACGTG) as well as 
another CACGTG E-box (region I -2465/-2460) with hm conservation. Region I and II: validated MYC 
binding sites (6). Region II and III: validated in vitro HIF-1 binding sites (5). 
 
e) human melanocorticotropin 1 receptor (MC1R): contains two E-boxes, one of which with hm conservation (-
461/-456) whose role in controlling MC1R expression in response to UVB (80mJ/cm2) is known thanks to 
the work of Corre et al. (1) .  
 
f) human BCL2/E1B 19 kDa interacting protein 3 (BNIP3): contains hmr conserved HRE (-251/-246), a 
validated functional HIF-1 site (3), which is identical to E-box palindrome. 
 
Suppl. Fig. S3 Mouse-rat-human alignments of relevant HRE, E-box palindrome or bibox containing 
promoter regions for genes TYR, PHD2, LDHA and BNIP3. TYR with two hmr conserved CATGTG E-
boxes (italics + underlined). PHD2 with known functional HRE (underlined). LDHA with known functional 
HRE (underlined) and E-box palindromes (italics + underlined). BNIP3 with known functional HRE (underlined) 
and conserved CACGCN regions, three nucleotides apart on either side of the HRE (boxed). 
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 Supplement Fig. S4: Stable HIF-1α and USF2a shRNA knockdown clones of MCF7 cells  
 
We also evaluated DNA-level convergence of HIF-1 and USF1/2 pathways using stable shRNA-based HIF-1α 
and USF2a knockdown clones in MCF7 cells (see Materials & Methods for details). Western analyses of two 
independent clones demonstrated the strong suppression of HIF-1α (i.e. HIF-1α kd) and USF2a (i.e. USF2a kd) 
protein levels, respectively, and showed, as expected, that either knockdown did not impact the other pathway in 
question. The chosen control clone also underwent shRNA transfection and selection yet did not show signs of a 
down-regulated USF2a expression (Fig. S4A). As with the transient siRNA-based USF2a silencing in Hep3B 
cells (Fig. 6A), we noted again that USF-1 levels were visibly reduced in the USF-2a knockdown clone (Fig. 
S4A; see text for discussion). 
 
All three MCF7 clones were transfected with TYR (USF target), PHD2 (HIF-1 target) and LDHA (bibox 
promoter) reporter constructs to elicit the relative normoxic (N) versus hypoxic (H) luciferase activity in 
response to intact versus dysfunctional HIF-1 or USF2a signalling pathways (a. control: white/black bars; b. 
HIF-1α kd: white/black dotted bars; c. USF2a kd: white/black hatched bars; Fig. S4B-D). Due to the extremely 
weak expression of the human TYR gene construct in MCF7 cells (comparable to expression of empty vector; 
bVec), we did not succeed in measuring a reliable expression impairment in USF2a kd clone relative to control 
cells (Fig. S4B). Only upon co-transfecting cells with USF1 and USF2a expression plasmids did we manage to 
detect a differential luciferase activity of the TYR construct with a ~4-fold higher activity in normoxic and 
hypoxic control and HIF-1α kd than USF2a kd cells, in line with a strict requirement of USFs to activate TYR 
transcription (Fig. S4B). In contrast, the hypoxic induction of the PHD2 reporter, amounting to a nearly 7-fold 
H/N differential expression in the control and kd USF2a kd clone, was completely lost in the HIF-1α kd clone. 
Over-expression of HIF-1α restored some of this induction (Fig. S4C). 
 
The ~7-fold hypoxic induction by endogenous pathways of the LDHA reporter, was further enhanced in the 
USF2a kd clone (9.3-fold; due to significantly reduced normoxic reporter activation to ~60% of control cells), 
and completely obliterated in the HIF-1α kd clone (Fig. S4D). Over-expressed HIF-1α elevated both the 
normoxic and hypoxic activities of the reporter in control and HIF-1 kd MCF7. In contrast, in USF2a kd cells, 
over-expressed HIF-1α augmented primarily the normoxic reporter activity, hinting to HIF’s take-over of the 
USF-deficient control of the LDHA promoter (Fig. S4D; see ? arrow). When adding exogenous USF1 and 2a, 
the LDHA reporter responded again with a marked increase of it’s a) normoxic activity (control + USF2a kd 
cells) and b) normoxic and hypoxic activities (HIF-1α kd cells; Fig. S4D; see ? ? arrow). It thus appears that 
HIF-1 and USFs substitute one another in the LDHA promoter and compensate the loss-of-function of the other 
activity. 
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Suppl. Fig. S4 Regulation of LDHA promoter activity in stable HIF-1α and USF2a knockdown clones of 
MCF7 cells (A) Protein expression in normoxic (N) and hypoxic (H) MCF7 knockdown clones as indicated. 
Stable silencing of HIF-1α or USF2a expression was achieved using shRNA expressing plasmids (see “Materials 
and Methods” for details). (B) Luciferase assay of USF control TYR reporter (transfected with 1.5μg TYR 
reporter). (C) Luciferase assay of HIF-1 control PHD2 reporter (transfected with 0.5μg PHD2 reporter). (D) 
Luciferase assay of experimental LDHA bibox reporter (transfected with 0.5μg LDHA reporter). % RLA value 
represents mean ± SD of relative luciferase activity, normalized to activity of co-transfected β-galactosidase (3 
independent experiments). N: air; H: 1% O2 16h. 
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Supplement Table ST 1: PCR primers for generation of luciferase constructs (HindIII site: underlined) 
 
Primer name Sequence  
4EBP1_F1 5’-GTTGGTTCACTCCTCCTC-3’ 
4EBP1_R1 5’-CCAACAGATAATACCCATCC-3’ 
4EBP1_F2 5’-AGCATAACTACTCAATCCCC-3’ 
4EBP1_R2 5’-CGTGTTTGTTAGGTGTCAG-3’ 
MC1R_F1 5’-CTGAAAACACCAACCTCTCC-3’ 
MC1R_R1 5’-CCACACAATATCACCACCTC-3’ 
MC1R_F2 5’-CTTTCACGCTCTGCCC-3’ 
MC1R_R2 5’-CACAGCCATAGTCCTGTCC-3’ 
LDHA_F1  5’-GAGTGGGAGCTGGTAGG-3’ 
LDHA_R1  5’-GCTATCCAAGGCACAGG-3’ 
LDHA_F2  5’-CAGGGATGAAGAAGAAACAG-3’ 
LDHA_R2  5’-TGAGATTTGAGTGGGAGAAC-3’ 
Tyros_F1 5’-TTGTAGCCTCTTTATGGTCTC-3’ 
Tyros_R1 5’-TTATTTCCCAAACATTCCTG-3’ 
Tyros_F2 5’-CTCTATTCCTGACACTACCTCTC-3’ 
Tyros_R2 5’-CCAATTAGTCTGGGATAAGG-3’ 
pCRII--F1 5’-CACACAGGAAACAGCTATGAC-3’ 
LDHA/pCRII-R1 5’-GATAAGCTTTAGAGGATGGGGTCAAGG-3’  
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Supplement Table ST 2: Oligonucleotide sequences used for EMSA and pull-down experiments. Binding 
motifs, HREs or E-box palindromes, are underlined and given in bold: 
Sequence name sequence 
Daphnia phb2 w-146HRE/+ 5’-GAACCATACACGTGCCTCGAGCAG-3’ 
Daphnia phb2 w-146HRE/- 5’-CTGCTCGAGGCACGTGTATGGTTC-3’ 
Daphnia phb2 m-146HRE/+ 5’-GAACCATACAATGTCCTCGAGCAG-3 
Daphnia phb2 m-146HRE/- 5’-CTGCTCGAGGACATTGTATGGTTC-3’ 
Daphnia phb2 w-107HRE/+ 5’-ACACGGCCTACGTGATGATAGCGC-3’ 
Daphnia phb2 w-107HRE/- 5’-GCGCTATCATCACGTAGGCCGTGT-3’ 
Daphnia phb2 m-107HRE/+ 5’-ACACGGCCTAATGTATGATAGCGC-3’ 
Daphnia phb2 m-107HRE/- 5’-GCGCTATCATACATTAGGCCGTGT-3’ 
hBNIP3 HRE wt /+ 5’-ACGCGCCGCACGTGCCACACGCAC-3’ 
hBNIP3 HRE wt /- 5’-GTGCGTGTGGCACGTGCGGCGCGT-3’ 
hBNIP3 HRE mut /+ 5’-ACGCGCCGCAATGTCCACACGCAC-3’ 
hBNIP3 HRE mut /- 5’-GTGCGTGTGGACATTGCGGCGCGT-3’ 
hLDHA reg.I wt/+ 5’-TCCCAGCGCACGTGGAGCAGTCTG-3’ 
hLDHA reg.I wt/- 5’-CAGACTGCTCCACGTGCGCTGGGA-3’ 
hLDHA reg.I mut/+ 5’-TCCCAGCGCAATGTGAGCAGTCTG-3’ 
hLDHA reg.I mut/- 5’-CAGACTGCTCACATTGCGCTGGGA-3’ 
hLDHA reg.II/III ww/+ 5’-CGACTCACACGTGGGTTCCCGCACGTCCGCCGGC-3’ 
hLDHA reg.II/III ww/- 5’-GCCGGCGGACGTGCGGGAACCCACGTGTGAGTCG-3’ 
hLDHA reg.II/III mw/+ 5’-CGACTCACAATGTGGTTCCCGCACGTCCGCCGGC-3’ 
hLDHA reg.II/III mw/- 5’-GCCGGCGGACGTGCGGGAACCACATTGTGAGTCG-3’ 
hLDHA reg.II/III wm/+ 5’-CGACTCACACGTGGGTTCCCGACATTCCGCCGGC-3’ 
hLDHA reg.II/III wm/- 5’-GCCGGCGGAATGTCGGGAACCCACGTGTGAGTCG-3’ 
hLDHA reg.II/III mm/+ 5’-CGACTCACAATGTGGTTCCCGACATTCCGCCGGC-3’ 
hLDHA reg.II/III mm/- 5’-GCCGGCGGAATGTCGGGAACCACATTGTGAGTCG-3’ 
 
 
Supplement Table ST 3: Double-stranded siRNA oligonucleotide sequences used for transient knockdown 
HIF-1α, USF1 and USF2a in Hep3B cells 
Gene Genbank accession No. Targeted region  
sense antisense 
HIF-1 AF304431.1 1380-1400 5’-CUGAUGACCAGCAACUUGAdTdT-3’ 5’-UCAAGUUGCUGGUCAUCAGdTdT-3’ 
USF1 NM_007122 79-97 5’-GACCCAACCAGUGUGGCUAdTdT-3’ 5’-UAGCCACACUGGUUGGGUCdTdT-3’ 
USF2a NM_003367 786-806 5’-UCCAGACUGUAACGCAGACAAdTdT-3’ 5’-UUGUCUGCGUUAACAGUCUGGAdTdT-3’ 
 
Supplement Table ST 4: PCR primers for LDHA and BNIP3 ChIP assay 
 
Sequence name Sequence 
LDHA forward 5’-ACTCAGGCTCATGGCTC-3’ 
LDHA reverse 5’-GGCTGGGGGTGGATG-3’ 
BNIP3 HRE forward 5’-TAGCCAGTGCCCAGAGAGTCC-3’ 
BNIP3 HRE reverse 5’-ATTGGCCGCGACTTGGG-3’ 
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Abstract 
Immunohistochemical analysis of myoglobin (Mb) in human breast cancer specimens (n=917) 
revealed endogenous expression in 71% of invasive breast carcinomas preferentially of luminal-type 
and correlated with hormone receptor status and favourable patient prognosis. A positive correlation 
with hypoxia-inducible factor 2α (HIF-2α) and carbonic anhydrase IX suggested oxygen to regulate 
Mb in breast carcinomas. Indeed, Mb mRNA and protein levels were robustly induced by prolonged 
hypoxia in breast cancer cell lines, in part via HIF-1/-2 dependent transactivation. Interestingly, 
hypoxically induced Mb mRNA originated from a novel, alternative transcription start site 6 kb 
upstream of the genuine ATG codon. Functionally, Mb knockdown in MDA-MB468 breast cancer 
cells resulted in an increased oxygen uptake during mild hypoxia, yet did not impair O2 diffusion in 
these cells even under respiration-limiting conditions. Alternative functions of Mb distinct from 
oxygen sensing and transport, e.g. fatty acid binding, have to be considered to interpret Mb’s positive 
effect on the proliferation and migration of cultured oxygenated breast cancer cells. These 
unprecedented findings may have fundamental implications for our understanding of non-muscle Mb 
in solid tumors.  
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1. Introduction 
Human myoglobin (Mb) is considered one of the best characterized proteins with more than 
11,200 PubMed-listed publications since Kendrew et al. have presented the first three dimensional 
model of this molecule in 1958 (1). It is commonly described as a cytoplasmic hemoprotein that is 
solely occurring at milli-to micromolar concentrations in cardiac myocytes and type I and IIa skeletal 
muscle fibers of mammals. In myocytes, Mb is widely accepted to function as  temporary “store” for 
oxygen, able to buffer short phases of exercise-induced increases in O2 flux during which it supplies 
the gas to mitochondria (2). Another, more controversially discussed role is Mbs´ facilitation of 
oxygen diffusion within muscle cells (3, 4). Although Mb knockout mice exhibited normal exercise 
capacity and no signs of compromised cardiac energetics due to multiple systemic compensations (5, 
6), follow-up studies stressed the importance of functional Mb in maintaining nitric oxide (NO) 
homeostasis in muscle through either scavenging (7) or producing the NO molecule (8). That way, Mb 
might participate in tuning vasodilatory responsiveness and protecting the respiratory chain from NO 
inhibition (9). Further possible functions of Mb in muscle include synthesis of peroxides (10), 
scavenging of reactive O2 species (11) and binding of fatty acids (12). 
In humans, Mb is synthesized at concentrations of ~200-300 M in striated muscle and, albeit 
at much lower levels, in a variety of human tumors including medullomyoblastoma (13), thymolipoma 
(14), acute leukaemia (15) and desmoplastic small round cell tumors (16). Following an accidental 
observation of positive Mb staining in several human carcinomas in 2001, we have since then 
systematically examined Mb expression, regulation, function and prognostic impact in human breast 
cancer. Now, we are presenting the first comprehensive analysis of Mb expression in a large and 
representative cohort of human breast cancer (n=917), including a portrayal of the associations 
between clinico-pathological parameters and the range of Mb synthesis seen in mammary carcinomas. 
We also observed that, in cultured breast cancer cells, the de novo expression of the Mb gene is 
induced by hypoxia, which, in part, required transactivation by functional hypoxia-inducible factor 
(HIF) 1 and 2. The functional association of Mb and HIF was further confirmed by tissue expression 
data. To elicit possible roles of endogenous Mb, we applied both stable and transient RNA 
interference knockdown approaches to breast cancer cells and recorded altered functional properties of 
the cells with regard to respiratory, proliferative and migratory activities. We finally shed some light 
on unusual functions of Mb in the oxygenated cancer by looking at the impact of steroids on the steady 
state level of the protein and on Mb´s involvement in fatty acid metabolism.  
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2. Results    
Human breast cancer tissue exerts a complex pattern of Mb expression  
Following the initial observation of Mb immunoreactivity in conventional immuno-
histochemistry analyses, Mb transcript levels were determined in breast biopsies and breast cell lines. 
Whereas low levels of Mb mRNA were detectable in four of ten cases of healthy breast tissue (Fig. 
1A), Mb expression was upregulated in nine of ten matched normal / tumor tissue samples with a 
median tumor-to-normal up-regulation of 352 fold. With regard to breast cell lines, Mb mRNA was 
not detectable in benign MCF12A epithelial cells as well as in MDA-MB436, Hs578T, Cal51 tumor 
cells (Fig. 1B). Ten breast cancer cell lines (MDA-MB231 to MCF7, see Fig. 1B) expressed detectable 
but low amounts of Mb mRNA while three breast cancer cell lines contained abundant quantities of 
the Mb transcript, i.e. EFM19, MDA-MB415 and MDA-MB468 cells.  
Using a validated monoclonal Mb antibody (Supplement Fig. S1), we next analysed Mb 
expression on tissue microarrays containing normal tissue (n=56), intratumoral ductal carcinoma in 
situ (DCIS; n=155) and invasive breast cancer (n=917, clinico-pathological parameters are given in 
Table 1). In normal breast tissue, staining was observed in secretory luminal epithelial cells, but not in 
myoepithelial cells (Fig. 2A). Altogether, in normal breast seven percent of cases were negative for 
Mb, 50% were weakly positive, 39% stained moderately positive and four percent of tissues stained 
strongly. DCIS showed more abundant Mb staining (Fig. 2B/C) which was pronounced in vital tumor 
cells near the central comedo necrosis (Fig. 2C). 12% of DCIS cases were negative, 38% weakly 
positive, 39% moderately positive and 10% were strongly positive. In invasive carcinoma, the number 
of Mb negative cases was markedly higher than in normal tissue: 29% were negative (Fig. 2D), 31% 
were weakly positive, 30% were moderately positive (Fig. 2E) and 10% were strongly positive (Fig. 
2F). A spotted, mosaic like expression pattern was frequently seen in DCIS and invasive carcinoma 
(Fig. 2E). Thus, with increasing transformation and aggressiveness (normal tissue ? DCIS ? invasive 
carcinoma) the proportion of Mb negative and strongly positive tissues both gain in frequency. 
Since myoglobin has been described as a marker of rhabdomyoid differentiation, we analyzed 
two breast tumors with strong Mb immunoreactivity by transmission electron microscopy (Fig. S2). 
However, no striated muscle elements could be observed in these cases, suggesting that increased 
expression of Mb occurs independently of rhabdomyoid tumor differentiation.  
 
Tumor-derived myoglobin expression is linked to estrogen receptor status and favourable prognosis 
and may present a marker for luminal type breast cancer 
In invasive breast carcinomas Mb expression was associated with better histological tumor 
differentiation according to BRE-grading (correlation coefficient (cc) =-0.116, p=0.001). Mb did not 
correlate with pT stage, nodal status or tumor type. Mb expression was positively correlated with 
estrogen (ERα) and progesterone receptor (PgR) positivity (cc=0.206, p=0.001 and cc=0.180, p=0.001) 
and negatively with the myoepithelial/basal phenotype marker CK5/6 (cc=-0.120, p=0.001). No 
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correlation with HER2 expression was found. Notably, positive correlations were found to the 
hypoxia-inducible factor 2α (HIF-2α) (cc=0.257, p=0.001), carbonic anhydrase IX (CaIX; cc=0.361, 
p=0.001), cytoglobin (Cygb; cc=0.361, p=0.001) and E-cadherin (E-Cad; cc=0.207, p=0.001). No 
significant correlation was found with HIF-1α, Glucose transporter 1 (GLUT1), Ki-67 and 
microvessel density. Figure S3 displays a typical example of an Mb positive invasive breast cancer 
case in conjunction with markers of hypoxia. In a repeated correlation analysis stratified for ERα 
status, the significant correlations between Mb and PgR, Cygb, CK19, HIF-2α and CaIX could be 
confirmed for ERα-positive tumors, but failed significance in ERα-negative cases. Analogous to 
invasive carcinomas, Mb positivity in DCIS was equally correlated with HIF-2α (cc=0.245, p=0.02) 
and CaIX (cc=0.240, p=0.026), but not with HIF-1α or GLUT1. The positive correlation of Mb with 
markers of tissue hypoxia (CaIX and -2α) implied a possible control of Mb expression by oxygen. 
Towards the prognostic value of Mb and tissue hypoxia markers, univariate Cox analysis 
revealed histological tumor grade, pT stage, nodal status and hormone receptor (ER/PR) status as 
significant predictors of overall survival in our patient cohort (Tab. 3). High Mb expression was also 
significantly associated with longer overall patient survival (five-year survival rate of Mb-pos. cases 
83% vs. 75% in Mb-negative cases, Fig. 3) but lost significance in bivariate Cox and multivariate 
analysis. This might point to the positive correlation of Mb with ERα as the underlying determinant 
for a beneficial prognosis. We additionally classified Mb levels in correlation with a publically 
available expression dataset (17) (GEO Profiles, http://www.ncbi.nlm.nih.gov/sites/entrez, GDS1329). 
Here, Mb levels are significantly higher (p=0.005, Kruskal-Wallis test) in the group of luminal tumors 
compared to basal or apocrine types. These findings along with the positive correlation of Mb with 
ERα, a better tumor differentiation and improved prognosis and with the negative correlation with the 
basal phenotype marker CK5/6 all point to Mb as a marker of luminal tumor differentiation. 
 
Myoglobin mRNA and protein is induced in breast cancer cells by HIF1/2 mediated hypoxic stimuli 
and may be induced by hypoxia in vivo 
To study the responsiveness of the Mb gene, the effect of hypoxia (1% O2; 4, 8, 24, 48, 72h) 
was analyzed by quantitative real-time PCR (qPCR) in four different cell lines: the benign breast cell 
line MCF12A, the ERα-negative breast cancer cell lines MDA-MB-231 (low basal Mb expression, see 
Fig. 1B) and MDA-MB-468 (high basal Mb expression), and the ERα positive cell line MCF7 
(medium basal Mb expression). Whereas transcription of the Mb gene was unaltered by hypoxia in the 
benign MCF12A cells (data not shown), normalized steady state levels of Mb mRNA increased 3-4 
fold in hypoxic MDA-MB-468, MDA-MB-231 and MCF7 cells (for MCF7 cells, Fig. 4A). In all cases, 
a robust activation of the Mb gene required at least 24h or 48h of hypoxia to take effect. Proper 
hypoxic responsiveness of MCF7 cells was confirmed through assessment of transcription of the 
highly hypoxia-inducible CaIX transcript (Fig. 4A). 
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Using a commercial chemiluminescence based Mb-assay we determined the amount of Mb 
protein present in 106 MDA-MB-468 cells to correspond to ~65 ng or 4 pmol. Mb protein level 
response to hypoxia was analysed for MDA-MB-468 and MCF7 cells subjected to 72h normoxia or 4, 
8, 24, 48 and 72h hypoxia (1% O2). Representative Western blots for MDA-MB-486 (left) or MCF7 
(right) are shown at the top of Fig. 4B. The densitometric summary from three independent 
experiments is depicted as normalized mean intensity (±SD) of the Mb band, relative to its normoxic 
intensity (=1), in the respective graphs underneath. In agreement with RNA expression levels, both 
cell lines induced Mb protein between 3.4 and 5.1-fold following a hypoxia exposure of 48h or longer. 
In addition, the HIF response was transient in hypoxic MCF7 cells. Here, induction of the predominant 
species, HIF-1α, peaked at 4h hypoxia, followed by a steady decline of the protein content thereafter. 
In contrast, hypoxic MDA-MB-468 cells expressed preferably HIF-2α whose induction persisted for 
up to 72h of 1% O2 (Fig. 4B). 
To study the role of HIF in the hypoxic induction of Mb, we utilized siRNA oligonucleotides 
specifically directed against nucleotides 1380-1400 of HIF-1α mRNA (Entrez accession number: 
AF304431.1) and nucleotides 1260-1280 of HIF-2α mRNA (Entrez accession number: 
NM_001430.3), respectively. Since induction of Mb protein levels was robustly detected from 48h 
hypoxia onwards (Fig. 4B), the siRNA assay focused on control and HIF-1α (= siHIF-1α), -2α (= 
siHIF-2α) and combined knockdown effects (= siHIF-1α/2α) after 52h to 96h of exposure to 1% O2 
(Fig. 4C). Induction of myoglobin steadily increased during the siControl transfections until a 
maximum of ~7-fold was reached at 72h hypoxia (Fig. 4C, bottom graph; siControl time course). This 
72h-peak induction was reduced to ~4-fold upon HIF-1α or -2α single siRNA treatment. Moreover, 
the combination of both siRNAs, with ~20% residual content of either HIF factor remaining, 
significantly attenuated the Mb induction to ~1.7 fold at 72h hypoxia. Our data imply both HIF-1 and 
HIF-2 in participating in the peak stimulation of Mb to low oxygen. 
To clarify if Mb expression also correlates with hypoxic tissue areas in vivo, we reanalysed the 
155 ductal carcinoma in situ (DCIS) cases. DCIS represents an interesting in vivo model for hypoxia 
research since this tumor has no intraductal vasculature. Thus, oxygen can only be supplied by 
diffusion from the outer basal membrane. This leads to the formation of a radial O2 diffusion gradient 
(normoxic rim; hypoxic to anoxic centre) along with a central necrotic area (Fig. 5). Expression of the 
hypoxia-driven GLUT1 protein closely followed this gradient in our cohort of DCIS and showed a 
typical zonal distribution in 65% of cases (Fig. 5A). However, with regard to Mb only in 27% of Mb-
positive DCIS cases a hypoxia-like gradient with stronger staining in the peri-necrotic region was 
found (Fig. 5A). The majority of cases (73%) showed a diffuse Mb immunoreactivity (Fig. 5B). This 
indicates that hypoxia may up-regulate Mb in vivo, although in the majority of cases low oxygen alone 
is insufficient for Mb induction. A similar conclusion was reached when we assessed the possible co-
localization between Mb and hypoxic tumor areas as indicated by the hypoxia marker pimonidazole 
(Fig. S4). 
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 Hypoxic Mb transcript in MDA-MB-468 cells are derived from an alternative Mb gene promoter 
Inspection of the human Mb gene locus in comparison to expressed sequence tag (EST) 
libraries and our own RT-PCR expression data (not shown) indicated the presence of alternatively 
spliced Mb transcripts in addition to the published mRNA (18). These transcript variants contain 
different non-coding 5’- untranslated regions (5´-UTR), hence are transcribed from different Mb 
promoters (Fig. 6A). Comparison of EST numbers revealed that mRNA NM_005368 is the dominant 
‘standard’ transcript (Mb-s) in skeletal and heart muscle tissue. Transcript NM_203377, starting with 
an upstream exon (designated “-1” by us), was annotated to be derived from seven EST reads, which 
originated from adenocarcinoma, gastric cancer and adrenal cortex carcinoma cell lines (designated 
Mb-a for “alternative”). Mb-a mRNA thus represented a candidate for analyzing its expression in 
breast cancer cells. Calculation of mRNA expression levels of Mb-s compared to Mb-a in the 
normoxic MDA-MB468 breast cancer cell line revealed a clear preference in expressing the alternative 
transcript Mb-a, which was roughly 300 fold more abundantly expressed than Mb-s (Fig. 6B). 
Furthermore, when determining the steady-state levels of Mb-s and Mb-a in MDA-MB-468 cells 
subjected to either 1 % O2 for 72 h or normoxia, we found an unaltered Mb-s expression, while the 
tentatively tumor-associated transcript variant Mb-a exhibited a statistically significant 2.2 fold 
expression increase in hypoxic compared to normoxic cells. This observation prompted us to inspect 
the genomic regions of human and mouse Mb/Mb genes for the presence of HIF binding hypoxia 
response elements (HREs). HREs are usually characterized by a conserved consensus binding motif 
5´-RCGTG-3´ (19). Using the rVISTA tool we indeed detected one interspecifically conserved 
putative HRE at approximately 2.7 kb upstream of exon 1 (Fig. 6A), which consists of two inverted 
HIF-1 binding sites at an interval of 6 bp contained within a conserved stretch of 53 bp. Further 
sequence comparisons showed that this candidate HRE from the Mb gene has 93% sequence similarity 
to an upstream promotor region from the human heat shock protein HSPB1 gene (Fig. 6C).  
 
High-resolution respirometry on Mb control and knockdown MDA-MB-468 cells  
To test if Mb facilitates the diffusion of oxygen between the cell membrane and mitochondrial 
compartment of breast cancer cells, we generated short-hairpin RNA (shRNA)-derived stable Mb 
knockdown clones of MDA-MB-468 cells using four different shRNA constructs (#83-86) to target 
distinct Mb mRNA nucleotides. Applying Fick’s law of diffusion, we aimed to see if the shRNA-
mediated loss-of-function (LoF) of Mb protein would yield a steeper oxygen diffusion gradient 
reflected by a higher p50(O2) of cell respiration at identical oxygen flow (=per-cell consumption rate, in 
units of pmol O2·s-1·10-6 cells).  
O2 consumption kinetics were investigated by high-resolution respirometry using two control 
(con) clones (boxed: 84#5 and 85#14) and two knockdown (kd) clones (boxed: 83#4, 84#31) (Fig. 7A). 
Mb protein from MDA-MB468 cells versus Mb from positive control skeletal muscle biopsies (Fig. 
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7A, pos.) migrated in SDS PAGE gels with equal mobility. Oxygraph-2k respirometers recorded the 
O2 flow per second and million cells (Fig. 7B, red trace) as a function of oxygen concentration (Fig. 
7B, blue trace) for the aforementioned clones of MDA-MB-468 cells during four different cellular 
activity states: i) routine respiration without glucose [= R(-G)]; ii) routine respiration with glucose (25 
mM) added [= R(G)]; iii) maximal respiration through uncoupling of oxidative phosphorylation by 
FCCP [= ETS, capacity of the electron transport system]; iv) residual O2 consumption, ROX, 
subsequent to poisoning of mitochondria with myxothiazol (see Fig. 7B, annotation). Culture medium 
was prepared for respirometry by adding 280 IU/ml of catalase to generate, following the injection of 
40 M H2O2 during the measurement, a controlled amount of O2. Thus, extra transitions between oxy-
regulated and oxy-conform respiration were added for improved accuracy in the determination of p50 
data (below). Moreover, addition of glucose reduced rates of routine respiration as a reflection of the 
Crabtree effect (Fig. 7B), thus allowing to measure oxygen consumption at higher [R(-G)] versus 
lower [R(G)] fluxes. 
Figures 7C and D display O2 consumption rates and cellular p50(O2), respectively, for each 
individual clone to portray the variability inherent in these data. When comparing routine respiratory 
activities with and without glucose, we found that glucose addition on average reduced oxygen 
consumption rates by 9-27%. Surprisingly, all mitochondrial (R(-G), R(G), ETS) and residual (ROX) 
O2 fluxes were significantly increased in Mb kd cells compared to con cells (con vs. kd pooled data) 
(Fig. 7C). In contrast, mean ± SD cellular p50(O2) values under R(-G) and R(G) conditions were 
statistically indistinguishable (ns: non-significant) in con versus kd comparisons for either glucose-
deficient or -proficient respiration (Fig. 7D). Also, differences in p50 values from high versus low 
oxygen fluxes were non-significant (Fig. 7D). This surprising result was confirmed when plotting the 
flux control ratio Rmax/ETS as an exquisitely sensitive marker for cytochrome c oxidase (Cox) turnover 
under routine states of activity, R, and kinetic oxygen saturation of respiration. Again, no direct 
relationship between p50 and oxygen flow at R(-G) versus R(G) was found (not shown). 
 
Mb knockdown cells exhibit reduced proliferative and migratory capacities 
 The impact of the Mb LoF on cellular proliferation during a 0-48-96h time course of wildtype 
(wt), Mb-control (con) and Mb-knockdown (kd) MDA cells was examined under normoxic (Fig. 8A) 
and hypoxic (1% O2, Fig. 8B) atmospheres by employing MTT (continuous lines) and Trypan Blue 
(dotted lines) assays. Whereas the MTT (short for: Dimethylthiazolyldiphenyltetrazolium Bromide) 
assay infers growth rates from the activity of mitochondrial dehydrogenases that catalyze a tetrazolium 
? formazan reduction as colorimetric readout, exclusion of Trypan Blue (TB) by intact cellular 
membranes allows directly, and independently of mitochondrial confounders, to count the numbers of 
viable cells. The data in Fig. 8A/B are presented in reference to the 0h time point. 96h proliferation 
ratios (wt/kd, con/kd) are given relative to the growth of kd cells set to 1 (inverted numbers). As 
illustrated by those ratios, Mb LoF in kd cells slows proliferation and activity of mitochondrial 
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enzymes more profoundly under hypoxic than normoxic conditions. Mb, it seems, aids in maintaining 
both proliferative and oxidative capacities of breast cancer cells during prolonged hypoxia.  
However, Mb LoF was also linked with a diminished migratory potential in completely 
aerobic MDA-MB-468 cells. Scratch wound assays determine the dynamics of cell migration precisely 
by analyzing the time frame of wound closure (Fig. 8C). Already 24 h after wounding, a remarkable 
retardation of in vitro motility was observed in one clone of Mb kd cells (83#4) while the behavior of 
a second kd clone (83#8) corresponded more closely with the two Mb-expressing con clones. This 
retardation of in vitro motility in the 83#4 Mb kd cells became even more obvious 48 h and 72 h after 
wounding. Thus Mb-con MDA-MB-468 cells tend to close the wound much faster, showing that loss 
of Mb expression in this breast cancer cell line is associated with decreased in vitro motility of tumor 
cells under normoxia. Due to the variable outcome with these shRNA-based kd cells, we opted to 
repeat these experiments based on the transient siRNA-driven knockdown of Mb RNA in MDA-MB-
468 cells. Here again, we found a good agreement with the more severe shRNA phenotype, i.e., the 
knock-down of Mb function to 10% of normal Mb protein levels resulted in a significant retardation of 
the wound healing reaction of breast cancer cells under normoxic conditions (Fig. 8D). 
 
Non-respiratory functions of Mb in human breast cancer? 
The amount of Mb detected in human breast cancer tissue and MDA-MB-468 cells was 
similar in Western blot analysis (data not shown) and equalled 65 ng per 106 tumor cells as described 
above. Since this minute amount of Mb cannot play a significant role in the maintenance of cellular 
oxygenation, and since we ruled out a significant impact of Mb on O2 diffusion gradients in MDA468 
cells (Fig. 7 D), Mb functions alternative to respiration support appear more likely. The association of 
Mb with characteristics of the luminal tumor subtype, namely ERα positivity led us to investigate this 
point further. 
Publically available DNA array expression data (Geoprofiles, GDS2324) (20) had already 
indicated a tight co-regulation of Mb and ERα mRNAs in the breast cancer cell line MCF7 by 
showing that estrogen starvation was able to induce, while estrogen application suppressed, Mb 
transcript in either a time or dose dependent manner (Fig. S5). We repeated this experiment in vitro 
and could confirm the in silico data in that application of estrogen to MCF7 breast cancer cells 
repressed Mb expression potentially in a dose dependent manner (Fig. 9). This prompted us to further 
analyse the spatial association of both proteins. In normal lobular breast parenchyma, approximately 
90% of the strongly Mb positive cells interspersed in secretory epithelia demonstrated a co-
localisation of cytoplasmic Mb and nuclear ERα staining (Fig. 10A). In invasive breast carcinomas, 
this co-expression still was apparent in well differentiated carcinomas (Fig. 10B). 
Recently, Mb was described again as a fatty acid (FA) binding protein and suggested to have a 
role in the transport of FAs in oxygenated cells (12, 21, 22). This prompted us to investigate the 
possible co-localization of Mb and fatty acid synthase (FASN) in both healthy and cancerous breast 
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tissue. FASN catalyses the synthesis of unbranched fatty acids and is upregulated in the broad majority 
of malignant tumors (23). In a direct comparison with Mb in a subset (n=293) of our breast cancer 
cohort, a highly significant correlation of both proteins was found (CC=0.297, p=0.001). Moreover, in 
normal breast tissues, a striking spatial concordance in the expression of Mb and FASN was seen 
(Figure 11A), which was partially retained in (Figure 11B). To check for a possible functional 
association of Mb expression and intracellular fatty acid levels, we used the FASN inhibitor C75. This 
inhibitor has been characterized as FASN specific, leading to an almost immediate and irreversible 
enzyme inhibition (24).  In MDA-MB-468 cells, we observed a strong time dependent down-
regulation of Mb on transcript and protein level upon FASN inhibition in comparison to control cells 
(Figure 12), suggesting that Mb expression is indeed regulated by intracellular FA levels and that non-
muscle Mb in tumor cells might be involved in controlling fatty acid metabolism. 
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3. Discussion 
This report is the first systematic examination of myoglobin (Mb) expression in a large cohort 
of breast cancer specimens. It integrates clinical, molecular and functional results to describe novel 
and unexpected facets of this hemoprotein. We first noticed a supposedly aberrant Mb 
immunoreactivity in a small series of breast carcinomas. To address whether Mb is being actively 
produced by tumor cells or, rather, taken up from e.g. adjacent musculature as suggested (25), we 
analyzed its expression both in vitro and in vivo. On transcript level, we found Mb strongly 
upregulated in breast tumors in comparison with adjacent normal ductal tissue. Mb mRNA was also 
detectable in breast cancer cell lines, in a small subset even at surprisingly high levels. This pointed to 
an active expression of endogenous Mb in ordinary invasive ductal breast cancer, which were neither 
muscle-invasive nor did they, as assessed by light microscopy, possess any rhabdomyogenous 
differentiation. Transmission electron microscopy did also not reveal any striated muscle elements in 
two strongly Mb positive breast cancer cases. We therefore conclude that Mb is de novo expressed in 
breast cancer cells although rare cases of so-called metaplastic carcinomas of the breast might exist 
where Mb-positivity stems from the rabdomyogenous differentiation of the cells (26, 27).  
On the basis of these encouraging preliminary findings, a large recently described (28) cohort 
of primary breast cancer including 917 invasive carcinomas and 155 cases of Ductal Carcinoma in situ 
(DCIS) was analysed for Mb expression. In total, 40% of invasive carcinomas showed moderate to 
strong Mb expression. However, Mb was also consistently seen in mature secretory epithelia of the 
healthy breast showing a basal expression in most cells with a particularly clear expression in estrogen 
receptor positive cells (Fig. 2A). Contrary to earlier reports that found normal epithelia invariably Mb 
negative (29), luminal cells in healthy breast clearly have the ability to express Mb at detectable levels. 
That recent small scale pilot study identified endogenous Mb in human epithelial tumors including 
breast cancer and elucidated several signals, among them hypoxia, that were able to stimulate Mb 
expression in cultivated MCF7 breast cancer cells (29). However, the study lacked any prognostic, 
mechanistic and detailed functional data. 
Regarding its occurrence in tumors, Mb is preferentially detected in better differentiated, 
hormone receptor (ER/PR) positive tumors and is associated with a significantly better prognosis. All 
these features are characteristics of the so called luminal subtype of breast cancer according to Perou 
et al. (30) which shares many molecular similarities with normal secretory epithelia including a strong 
expression of cytokeratins typical of mature secretory epithelia (CK8/18), hormone receptor (ER/PR) 
positivity and negativity for HER2 and the basal cell cytokeratins CK5/6. Further support for 
considering Mb a diagnostic marker of the luminal breast cancer subtype comes from the in silico 
analysis of Farmer et al., in which Mb transcript levels were highest in tumors classified as the luminal 
subtype (17). Our own immunofluorescent double stainings detected co-localisation of cytoplasmic 
Mb and nuclear ERα in secretory cells of normal breast tissue. The same intracellular co-localization 
was found in strongly Mb and ERα-positive invasive ductal carcinomas. Beyond this spatial co-
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existence, Mb and ERα transcripts are also co-ordinately and dose-dependently down-regulated when 
MCF7 cells are subjected to a E2 treatment protocol as we show in silico and in vitro. This hitherto 
undescribed co-regulation of Mb with ERα by estrogen is likely to explain the co-expression of the ER 
with Mb and, hence, the better prognosis of Mb positive tumors.   
Mb has different known or alleged functions in muscle tissue including short-term O2 storage 
and buffering, facilitating O2 diffusion, scavenging of NO and ROS and also the reverse (peroxidase 
activity, NO production) and might be involved in fatty acid metabolism (2, 3, 7, 8, 10-12, 31). The 
significant correlation of Mb occurrence with established hypoxia markers (HIF-2α, CaIX) in breast 
carcinomas plus the fact that we observed a hypoxia-associated up-regulation of Mb in 27% of DCIS 
all aimed our focus on the role of oxygen on Mb expression and function in breast cancers and cancer 
cell lines. More than 50 years after Thomlinson’s and Gray’s pioneering discovery to link 
radiosensitivity with oxygen tension in tumor tissue (32, 33), the existence of regional hypoxia in most 
solid tumors (for review: (34-37) including breast cancer is of high clinical relevance (38). Also, the 
immunohistochemical detection of the exogenous hypoxia marker pimonidazole led Arcasoy et al. to 
conclude in a series of 26 breast cancer cases that 62% of tumors of the breast are pimonidazole-
positive and thus hypoxic (39). 
In accordance with the data of Flonta et al. (29), we demonstrate the de novo expression and 
hypoxic responsiveness of human Mb mRNA and protein in human breast cancer cell lines. We found 
a 3-4 fold up-regulation of Mb mRNA in response to prolonged (>24-48h) exposure to 1% O2. It is of 
importance to note, that this hypoxia dependent up-regulation was restricted to tumor cell lines and 
could not be evoked in the non-transformed epithelial cell line MCF12A. A corresponding 3-5 fold 
elevation of Mb protein levels during prolonged hypoxia was noted for both MDA-MB-468 and 
MCF7 breast carcinoma cells. 
Towards the control of this induction, we noted distinct HIF-gene preferences and stabilization 
kinetics in breast cancer cells. Whereas HIF-2α was the predominant factor and persistently elevated 
in hypoxic MDA-MB-468 cells, a transient induction of HIF-1α was the leading HIF response in 
hypoxic MCF7 cells. To our surprise, siRNA transfections in MDA-MB-468 cells directed against 
HIF-1α, -2α or both factors revealed that the ~7-fold peak induction of Mb protein during prolonged 
(72h) hypoxia (1% O2) requires the involvement of both HIF species. Thus, both HIF-1 and HIF-2 
contribute to the hypoxia transactivation of the Mb gene in breast cancer cells in vitro.  
The standard promoter of the Mb gene that is driving the expression in striated muscle cells 
has been characterized in 1984 by Weller et al. for the human and in 1986 by Blanchetot et al. for the 
mouse Mb gene (18, 40). This TATA box promoter contains no candidate HRE (41). Consequently, 
expression of the standard Mb transcript (NM_005368; Mb-s) is not affected by O2. However, we also 
observed the hypoxia-activated transcription of a non-canonical Mb mRNA (NM_203377; Mb-a), 
transcribed from a promoter that is located proximal to the 5’ UTR exon -1. EST evidence and our 
own comparison of the copy numbers of the alternative versus standard Mb mRNAs expressed in 
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MDA-MB-468 cells (Fig. 6B) suggested that Mb-a, tentatively, can be regarded as a cancer-specific 
transcript. Discovery of the O2-responsiveness of Mb-a, in conjunction with the found HIF-1/-2-driven 
transactivation of the Mb gene during hypoxia (Fig. 6A-C), led us to search for candidate HREs as 
potential regulatory sites for the alternative transcript. Scanning the complete genomic region of 
human and mouse Mb genes for HRE motifs we discovered a candidate HRE of the Mb gene, which 
consists of two inverted HIF-1 binding sites at an interval of 6 bp, embedded in a conserved stretch of 
53 bp (Fig. 6C). This Mb-HRE has 93% sequence similarity to an upstream promoter region from the 
human heat shock protein HSPB1 gene that encodes the Hsp27 protein. Interestingly, promoter assays 
had already suggested that this observed HRE of HSPB1 is indeed functional in mediating HIF-1 
responses (42). 
Based on these findings, breast cancer cells induce the Mb gene in response to longer periods 
of low oxygen via an alternative, and perhaps, tumor specific promoter whose enhanced activity 
depends, in part, on the binding of HIF-1/-2 to the HRE located 2.7 kb upstream from the ATG. We 
thus are beginning to obtain a mechanistic rationale for the significant positive correlation of Mb with 
HIF-2α and CAIX in breast carcinomas. However, our in vivo data also provide evidence, that Mb can 
be expressed by breast epithelia irrespective of hypoxia (i.e. normal secretory ductal cells: Fig. 2A; 
DCIS with diffuse staining: Fig. 5B) and that even severe hypoxia does not necessarily induce Mb 
expression, as the comparison of Mb and pimonidazole stainings illustrates for breast carcinoma. In 
the majority of DCIS cases, the expression of Mb did not follow the hypoxia gradient, which clarifies 
that hypoxia is not acting as sole stimulus to induce Mb in vivo. Furthermore, the in vivo data linked 
Mb with HIF-2α rather than HIF-1α, perhaps as a consequence of the mutually exclusive status 
between active HIF-1α and ERα/PgR signalling in breast cancer cells (43, 44). The positive 
correlation between Mb and ERα or PgR positivity might preclude a significant linkage of Mb with 
HIF-1α, or HIF-1α dependent effector genes (e.g. GLUT1), in the investigated carcinoma and DCIS 
entities.  
Towards possible functions of this hemoprotein in tumor cells, we generated shRNA Mb 
knockdown clones of MDA-MB-468, the breast cancer cell line with the most abundant transcript 
levels. These knock down cells were comparatively analysed concerning their in vitro respiratory and 
tumorigenic properties. To assess whether Mb confers O2-buffering or facilitates O2 diffusion we used 
high-resolution respirometry to measure O2 consumption kinetics in Mb expressing (con) and 
knockdown (kd) MDA-MB-468 cells. We would expect a lower respiration p50(O2), i.e. a higher Cox 
turnover, in controls relative to knock down cells provided that cell number and oxygen flux, as well 
as cell size are comparable between both cell types. We either controlled for these parameters during 
measurements (cell number, O2 flux) or found them to be largely overlapping between both genotypes 
(cell size; not shown). Since cellular p50(O2) measures lie below 0.1 kPa, there exists only a small 
scope for oxygen gradients, considering that the p50(O2) of isolated mitochondria is 0.04 to 0.06 kPa in 
the active state (Scandurra and Gnaiger, 2009). Within these physical constraints the present study was 
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unable to provide any evidence for O2 gradients that are differentially impacted by the presence or 
absence of Mb protein. In fact, the p50(O2) of MDA-MB-468 cells was found to lie in a similar range 
(0.08 kPa), irrespective of expression or knockdown of intracellular Mb (Fig. 7D). While these results 
do not suggest a functional role of Mb for oxygen transport in small, suspended cells in vitro, they do 
not exclude the possibility of large oxygen gradients developing in the solid tumor and a potential 
contribution of Mb to facilitated oxygen diffusion under in vivo conditions. Regarding the control of 
mitochondrial function, in MDA-MB-468 cells, routine respiration in the absence of glucose activated 
only ~55% of the mitochondrial capacity for electron transport, and this was reduced to ~40% in the 
presence of glucose, which is comparable to various primary cultured cells, such as HUVEC and 
fibroblasts (45, 46). Mitochondrial oxygen kinetics and coupling control in the malignant MDA-MB-
468 cells, therefore, is not indicative of a mitochondrial deficiency frequently considered as a specific 
feature (Warburg effect) of cancer cells.  
In addition to these high resolution respiromety data obtained under O2-limiting hypoxia, we 
surprisingly noticed that under mild hypoxia MDA kd cells, relative to control cells, revealed an 
intensified O2 uptake rate across all four physiological activity states considered (Fig. 7C; R(-G), R(G), 
ETS, ROX). As hemoprotein Mb can effectively interact with the gaseous nitric oxide (NO). Mb 
knockout mouse models (5, 6) have been instrumental to elicit Mb`s critical role in maintaining NO 
homeostasis in muscle tissue. Whether Mb expressed in neoplasms exerts similar controls remains to 
be seen. At this point we can only speculate that the activated respiration triggered by the LoF of Mb 
in MDA kd cells (Fig. 7C) might result from the proteins’ capacity to bind, and scavenge, with NO a 
key stimulus of the mitochondrial biogenesis (see (47) for review).  
To our knowledge, only two studies have so far analysed the functions of myoglobin in vivo 
by employing an artificial Mb expression system. Nitta et al. induced Mb expression in hepatocytes by 
an adenoviral gene transfer in rodents, which were henceforth significantly more resistant to hypoxia 
(48). Galluzzo et al. were the first to introduce Mb into tumor cell lines. They engineered A549 human 
lung carcinoma cells to ectopically express mouse Mb (49). Experimental tumors expressing Mb 
displayed reduced or no hypoxia, minimal HIF-1α levels, lesser vessel density along with a more 
differentiated cancer cell phenotype and largely suppressed local and distal metastatic spreading. The 
authors correlate these beneficial outcomes of Mb over-expression primarily with the reduction of 
tumor hypoxia (49). Although it is tempting to compare their model in vivo finding with our in vivo 
observations from patients, given that higher Mb levels correlate to less aggressive tumor behavior, 
both situations are quite different. We estimated the amount of endogenous Mb in normoxic MDA-
MB-468 breast cancer cells to equate to ~65 ng or 4 pmol of Mb protein present in 106 cells. This 
quantity is certainly far below the μM levels reached by the lentiviral gene transfer (49). While such 
excessive amounts of ectopic Mb in tumor cells will have a significant impact on tumor respiration 
and tumor growth, the endogenous picomole quantities of Mb we detected are unlikely to confer 
meaningful O2 storage/buffering capacity to the cell. In addition, our respirometry data failed to 
 152
provide evidence in support of a functional role of Mb to transport oxygen in small, suspended breast 
cancer cells in vitro. Thus, for these cells, functions of Mb that are not directly linked to the binding 
and transport of O2 have to be considered to comprehend the physiological relevance of this protein in 
breast cancer. 
One possible function of Mb that might be tremendously relevant for tumors is fatty acid 
metabolism. In a multitude of tumors, growth is accompanied with increased fatty acid synthesis and 
consequently enzymes catalysing these steps are up-regulated and can be used diagnostically and 
therapeutically (for recent reviews see (23, 50)). The co-localisation of Mb with fatty acid synthase 
(FASN) we discovered might give a hint towards the fatty acid binding function of tumor Mb. Fatty 
acid binding properties of Mb have been reported and predicted early (21, 51) and have recently 
gained further attention (52). According to Flögel and colleagues, lack of Mb in the heart of knockout 
mice leads to a biochemical shift in cardiac substrate utilization from fatty acid to glucose oxidation 
which, not only corresponds to an adaptive reduction in O2 consumption for the equimolar production 
of ATP, but more so implicates the protein in providing fatty acid substrates for the mitochondrial-
oxidation breakdown in vivo (53). Our indirect demonstration, that Mb is likely to be regulated by 
intracellular fatty acid levels as shown by the inhibition of fatty acid synthase (FASN) now indicates a 
role for Mb in fatty acid metabolism of cancer cells and clearly warrants further study. 
In summary, Mb is endogenously expressed in normal breast tissue and abundantly in a subset 
of breast cancer cases. The strong functional association of Mb expression with presence of the 
estrogen receptor (ERα) explains the generally better prognosis of Mb positive tumors, compared to 
Mb negative tumors. In breast cancer cells, Mb abundance is regulated by hypoxia, estrogen signalling 
and possibly fatty acid levels. The functional data generated under normoxia implicate unconventional 
functions of myoglobin, not directly related to the transport of oxygen. Mb`s prospective role in the 
lipid metabolism of ER-positive tumors provides a reasonable working hypothesis able to link a loss-
of-function of this hemoprotein with the observed impairment of the proliferative and migratory 
capacities of oxygenated cells. Beyond these functional aspects, the regulation in normal and tumor 
tissue might also be fundamentally different, as the novel description of a tumor specific Mb transcript 
suggests. Taken together, these findings further broaden our view on the role of non-muscle Mb that 
may have fundamental implications for our conception of the biology of solid tumors. Finally, we 
acknowledge that this study has in consequence generated even more pressing questions concerning 
the functional role of non-muscle Mb for further analysis. 
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5. Material and methods 
 
5.1 Clinical materials/Patients 
The matched tumor/normal samples of invasive ductal breast carcinomas and corresponding 
normal breast epithelium (n=10) analyzed in this study, have recently been described (54). For 
immunohistochemistry, our study included tissue micro arrays of normal tissue, intratumoral ductal 
carcinoma in situ and invasive breast cancer of patients diagnosed at the Institute of Surgical 
Pathology (University Hospital, Zurich, Switzerland), as described (28). Tumor histology was 
determined according to the criteria of the World Health Organization (2003), staging the disease 
followed UICC guidelines (2002). Tumors were graded according to Bloom and Richardson, as 
modified by Elston and Ellis (55). Clinico-pathological characteristics of the patients/tumors are given 
in Table 1. For statistical analysis, only cases with clinical follow-up data were considered. The 
median observation time for overall survival was 59 months for patients still alive at the time of 
analysis. Two-hundred-and-twenty-five patients (24%) died during follow-up. Data on adjuvant 
therapy was not available. 
 
5.2 Cell lines 
The human mammary epithelial cell line MCF12A as well as the breast cancerous cell lines 
BT20, BT474, Cal51, EFM19, HBL100, Hs578T, MDA-MB231, MDA-MB361, MDA-MB453, 
MDA-MB415, MDA-MB436, MDA-MB-468, MCF7, SKBR3, T47-D and ZR75-1 were obtained 
from the ATCC (Rockville, MD, USA) and cultured under recommended conditions.  
 
5.3 Hypoxia experiments 
The benign breast cell line MCF12A and the breast cancer cell lines MDA-MB231, MDA-
MB-468 and MCF7 were used for hypoxic exposures. Culture conditions included: normoxia = 
ventilated room air in incubator in water-saturated, 5% CO2 atmosphere at sea level and 37°C = 141.6 
mmHg or 18.6% O2; hypoxia: water-saturated 1% O2 / 5% CO2 / balance N2 atmosphere at 37°C for 4, 
8, 24, 48 and 72h respectively. Albeit we approximated the normoxic concentration of O2 with 20% in 
some figures (e.g. Fig. 3), we are fully aware that the calculated tension in incubators is slightly lower. 
We used Hera cell240 incubators (MultiTemp Scientific AG, Kloten, Switzerland) or an InvivO2 400 
Hypoxia Workstation (Ruskinn Technology Ltd, Leeds, UK) for hypoxic exposures. 
 
5.4 Quantitative real-time reverse transcription PCR 
At RWTH Aachen qPCR experiments used the LightCycler® system (Roche Diagnostics, Germany) 
as recently described (54). At the Universities of Zurich and Mainz qPCR experiments used the ABI 
Prism 7500 Fast SDS (Applied Biosystems, Darmstadt, Germany)  (see (56) for details). 
Mean (±SD) expression levels of standard (NM_005368, Mb-s) and alternative (NM_203377, Mb-a) 
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Mb transcript were calculated by the standard-curve approach measuring Ct-values for hypoxic and 
normoxic samples (Fig. 6B; n=2 experiments, triplicate assays). Differences in relative abundance 
between Mb-s and Mb-a transcripts in normoxic MDA-MB-468 cells were calculated using the 
standard-curve method and a standard plasmid construct harbouring both amplicons, Mb-s and Mb-a 
(Fig. 6B, n=4 experiments, duplicate assays). 
 
5.5 Western blots 
Following normoxic exposure for 72h and hypoxic (1% O2) exposure for 4, 8, 24, 48 and 72h, 
MDA-MB-468 and MCF7 were harvested with a lysis buffer containing 0.1% NP-40, 400mM NaCl, 
1mM EDTA (pH8.0), 10mM Tris-HCl (pH8.0) and protease inhibitors. Protein extracts were 
electrophoresed on a 15% SDS-PAGE gel. Monoclonal antibody mouse anti-myoglobin (No. 113-
0533, Zytomed Systems GmbH, Berlin, Germany) was used for immunoblotting (1:1000 dilution). For 
equal loading control, blots were stripped and re-probed by monoclonal antibody mouse anti-β-actin at 
a 1:5000 dilution (A5441 Sigma-Aldrich, Basel, Switzerland). For HIF-1α and -2α immunoblots, 
mouse monoclonal anti-HIF-1α (mgc3) and rabbit polyclonal anti-HIF-2α (NB100-480, Novus 
Biologicals, LLC, Littleton, USA) were used at 1:500 and 1:750 dilutions, respectively. 
 
5.6 Immunohistochemistry and immunofluorescence 
Tissue sections were processed using automated immunohistochemistry platforms (BOND, 
Labvision; Benchmark, Ventana). Validation of the specificity of used Mb antibodies (Supplement Fig. 
S1) and a summary of employed immunohistochemical (Supplement Tab. ST1) are given as indicated. 
Intensity of Mb, Cgb, GLUT1, CAIX and FASN immunohistochemistry was evaluated by two clinical 
pathologists (GK, FFR) and semiquantitatively scored as negative, weakly, moderately or strongly 
positive (0 to 3+). ER, HIF-1α/-2α was evaluated in percent of positive nuclei. Double 
Immunofluorescence was performed as recently described (57). 
 
5.7 Identification of candidate transcription factor binding sites 
Genomic sequences covering the analyzed gene loci were extracted from the NCBI database 
(www.ncbi.nlm.nih.gov): human MB (NC_000022), mouse Mb (NC_000081) and human HSP27 
(NC_000007). For the identification of putative transcription factor binding sites conserved across 
different species, the rVISTA program was used (58) (http://rvista.dcode.org). A global sequence 
alignment file as prepared by the program Mulan (http://mulan.dcode.org/) was used as input. 
Transcription factor binding site searches in rVISTA are based on the TRANSFAC database 
(http://transfac.gbf.de/TRANSFAC/) (59). The default program values (core similarity: 0.9; matrix 
similarity: 0.85) were used in the sequence motif search. 
 
5.8 Stable and transient RNA interference 
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5.8.1 Targeting HIF 
To target nucleotides 1380-1400 of human HIF-1α mRNA (accession no. AF304431.1), HIF-
1α RNA oligonucleotides were synthesized as sense 5’-CUGAUGACCAGCAACUUGAdTdT-3’ and 
antisense UCAAGUUGCUGGUCAUCAGdTdT-3’ sequences. HIF-2α specific siRNA 
oligonucleotides  were synthesized as sense 5’-CAGCAUCUUUGAUAGCAGUdTdT-3’; and 
antisense 5’-ACUGCUAUCAAAGAUGCUGdTdT-3’ sequences to target nucleotides 1260-1280 of 
human HIF-2α (accession no. NM_001430). Both siRNAs, and the SiCONTROL non-targeting pool 
#2 of scrambled siRNAs, were purchased from Dharmacon Research Inc (Lausanne, Switzerland). 
Oligofectamine transfections (Invitrogen, Basel, Switzerland) of siRNAs used final concentrations of 
200nM of either HIF-1α or -2α single siRNA, and 100nM each of HIF-1α and -2α siRNA in 
combined transfections. MDA468 cells were transfected as a pool in 6-well plates and divided into 
6cm plates after 3-4 h post-transfection. At 18 h post-transfection, cells were exposed to 1% oxygen 
for 52, 56, 72 or 96 h. Cells were lysed in the 0.1% NP-40 lysis buffer. 
 
5.8.2 Targeting Mb 
Short hairpin RNAs (shRNA) were used for targeting of the human myoglobin mRNA 
(GenBankTM accession number NM_203377) at nucleotides 284-304 (construct #83), 483-503 (#84), 
340-360 (#85) and 415-435 (#86). Inserted into the mammalian expression vector pLKO.1-puro, these 
four shRNA constructs, were purchased as bacterial glycerol stock from Sigma-Aldrich (Basel, 
Switzerland). Stable shRNA Mb knockdown MDA-MB-468 cells were established by overnight 
calcium phosphate transfection followed by selection and maintenance in 0.75μg/ml puromycin 
containing medium. Mb protein levels in knockdown and control cells were analyzed by Western blot 
as described above. 
For transient knockdown, MDA-MB-468 cells were transfected with 10nM siRNA solutions 
(#6, #8 and allStars negative control, Qiagen, Hilden, Germany) immediately after seeding using 
Lipofectamine 2000 (Invitrogen, Carlsbad, California). 24h post-transfection the medium was changed. 
Knockdown efficiency was confirmed on protein and RNA level in a Western Blot analysis and real-
time qPCR, respectively. 
 
5.9 High-resolution respirometry 
Oxygen kinetics of trypsinized, suspended and heavily stirred MDA-MB-468 cells, both of 
Mb control and knockdown make-up, were measured at ~1x106/ml densities in twin-chamber 
Oroboros® Oxygraph-2k respirometers. Each chamber was filled with cells suspended in 2 ml culture 
medium (glucose-free DMEM + 10%FBS + penicillin /streptomycin + 0.75 μg/ml puromycin). Details 
regarding the deconvolution of the oxygen signal (60), instrumental design and data analysis (45, 60, 
61) are summarized in earlier publications. The systems inherent high signal stability and dynamic 
background correction for oxygen consumption of the oxygen sensor and oxygen back-diffusion 
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provide the basis for high resolution of oxygen flux (<2 pmol.s-1.cm-3). To measure routine respiration, 
the medium was initially free of glucose, but contained 280 IU/ml of catalase. Later, 25 mM of 
glucose were added to measure the extent of its inhibition on respiration (Crabtree effect). In addition, 
injection of 40 μM H2O2 triggered the catalase-driven release of controlled amounts of oxygen to 
record additional oxy-regulated/oxy-conform transitions of respiratory activity of MDA-MB-468 cells 
(see Fig. 7B). Alternatively, 400 μM H2O2 were added to achieve full reoxygenation via the catalase 
reaction. For the recording of electron transport saturated (ETS) oxygen flows, oxidative 
phosphorylation was uncoupled with increasing doses (4.0 - 5.5 μM) of the protonophore 
carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP). Finally, mitochondria were poisoned 
through injection of 0.5 μM of myxothiazol to obtain the residual O2-consumption (ROX). 
 
5.10 In vitro proliferation and migration assays 
 Proliferation rates of wildtype (wt) and selected stable Mb-control (con) or Mb-knockdown 
(kd) MDA-MB-468 cells was determined over a 96h time course in normoxic and hypoxic 
atmospheres either by direct counting of viable cells (Trypan Blue exclusion assay, dotted lines) or by 
using the MTT assay (continuous lines), which correlates cellular growth indirectly with a colorimetric 
determination of the activities of mitochondrial enzymes (n=4 independent measurements/assay; data 
as mean rate ± SD, relative to 0h time point = 1x). To extract the impact of the Mb knockdown on 
cellular growth, 96h proliferation ratios (wt/kd, con/kd) were calculated relative to the growth of kd 
cells (=1) at high and low oxygen tensions. 
The in vitro motility of MDA-MB-468 cells was assessed for stable Mb kd clones as well as 
for transiently siRNA transfected cells by performing a monolayer scratch wound assay (62). Once 3 x 
105  plated MDA cells had reached 100% confluence, the monolayer was linearly scratched with a 
100µl pipette tip, washed twice gently with PBS and cultured further with complete (10% FBS) 
medium. Pictures of the wound were taken with a Canon digital camera fitted to a light microscope at 
0, 24, 48 and 72h after scratching. The wound closure dynamics was determined as “percentage of 
remaining wound size” by evaluation the acellular gap width in relation to the initial wound width at 
three different sites for each wound in each picture (data as mean relative wound size ± SD of 
triplicate measurements/clone).  
 
5.11 Electron Microscopy (EM) 
Tissues from two breast tumors were fixed with 2.5% glutaraldehyde, postfixed with osmium 
tetroxide, embedded in epoxy resin, cut with an ultramicrotome, mounted on 200 mesh copper grids, 
stained with uranyl acetate and lead citrate and examined with a Zeiss EM10 transmission electron 
microscope (Zeiss, Oberkochen, Germany) at 60 kV. 
 
5.12 Expression of Mb gene after incubation of MCF-7 cells with ß-Estradiol 
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MCF7 cells (8x105) were seeded into a 10cm culture dish and 24h later ß-Estradiol (Sigma-Aldrich, 
Deisenheim, Germany) dissolved in 5 µl ethanol abs., was applied to the cells at a final concentration 
of 0 pM, 20 pM, 40 pM and 60 pM. Cells without ß-Estradiol and Ethanol served as internal control. 
PCR primers used are shown in Table 2. 
 
5.13 Expression of Mb gene after incubation of MDA-MB-468 cells with the FASN inhibitor C75 
3x105 MDA-MB-468 cells were seeded into 6 well-plates and exposed to 10 μg/ml final concentration 
of the FASN inhbitor C75 (Sigma-Aldrich, St. Louis, MO, USA) for 8, 24 and 48h. RNA and proteins 
were isolated following standard procedures. 
 
5.14 Statistical Analysis 
Expression data were analyzed with the software package SPSS, version 16.0 (SPSS Inc., 
Chicago, USA). Comparison of the delta CT values of the real time qPCR results between specific 
groups used the non-parametric Mann-Whitney-U-test. Fisher’s exact and chi-square tests for trends 
were used to asses the statistical significance of associations between Mb expression and clinico-
pathological parameters (Tab. 1). Bivariate correlations according to Spearman were applied to the 
immuno-intensity of normal tissue, intraductal and invasive carcinomas. Univariate survival analysis 
was performed with univariate Cox analyses and Kaplan-Meier curves (Log rank test).  
SiRNA and respirometry results were analyzed with the software package STATA 10.0 
(Stata™ 10.0; StataCorp, College Station, USA). Extent of Mb induction was compared for 
corresponding time points between siControl versus siHIF-1α or siHIF-2α or the combined siHIF-1α/-
2α treatments. Mean O2 consumption rates or p50 measurements were compared pairwise between 
pooled Mb control (con) and knockdown (kd) samples. Statistical significance was calculated in 
accordance with prior testing for variance equality between compared data, i.e. by standard Student t-
tests when variance equality was ascertained (e.g. R(-G), R(G), ROX O2 consumption rates, all p50 
data) or by a Welch-approximated t-test that takes unequal variances into account and (e.g. siRNA 72h 
hypoxia time point comparison; ETS consumption rate). For all analyses, p values < 0.05 were 
considered significant. 
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 Table 1 Clinico-pathological parameters of invasive breast cancer cases and relation to 
myoglobin expression  
Characteristic Number of 
cases (%) 
MB 
negative 
MB 
weak 
MB 
moderate 
MB 
strong 
p-
value 
 917 (100%)      
<60 years 416 (45.4%) 125 132 130 29 
>=60 years 501 (54.6%) 142 157 142 60 
0.170# 
Pre-menopausal 198 (21.5%) 67 64 60 7 
Post-
menopausal 
719 (78.5%) 200 225 212 82 
0.007# 
Invasive ductal 739 (80.6%) 214 221 228 76 
Invasive lobular 
125 (13.6%) 39 49 29 8 
NOS 
53 (5.8%) 14 19 15 5 
0.375* 
pT1 335 (36.5%) 91 108 106 30 
pT2 410 (44.7%) 115 134 119 42 
pT3 66 (7.2%) 27 19 17 3 
pT4 106 (11.6%) 34 28 30 14 
0.479# 
pN0 346 (42.5%) 92 107 111 36 
pN1 369 (45.3%) 113 120 105 31 
pN2 69 (8.5%) 21 20 16 12 
pN3 31 (3.8%) 10 8 12 1 
0.355# 
G1  126 (13.7%) 30 40 46 10 
G2  460 (50.2%) 112 155 141 52 
G3  331 (36.1%) 125 94 85 27 
0.001# 
ER-negative 163 (18.7%) 78 45 34 6 
ER-Positive 709 (81.3%) 171 226 231 81 
0.001# 
PR-negative 314 (34.8%) 114 104 82 14 
PR-positive 588 (65.2%) 145 183 187 73 
0.001# 
HER2 0, 1+,2+, 776 (88.1%) 223 241 239 73 
HER2 3+ 105 (11.9%) 33 37 25 10 
0.346# 
* Pearson Chi-Square, # Chi-Square for trends 
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Table 2 Primers used for real time PCR. 
Gene Primer sequence Product size 
5´- GGCATCATGAGGCAGAGATT – 3´ 
Myoglobin 
5´- TCTGCAGAACCTGGATGATG – 3` 
111 bp 
5’-GAAGGTGAAGGTCGGAGTCA-3’ 
GAPDH 
5’-TGGACTCCACGACGTACTCA-3’ 
289 bp 
5’- GGACGACATGGAGAAAATC-3’ 
ß-Actin 
5’- ATAGCACAGCCTGGATAGC-3’ 
185 bp 
5´- CCCAGTGAGCCCATACTTGC -3´ 
HsaMb NM_005368 
5´- GTCAGAGGACGAGATGAAGGC -3´ 
219 bp 
5´- GCATGTTGGCCTGGTCCTTTGC -3´ 
HsaMb NM_203377 
5´- GTCCTCATCAGGCTCTTTAAG -3´ 
275 bp 
5´-GCAATTCCTTCCGCTACAAC-3´ 
L28 NM_000991 
5´- TGTTCTTGCGGATCATGTGT -3´ 
198 bp 
 
Table 3 Univariate Cox analysis of clinicopathological variables and markers of hypoxia 
including myoglobin expression 
Parameter Relative risk 95%-Confidence 
interval 
p-value 
Age (<= 60 vs. >) 1.881 1.495-2.367 0.001 
Menopausal status 1.569 1.172-2.100 0.002 
pT (1-4) 1.699 1.537-1.877 0.001 
pN (0-3) 1.610 1.403-1.846 0.001 
G (1-3) 1.616 1.360-1.920 0.001 
ER (neg. vs. pos.) 0.549 0.425-0.709 0.001 
PR (neg. vs. pos.) 0.527 0.408-0.680 0.001 
HER2 (0-2+ vs. 3+) 1.839 1.372-2.465 0.001 
CK5/6 (neg vs. pos) 1.669 1.166-2.390 0.005 
Hif1α* 0.860 0.504-1.468 0.580 
Hif2α* 0.426 0.239-0.760 0.004 
GLUT1* 1.650 1.026-2.654 0.039 
CAIX* 0.619 0.345-1.111 0.108 
MB* 0.686 0.516-0.913 0.010 
   dichotomized by the median 
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